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Comprehensive molecular epidemiological data are prerequisite for establishing 
control over methicillin-resistant S. aureus (MRSA) in the hospital setting; however, 
there is currently a paucity of molecular epidemiological data available on MRSA 
from South Africa.  A molecular characterisation of one hundred MRSA isolates 
collected between January 2007 and December 2008 from patients in five hospitals 
in Cape Town was carried out in this study. 
 
PCR assays did not detect the Panton-Valentine leukocidin toxin in any of the 
isolates.  The majority (92.00 %) of the MRSA segregated into six pulsed-field gel 
electrophoresis clusters, each of which contained isolates from at least 2 hospitals, 
suggesting the transmission of MRSA within and between hospitals in Cape Town.  A 
combination of SCCmec typing, multilocus sequence typing, spa typing and dru 
typing was used to further characterise the MRSA.  The six PFGE clusters and five of 
the sporadic isolates correspond to four clones, while the remaining three MRSA 
were consistent with sporadic clones.  Three of the predominant clones 
corresponded to frequently described pandemic clones: ST239-MRSA-III, ST36-
MRSA-II and ST5-MRSA-I.  ST239-MRSA-III and ST36-MRSA-II were minor clones, 
accounting for 4.00 % and 12.00 % of the isolates, respectively.  ST5-MRSA-I was 
the second-most prevalent clone identified in this study and accounted for 37.00 % of 
the isolates.  The sporadic clones included ST22-MRSA-IVh, ST72-MRSA-V and 
ST650-MRSA-IVb.  While ST22-MRSA-IVh also corresponded to a pandemic clone, 
ST72-MRSA-V a d ST650-MRSA-IVb both represent unusual MRSA genotypes. 
 
The dominant clone identified in this study was the infrequently described multidrug-
resistant ST612-MRSA-IVd, which was detected in all five hospitals.  This clone 
appears to be endemic to South Africa, but has otherwise only been reported 
infrequently in Australia and the United Kingdom.  The identification of the same 
uncommon rifampicin resistance genotype in ST612-MRSA-IV from Cape Town and 
isolates previously described in South Africa and Australia, combined with the spa 
typing and dru typing data, suggest that ST612-MRSA-IV has undergone clonal 


















1.1 The staphylococci and their clinical relevance 
The bacterial genus Staphylococcus includes more than 40 species of non-spore-
forming, non-motile, Gram-positive cocci (Winn et al., 2006; Rogers et al., 2009).  
The genus name is derived from the Greek staphyle meaning ―grapes‖, and kokkos 
meaning ―berries‖, because, while staphylococci occur singly, in pairs, tetrads and 
chains, they are most commonly observed in grape-like clusters (Winn et al., 2006; 
Brooks and Carroll, 2007b; Mathema et al., 2009).  Most staphylococci are facultative 
anaerobes and are also typically catalase-positive, which distinguishes members of 
the genus from other Gram-positive cocci, such as the streptococci and enterococci 
(Winn et al., 2006; Brooks and Carroll, 2007b).   
 
The staphylococci are frequent colonisers of the skin and mucous membranes of 
humans and other animals, and have the potential to cause disease when the host‘s 
immune system is compromised (Oliveira et al., 2002; Aires-de-Sousa and de 
Lencastre, 2004; Winn et al., 2006; Gordon and Lowy, 2008).  Staphylococcus 
aureus is recognised as the most important human pathogen within the 
Staphylococcus genus (Winn et al., 2006).  When grown on rich media, S. aureus 
tends to form large colonies that are white-grey to golden-yellow in colour, hence the 
species name aureus, meaning ―golden‖ (Brooks and Carroll, 2007b; Mathema et al., 
2009; van Belkum et al., 2009).  S. aureus is distinguished from other staphylococci 
by the production of coagulase, a virulence factor that clots blood plasma and aids in 
immune evasion (Winn et al., 2006; Brooks and Carroll, 2007b).   
 
In contrast to S. aureus, the coagulase-negative staphylococci (CNS) typically form 
relatively small grey-white colonies when grown on rich media (Brooks and Carroll, 
2007b).  In the past, these less virulent species were not deemed important human 
pathogens, but that perception has gradually shifted with the CNS emerging as an 
important cause of nosocomial infections (Huebner and Goldmann, 1999; Livermore, 















infections in immunocompromised individuals, and are also frequently implicated in 
infections associated with indwelling medical devices (Huebner and Goldmann, 1999; 
Livermore, 2000; Rogers et al., 2009; Garza-González et al., 2010).  Seven CNS 
species are known human pathogens, the most important of which are 
Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus 
lugdunensis and Staphylococcus saprophyticus (Rogers et al., 2009).  Additionally, 
certain CNS species are known veterinary pathogens that, although not frequently 
isolated from humans, have zoonotic potential as they have been found to infect 
those  working  in  close  contact  with  animals  (Winn et al., 2006;  Garza-González  















1.2 S. aureus: pathogen extraordinaire  
Although  certain  CNS species are now  recognised as common  human  pathogens,  
S. aureus remains the most important member of the staphylococci (Winn et al., 
2006).  S. aureus can be found on inanimate objects in the environment, and as a 
component of the normal flora of humans and other animals (Lowy, 1998; Livermore, 
2000; Winn et al., 2006; Gordon and Lowy, 2008).  In humans, S. aureus commonly 
colonises the anterior nares, axillae, perineum, vagina and gastrointestinal tract 
(Lowy, 1998; Winn et al., 2006; Gordon and Lowy, 2008).  Studies of S. aureus nasal 
colonisation rates have estimated that approximately 20 % of individuals are 
persistently colonised, and a further 30 – 60 % intermittently colonised, with these 
individuals serving as vehicles of transmission in both the hospital and community 
settings (Livermore, 2000; Aires-de-Sousa and de Lencastre, 2004; Albrich and 
Harbarth, 2008; Gordon and Lowy, 2008; Struelens et al., 2009). 
 
S. aureus is an opportunistic pathogen that can be carried asymptomatically for 
extended periods of time on mucous membranes, or briefly on the skin (Archer, 
1998).  Once the barriers of the host‘s immune system are breached and S. aureus is 
provided access to adjacent tissues or to the bloodstream, this organism is capable 
of causing a wide variety of infections (Archer, 1998; Lowy, 1998; Harris and 
Richards, 2006; Gordon and Lowy, 2008).  These infections range from relatively 
benign skin and soft tissue infections to more severe, life-threatening infections such 
as  bacteraemia,  pneumonia,  endocarditis  and  osteomyelitis  and,  like  the  CNS,  
S. aureus is a common cause of chronic indwelling device-related infections (Lowy, 
1998; Livermore, 2000; Aires-de-Sousa and de Lencastre, 2004; Harris and 
Richards, 2006; Gordon and Lowy, 2008).   Due to the production of toxins, certain  
S. aureus strains also cause a variety of toxinoses (Lowy, 1998; Gordon and Lowy, 
2008), as will be described later in this chapter [1.3].   
 
In addition to causing disease in humans, S. aureus is also a significant veterinary 
pathogen (Winn et al., 2006).  Particular S. aureus lineages are known to cause 
disease in companion animals, and also in economically important livestock, such as 
cows, chicken, goats, pigs, rabbits and sheep (Winn et al., 2006; Pantosti and 
Venditti, 2009; Rogers et al., 2009; McCarthy and Lindsay, 2010).  Given their 















health concerns (Ben Zakour et al., 2008).  A selection of these lineages will be 
















1.3 The contribution of virulence factors to S. aureus pathogenesis 
S. aureus has the ability to cause a broad spectrum of infections involving any organ 
in its human host (Archer, 1998).  The extensive array of virulence factors available 
to S. aureus is recognised as a pivotal factor in its pathogenesis (Archer, 1998; Lowy, 
1998; Foster, 2005; Gordon and Lowy, 2008; Skrupky et al., 2009; Mathema et al., 
2009).  While the precise combination of virulence factors varies from strain to strain, 
the majority of virulence determinants can be assigned to one of five groups based 
on their roles in S. aureus pathogenesis, as defined by Gordon and Lowy (2008) 
(Table 1.1).  These five categories group virulence factors that are involved in 
attachment, persistence, immune evasion, tissue invasion and toxin-mediated 
disease.  In essence, virulence factors enable S. aureus to colonise a host, establish 
















Table 1.1 Five major categories of S. aureus virulence factors defined according to roles in pathogenesisa 




colonisation and early 
stages of infection) 
Device-related infections; 
osteomyelitis; septic arthritis; 
endocarditis 
MSCRAMMs including clumping factors (clfA; clfB), fibronectin-binding proteins (fnbA; 
fnbB), collagen-binding protein (cna), and bone sialprotein-binding protein (bbp) 
Persistence 
Device-related infections; 
osteomyelitis; septic arthritis; 
endocarditis; recurrent infections  
Aminolevulinic acid dehydratase (hemB) mutants (SCV phenotype); polysaccharide 
intercellular adhesion (ica) and accessory gene regulator (agr) (biofilm production); 
intracellular persistence 
Destruction and/or 
evasion of components 
of host‘s immune system 
Necrotising pneumonia; invasive 
skin and soft tissue infections; 
recurrent infections 
Panton-Valentine leukocidin (lukS-PV; lukF-PV); γ-toxin (hlg); leukotoxin D, E (lukD; 
lukE); staphylokinase (sak); capsular polysaccharides, particularly 5 and 8 (cap5 and 
cap8 gene clusters); protein A (spa); phenol soluble modulins (psm-α gene cluster); 
coagulase (coa); CHIPS (chp); extracellular adherence protein (eap); MHC class II 
analogous protein (map); staphylococcal inihibitor of complement (scn); aureolysin (aur) 
Tissue invasion (during 
later stages of infection) 
Destruction of host tissue; 
metastasis 
Proteases (V8); nucleases; lipases; elastases/metalloproteases (sepA); phospholipase 
C (plc); hyaluronate lyase (hysA) 
Toxinoses and/or sepsis 
Toxic shock syndrome; bullous 
impetigo; staphylococcal scalded 
skin syndrome; food poisoning; 
sepsis 
Toxic shock syndrome toxin-1 (tstH); exfoliative toxins A, B and D (eta; etb; etd); 
entertoxins A – Q, excluding F (sea – seq, but not sef); α-toxin (hla); peptidoglycan; 
lipoteichoic acid 
a
 Adapted from Foster (2005), Winn et al. (2006), Gordon and Lowy (2008), and Malachowa and DeLeo (2010). 
b















A number of virulence factors play an important role during colonisation and the early 
stages of infection as they promote bacterial adhesion.  These cell-surface proteins 
are known as ―microbial-surface components recognising adhesive matrix molecules‖ 
or MSCRAMMs (Table 1.1) (Archer, Foster and Höök, 1998; Lowy, 1998; Gordon 
and Lowy, 2008).  The MSCRAMMs bind extracellular matrix components including 
fibronectin, fibrinogen and collagen (Foster and Höök, 1998; Gordon and Lowy, 
2008).  These plasma components are known to coat the surfaces of indwelling 
medical devices, thereby making it possible for S. aureus to adhere to both host and 
indwelling-device surfaces (Dancer, 2008).  Due to their adhesive properties, the 
MSCRAMMs appear to be particularly important in establishing device-related 
infections, bone and joint infections and endovascular infections (Foster and Höök, 
1998; Gordon and Lowy, 2008). 
 
After establishing an infection, S. aureus exploits several virulence strategies to 
persist within its host.  An important requirement for persistence is immune evasion 
and, during the earlier stages of infection, S. aureus produces a number of virulence 
factors   that   help  thwart  the  host‘s  immune  system   (Table 1.1)   (Foster, 2005). 
S. aureus employs several other strategies to persist within its host, including biofilm 
production and the invasion of host cells (Table 1.1).  Biofilms consist of sessile 
populations of bacteria within an extracellular matrix, which shields the bacteria from 
antimicrobial agents and host defences (Yarwood et al., 2004; Harris and Richards, 
2006; Dancer, 2008).  The ability to persist intracellularly in both phagocytic and non-
phagocytic cells is thought to play an important role in chronic and recurrent 
infections as S. aureus is protected from host immune responses and certain 
therapeutic agents (Foster, 2005; Harris and Richards, 2006; Gordon and Lowy, 
2008).  The formation of small-colony variants (SCVs) is thought to play a similar role 
in persistent and recurrent infections (Gordon and Lowy, 2008; Sendi and Proctor, 
2009).  SCVs show increased uptake by host cells and survive intracellularly 
because they cause minimal damage to the cell.  SCVs also exhibit decreased 
activation of host immune responses, and are refractory to the host‘s defences and 
certain antimicrobial agents (Sendi and Proctor, 2009). 
 
Although the expression of bacterial adhesins is vital during the early stages of 
infection, it becomes important to alter the expression of these virulence genes 















for S. aureus to disseminate to peripheral sites, it is necessary for the organism to 
down-regulate the expression of genes involved in adhesion and up-regulate the 
expression of those involved in tissue invasion and penetration (Table 1.1) (Lowy, 
1998; Novick and Geisinger, 2008).  The up-regulation of proteases, lipases, 
elastases and other cytotoxins enables S. aureus to penetrate host tissues, 
disseminate to peripheral sites and establish additional foci of infection (Foster, 2005; 
Gordon and Lowy, 2008; Skrupky, 2009).  S. aureus is also able to interact with and 
activate the host‘s immune system and coagulation pathways to cause septic shock 
(Gordon and Lowy, 2008). 
 
Several regulatory systems have been implicated in the temporal control of virulence 
factor expression in S. aureus, including the accessory gene regulator (agr), the 
staphylococcal accessory regulator (sar), the repressor of toxins or Rot (rot), the 
multiple gene regulator (mgr) and SaeRS (saeRS) (Lowy, 1998; Gordon and Lowy, 
2008).  Of these regulatory systems, the agr global regulator, an auto-inducing two-
component system, is undoubtedly the best understood.  As the number of bacteria 
present at the site of infection increases, so does the concentration of the 
autoinducing peptide (AIP).  Once the AIP reaches a threshold concentration, the agr 
system is activated resulting in the down-regulation of adhesins accompanied by the 
up-regulation of secreted virulence factors that enable tissue invasion and 
penetration (Lowy, 1998; Yarwood et al., 2004; Novick and Geisinger, 2008). 
 
Although not present in all strains, S. aureus isolates may also carry combinations of 
additional virulence determinants that cause various toxinoses (Table 1.1) (Lowy, 
1998; Foster, 2005; Gordon and Lowy, 2008; Skrupky et al., 2009).  These virulence 
factors are often located on mobile genetic elements and are disseminated by 
horizontal gene transfer (Fitzgerald et al., 2001; Malachowa and DeLeo, 2010; 
Novick et al., 2010).  For example, the exfoliative toxins that cause staphylococcal 
scalded-skin syndrome or bullous impetigo have been described on plasmids, 
phages and genomic islands (Gordon and Lowy, 2008; Malachowa and DeLeo, 
2010).  Similarly, enterotoxins known to cause food poisoning, as well as the toxic 
shock syndrome toxin and the Panton-Valentine leukocidin (PVL) toxin, which will be 
described in detail in Chapter 4 [4.1], have been described on phages and 
pathogenicity islands in S. aureus (Gordon and Lowy, 2008; Malachowa and DeLeo, 















1.4   An  overview  of  antimicrobial  chemotherapy  and   resistance  in 
S. aureus 
Although empirical treatments against bacterial infections have been in use since the 
1600s, antimicrobial chemotherapy only emerged as a science in the early twentieth 
century (Bryskier, 2005d; Brooks and Carroll, 2007a; Greenwood et al., 2007).  At the 
dawn of the antibiotic era, the medical community was optimistic that all infectious 
diseases would be treatable in the near future; however, this optimism was short-
lived as bacterial strains resistant to the newly introduced antimicrobial agents soon 
emerged (Lowy, 2003; Levy and Marshall, 2004; Greenwood et al., 2007).  Humans 
and bacteria have since been engaged in an ongoing battle as bacteria have 
consistently acquired resistance mechanisms to clinically relevant antimicrobial 
agents, which has necessitated the development of novel therapeutic agents, thus 
perpetuating the cycle (Greenwood et al., 2007). 
 
Extensive research on chemotherapeutic agents has resulted in the discovery of 
numerous classes of antibiotics.  The existing classes of antimicrobial agents target 
five major bacterial processes including cell wall, protein and nucleic acid synthesis, 
metabolic pathways, and cell membrane function (Levy and Marshall, 2004; Brooks 
and Carroll, 2007a; Greenwood et al., 2007).  Bacterial mechanisms of antimicrobial 
resistance to these antimicrobial agents vary depending on the bacterium and 
antibiotic in question, but can be divided into three categories: enzymatic degradation 
or modification of the antimicrobial agent, alteration of the drug target, and altered 
access to the drug target by decreased uptake, or increased efflux of the 
antimicrobial agent (Levy and Marshall, 2004; Smith, 2004; Greenwood et al., 2007). 
 
S. aureus has proved particularly adept at acquiring resistance mechanisms against 
clinically relevant antibiotics with multidrug-resistant strains posing a serious 
therapeutic challenge and economic burden (Oliveira et al., 2002; Ito et al., 2003; 
Lowy, 2003; Levy and Marshall, 2004; Shorr, 2007; Segreti, 2009).  In S. aureus, as 
in other bacteria, resistance mechanisms arise due to chromosomal mutations or 
horizontal transfer of mobile genetic elements encoding resistance determinants 
(Chambers, 1997; Ito et al., 2003; Lowy, 2003; Greenwood et al., 2007; Malachowa 
and DeLeo, 2010).  This organism‘s ability to consistently acquire resistance 















repertoire of virulence strategies, been a major contributor to its longstanding 
success as a pathogen (Oliveira et al., 2002).  A brief overview of major classes of 
chemotherapeutic agents used in mono- or combination-therapies for the treatment 
of S. aureus infections in Cape Town hospitals, as well as important resistance 
strategies, will be provided here. 
 
1.4.1.1 β-lactams 
The β-lactam class of antimicrobial agents comprises the largest group of bacterial 
cell wall synthesis inhibitors, including the penams, penems, cephems and 
monocyclic β-lactams (Bryskier, 2005b).  The most clinically relevant families of β-
lactam antimicrobial agents include the penicillins (penams), carbapenems (penems) 
and cephalosporins (cephems) (Figure 1.1) (Levy and Marshall, 2004; Bryskier, 















Figure 1.1 General structures of four major families of β-lactam antibiotics.  
The characteristic β-lactam ring essential for the antimicrobial activity of these 
groups is shown in blue.  The families are differentiated by the structure of the ring 
attached to the β-lactam ring, and by the side chains attached to that ring.  Adapted 
from Mims et al. (2004) and Russell et al. (2004). 
 
The penams, penems, cephems and monocyclic β-lactams share a common basic 
structure centred around the characteristic β-lactam ring that is crucial for their 















four families are differentiated on the basis of the ring bound to the central β-lactam 
ring (Figure 1.1) (Bryskier, 2005b).  These antimicrobial agents exert a bactericidal 
effect on S. aureus as they inhibit the penicillin-binding proteins (PBPs) responsible 
for transpeptidation of the peptidoglycan layer, thereby disrupting cell wall integrity 
(Brooks and Carroll, 2007a). 
 
The introduction of penicillin into clinical practice in 1940 correlated with decreased 
morbidity and mortality in patients with S. aureus infections; however, resistance to 
penicillin emerged rapidly in this organism with the first reports published in 1942 
(Oliveira  et al.,  2002;  Lowy,  2003).   It has been suggested that up to 80  –  95 % 
of S. aureus strains are currently penicillin-resistant (Bryskier, 2005c; Sakoulas and 
Moellering, 2008; Malachowa and DeLeo, 2010).  Penicillin-resistant S. aureus 
isolates produce β-lactamase, an enzyme that hydrolyses the β-lactam ring that is 
essential to the antimicrobial activity of the β-lactams (Lowy, 2003; Bryskier, 2005c; 
Greenwood et al., 2007).  In S. aureus, the blaZ gene that encodes β-lactamase is 
typically plasmid-borne, but has also been describ d on transposons, or within the 
bacterial chromosome (Lowy, 2003; Malachowa and DeLeo, 2010).  A number of β-
lactamase-stable β-lactam agents have been introduced into clinical practice in an 
attempt to combat penicillin-resistant S. aureus strains.  Among these agents are 
methicillin and the the isoxazolylpenicillins, including oxacillin and flucloxacillin 
(Bryskier, 2005e; Greenwood et al., 2007).  Resistance to these antibiotics emerged 
due to the acquisition of an alternative PBP, as will be discussed further later in this 
chapter [1.5].  Most recently, it has been shown that ceftaroline and ceftobiprole, 
investigational fifth generation cephalosporins, appear to have potential against 
isoxazolylpenicillin-resistant S. aureus strains as they are able to inhibit the 
alternative PBP (Ratnaraja and Hawkey, 2008; Skrupky et al., 2009). 
 
1.4.1.2 Aminoglycosides 
The aminoglycosides comprise a large family of protein synthesis inhibitors that exert 
a bactericidal effect mediated by binding to the 30S ribosomal subunit.  
Aminoglycoside binding is thought to impact on protein synthesis is several ways, 
one of which is by preventing the formation of the initiation complex (Lambert, 2004; 
Mims et al., 2004).  Additionally, aminoglycosides may inhibit translocation, and also 















particular mRNA codons (Lambert, 2004; Greenwood et al., 2007).  In S. aureus, 
aminoglycoside resistance commonly arises subsequent to the acquisition of a 
mobile genetic element, typically a plasmid or transposon, which encodes one or 
more aminoglycoside-modifying enzyme (Chambers, 1997; Malachowa and DeLeo, 
2010).  Aminoglycoside acetyltransferases, phosphotransferases and 
nucleotidyltransferases comprise the three known types of aminoglycoside-modifying 
enzymes, all of which have been described in S. aureus to date (Chambers, 1997; 
Lowy, 2003; Greenwood et al., 2007; Malachowa and DeLeo, 2010). 
 
1.4.1.3 Macrolides, lincosamides and streprogramins 
The macrolides, lincosamides and streptogramins comprise three classes of protein 
synthesis inhibitors that act at a similar point in the synthetic pathway, and all bind to 
the 50S ribosomal subunit (Lambert, 2004; Mims et al., 2004; Greenwood et al., 
2007).  The macrolides are thought to inhibit translocation and cause the peptide 
chain to dissociate from the ribosome (Greenwood et al., 2007), while the 
lincosamides and streptogramins inhibit elongation of the peptide chain (Lambert, 
2004).  Given that these three classes of antimicrobial agents have highly similar 
binding sites, it is hardly surprising that cross-resistance commonly occurs (Mims, et 
al., 2004).  In S. aureus, the most common mechanism of cross-resistance is 
methylation of the 23S subunit of the bacterial ribosome due to the activity of 
ribosomal methylases encoded by plasmid- or transposon-encoded erm genes 
(Lowy, 2003; Bryskier, 2005c; Malachowa and DeLeo, 2010).  Resistance may also 
arise due to acquisition of the plasmid-borne msrA and vga genes that encode 
components involved in the efflux of macrolides and streptogramins, and 
lincosamides, respectively (Malachowa and DeLeo, 2010).  Additionally, S. aureus is 
known to acquire plasmid-encoded acetyltransferases that modify the streptogramins 
(Lowy, 2003). 
 
1.4.1.4 Fusidic acid 
Fusidic acid is a protein synthesis inhibitor often used in combination therapies for 
the treatment of deep-seated S. aureus infections (Greenwood et al., 2007).  Of all 
the protein synthesis inhibitors, fusidic acid acts latest in the pathway (Mims et al., 
2004) by interacting with elongation factor G (EF-G) on the ribosome to inhibit 















fusidic acid emerges rapidly in S. aureus with two known mechanisms of resistance.  
Chromosomal mutations in fusA and rplF, which encode EF-G and the ribosomal 
protein L6, respectively, are known to decrease drug-target interactions (Greenwood 
et al., 2007; Lannergård et al., 2009).  The second mechanism of resistance involves 
the protection of the drug target due to acquisition of the plasmid-encoded fusB 
determinant (Lannergård et al., 2009; Malachowa and DeLeo, 2010). 
 
1.4.1.5 Quinolones 
The quinolones inhibit nucleic acid synthesis by targeting topoisomerase IV and DNA 
gyrase with the former serving as the primary target in S. aureus (Chambers, 1997; 
Greenwood et al., 2007).  These enzymes play an integral role during replication and 
transcription as they ensure that bacterial DNA is in the correct conformation and that 
its integrity  is  maintained  (Lowy,  2003;   Lambert,  2004;   Mims  et  al.,  2004).   In  
S. aureus, resistance to the quinolones usually arises due to the acquisition of 
chromosomal mutations in the grlA, gyrA and gyrB genes that result in the alteration 
of the drug target (Chambers, 1997; Lowy, 2003). 
 
1.4.1.6 Rifamycins 
The rifamycins constitute an important class of nucleic acid synthesis inhibitors, of 
which the semi-synthetic rifampicin has the greatest clinical importance (Greenwood 
et al., 2007).  The rifamycins inhibit bacterial transcription by binding to the β-subunit 
of DNA-dependent RNA polymerase (Brooks and Carroll, 2007b).  Resistance to the 
rifamycins arises due to alteration of the drug target and is mediated by the 
acquisition of chromosomal mutations in the rpoB gene, which encodes the β-subunit 
of the bacterial RNA polymerase (Greenwood et al., 2007).  Resistance to rifampicin 
in S. aureus will be discussed further in Chapter 6. 
 
1.4.1.7 Sulphonamides and diaminopyrimidines (trimethoprim) 
The sulphonamides and diaminopyrimidines represent two classes of antimicrobial 
agents that target tetrahydrofolate synthesis, a vital bacterial metabolic pathway 




































Figure 1.2 Flow-diagram illustrating the tetrahydrofolate synthesis pathway 
essential for the production of purines and pyrimidines in bacteria.  The key 
enzymes dihydropteroate synthase and dihydrofolate reductase are inhibited by the 
sulphonamides and trimethoprim, respectively, as indicated.  Adapted from Mims et 
al. (2004) 
 
The tetrahydrofolate synthesis pathway is essential for the production of the purines 
and pyrimidines required for nucleic acid synthesis; therefore disruption of the 
pathway indirectly inhibits nucleic acid synthesis (Mims et al., 2004).  The 
sulphonamides inhibit dihydropteroate synthetase, preventing the production of 
dihydropteroic acid, an essential intermediate in the pathway (Figure 1.2) (Mims et 
al., 2004; Lambert; 2004).  The diaminopyrimidines, the most important of which is 
trimethoprim, act later in the pathway inhibiting dihydrofolate reductase (DHFR) to 
prevent the production of tetrahydrofolic acid (Figure 1.2) (Mims et al., 2004; 
Greenwood et al., 2007).  The sulphonamides and trimethoprim act synergistically 
and, as a result, are prescribed in combination therapies with co-trimoxazole 















In S. aureus, resistance may arise to either the sulphonamide or trimethoprim 
components of co-trimoxazole.  The acquisition of chromosomal mutations in the 
sulA gene encoding dihydropteroate synthase confers resistance to the 
sulphonamides through the over-production of dihydropteroic acid.  In the case of 
trimethoprim resistance, chromosomal mutations within the dfrB gene encoding 
DHFR result in decreased drug-target interactions.  Alternatively, resistance to co-
trimoxazole may be mediated by the plasmid-borne dfrA and dfrK genes that encode 
alternative copies of DHFR with a low affinity for trimethoprim (Lowy, 2003; 
Malachowa and DeLeo, 2010). 
 
1.4.1.8 Glycopeptides 
The glycopeptides comprise the other major class of bacterial cell wall inhibitors, and 
are important in the treatment of drug-resistant S. aureus infections (Greenwood et 
al., 2007).  The most commonly used glycopeptides include vancomycin and 
teicoplanin, which is in fact a lipoglycopeptide (Bryskier, 2005b).  These molecules 
are large with a complex structure centred around a multi-peptide backbone 
(Greenwood et al., 2007).  The glycopeptides exert their bactericidal effect by binding 
to the D-alanyl-D-alanine peptide residues present in peptidoglycan precursors, 
thereby inhibiting transpeptidation (Skrupky et al., 2009). 
 
The increasingly frequent u e of vancomycin for the treatment of infections caused 
by Clostridium difficile, enterococci and multidrug-resistant staphylococci has 
inevitably led to the emergence of vancomycin-resistant staphylococci (Lowy 2003).  
Vancomycin resistance was first reported in a clinical S. haemolyticus isolate in 1987 
(Scwalbe et al., 1987).  A decade later, the first vancomycin intermediate S. aureus 
(VISA) isolate was reported in Japan (Hiramatsu et al., 1997).  Heterogeneous VISA 
(hVISA) strains give rise to both vancomycin-intermediate and -susceptible 
subpopulations, and are thought to represent precursors of true VISA strains (Liu and 
Chambers, 2003).  VISA and hVISA are characterised by decreased susceptibility to 
vancomycin with MICs ranging between 8 and 16mg/L and, importantly, these strains 
have been associated with treatment failure (Liu and Chambers, 2003; Appelbaum, 
2007).  Since the 1990s, there have been reports of VISA and hVISA strains 
worldwide (Liu and Chambers, 2003).  Of even greater concern has been the more 















was reported in the United States of America (USA) in 2002 with additional isolates 
subsequently reported in the USA (Appelbaum, 2007; Sievert et al, 2008), Brazil 
(Oliveira et al., 2001), India (Tiwari and Sen, 2006), Jordan (Bataineh, 2006) and Iran 
(Aligholi et al., 2008). 
 
It has been shown that the mechanism of reduced vancomycin susceptibility differs in 
VISA and VRSA isolates (Lowy, 2003).  In the case of VISA and hVISA isolates, 
reduced vancomycin susceptibility arises due to altered peptidoglycan synthesis.  
These isolates exhibit increased levels of peptidoglycan synthesis and decreased 
cross-linkage of the peptidoglycan chains.  As a result, more D-alanyl-D-alanine 
residues are available to bind and sequester vancomycin within the outer limits of the 
bacterial cell wall.  The sequestered vancomycin then aids in preventing additional 
vancomycin molecules reaching their targets and the cell wall, although thicker and 
irregularly shaped, remains intact (Lowy, 2003; Sakoulas and Moellering, 2008).  In 
VRSA isolates, vancomycin resistance is due to the acquisition of a plasmid-borne 
van operon obtained from vancomycin resistant ent rococci (Malachowa and DeLeo, 
2010).  The presence of the van operon results in the production of peptidoglycan 
precursors with D-alanyl-D-lactate terminal residues, which have a reduced affinity 
for vancomycin compared to D-alanyl-D-alanine residues; therefore cell wall 
synthesis is unaffected by the presence of this antimicrobial agent (Lowy, 2003; 
Malachowa and DeLeo, 2010).  The emergence of vancomycin-resistant 
staphylococci has driven the search for alternative antimicrobial agents and, as a 
result, several promising alternatives to vancomycin and teicoplanin are currently 
under investigation, including the glycopeptides telavancin and oritavancin, and the 
lipoglycopeptide dalbavancin (Ratnaraja and Hawkey, 2008; Skrupky et al., 2009). 
 
1.4.2 Waiting in the wings: newly available classes of antimicrobial agents 
In recent years the threat of multidrug-resistant S. aureus strains, particularly VISA 
and VRSA, has propelled investigations into new classes of antimicrobial agents, 
including the oxazolidinones, glycylcyclines and lipopeptides.  As a result, a number 
of new antimicrobial agents with activity against resistant S. aureus, including VISA 
and VRSA strains have recently been introduced into clinical practice, including 
linezolid, daptomycin and tigecycline (Ratnaraja and Hawkey, 2008; Skrupky et al., 















ribosomal subunit to prevent the formation of the initiation complex, thereby inhibiting 
protein synthesis (Greenwood et al., 2007; Ratnaraja and Hawkey, 2008).  
Daptomycin is a cyclic lipopeptide that exerts its activity by disrupting the 
phospholipid structure of the cell membrane (Bryskier, 2005a; Greenwood et al., 
2007).  Tigecycline is a glycylcycline that inhibits protein synthesis by interacting with 
the 30S ribosomal subunit (Brooks and Carroll, 2007a; Ratnaraja and Hawkey, 
2008).  Resistance to these three antimicrobial agents appears to be rare, although 
there are concerns regarding the reduced susceptibility of certain VISA strains to 
daptomycin, which is most likely due to the drug being sequestered by the thickened 
cell wall (Ratnaraja and Hawkey, 2008; Sakoulas and Moellering, 2008; Rossolini et 
al., 2010). 
 
1.4.3 Does antimicrobial chemotherapy represent a double-edged sword in 
the case of S. aureus? 
Antimicrobial chemotherapy has undoubtedly reduced morbidity and mortality due to 
bacterial infections; however, it is possible that, at least in the case of S. aureus, 
antimicrobial chemotherapy may represent a double-edged sword.  It appears that, in 
addition to providing the selective pressure that fosters the development of 
antimicrobial resistance, inappropriate or insufficient chemotherapy may in fact 
enhance S. aureus pathogenicity.  Linezolid and clindamycin are known to 
encourage S. aureus intracellular persistence, which, as described earlier, is an 
important feature of the pathogenesis of this organism.  It has also been suggested 
that the emergence of SCVs may be associated with failed antimicrobial therapies.  
Interestingly, it has been found that the horizontal transfer of mobile genetic elements 
is stimulated during the S. aureus SOS response, which is induced by certain β-
lactams, fluoroquinolones and trimethoprim.  Additionally, in vitro studies have shown 
that exposure to sub-inhibitory concentrations of β-lactam or fluoroquinolone 
antibiotics results in increased expression of hla and pvl encoding the α-toxin and 
PVL, respectively.  These findings suggest that inappropriate or insufficient 
chemotherapy may encourage intracellular persistence, enhance the transmission of 
mobile genetic elements carrying virulence factors and resistance elements, and lead 
to increased production of particular S. aureus virulence factors (Dancer, 2008).  
While additional studies are required to further investigate these issues, it may well 
















1.5 Methicillin-resistant Staphylococcus aureus (MRSA) 
1.5.1 The emergence and clinical significance of MRSA 
In 1940, the introduction of penicillin correlated with improved outcomes in patients 
with S. aureus infections; however, these effects were transient as penicillin-resistant 
S. aureus isolates were first reported in 1942 (Lowy, 2003).  The prevalence of 
penicillin-resistant S. aureus increased during the 1950s, which provided impetus for 
the search for β-lactamase-stable antimicrobial agents (Oliveira et al., 2002; 
Greenwood et al., 2007).  One such agent was methicillin, a semi-synthetic penicillin 
derivative with methoxy groups substituted at positions 2‘ and 6‘ of the benzene ring, 
thus rendering the molecule resistant to the action of β-lactamases (Bryskier, 2005e).   
 
Methicillin was introduced into clinical practice in Europe between 1959 and 1961 in 
an attempt to combat penicillin-resistant S. aureus strains (Oliveira et al., 2002; 
Lowy, 2003; Bryskier 2005c).  The success of methicillin against S. aureus infections 
was short-lived with the first resistant isolates described in England in 1961 (Jevons, 
1961).  Methicillin-resistant S. aureus (MRSA) went on to be described in other 
European countries and the USA by the end of the 1960s (Bryskier, 2005c; 
Grundmann et al., 2006; Deurenberg and Stobberingh, 2008).  By the close of the 
1970s, MRSA had been reported worldwide and MRSA prevalence rates have 
increased steadily over the past forty years (Ito et al., 2003; Bryskier, 2005c; 
Deurenberg and Stobberingh, 2008; Witte et al., 2008).  Although MRSA gained 
notoriety as a nosocomial pathogen, this organism is no longer confined to the 
hospital setting.  Since the 1990s, MRSA has been reported with increasing 
frequency in the community (Deurenberg and Stobberingh, 2008; Witte, 2009).  
Community-associated MRSA (CA-MRSA) will be discussed in more detail later in 
this chapter in the context of S. aureus evolution [1.7.3], and also in Chapter 4. 
 
MRSA is a human pathogen of major clinical importance and currently constitutes a 
global public health concern (Aires-de-Sousa and de Lencastre, 2004; van Belkum et 
al., 2009).  In comparison with infections caused by methicillin-susceptible S. aureus 
(MSSA), MRSA infections are associated with increased morbidity and mortality 
(Lowy, 2003; Shorr, 2007; Witte et al., 2008).  This is largely due to the fact that 
MRSA strains represent a therapeutic challenge as they are frequently resistant to 















Vancomycin remains the mainstay of chemotherapy for MRSA infections; however, 
the recent emergence of VISA and VRSA is of concern (Ratnaraja and Hawkey, 
2008; Lindsay, 2010).  The VISA and VRSA isolates described to date have been 
methicillin-resistant, which is worrying given the importance of vancomycin for the 
treatment of MRSA infections; however, the situation is not yet dire as antimicrobial 
agents recently introduced into clinical practice remain active against VISA and 
VRSA [1.4.2], while new fifth generation cephalosporins, glycopeptides and 
lipoglycopeptides with activity against MRSA are currently under investigation 
[1.4.1.1 and 1.4.1.8] (Ratnaraja and Hawkey, 2008). 
 
In addition to being associated with therapeutic challenges and poorer patient 
outcomes, MRSA infections also represent an economic burden (Aires-de-Sousa and 
de Lencastre, 2004; Shorr, 2007; van Belkum et al., 2009).  These infections are 
associated with elevated treatment costs that arise due t  the need for prolonged 
hospitalisation and additional procedures, diagnostic tests and antimicrobial agents 
(Aires-de-Sousa and de Lencastre, 2004; Grundmann et al., 2006; Shorr et al., 
2007).  The costs incurred during the containment of nosocomial MRSA outbreaks 
vary depending on the prescribed interventions, but tend to be significant 
(Grundmann et al., 2006).  Additionally, there are also indirect societal costs 
associated with MRSA infections that arise due to short- and long-term losses of 
productivity, and also due to mortality (Grundmann et al., 2006). 
 
1.5.2 The global prevalence of MRSA 
While MRSA is prevalent worldwide, surveillance studies indicate that prevalence 
rates vary greatly between and even within countries (Oliveira et al., 2002).  
Grundmann et al. (2006) reviewed antimicrobial surveillance studies carried out 
between 1998 and 2006 to provide an estimate of global MRSA prevalence rates.  
The authors found that only certain Scandinavian countries, such as Norway, 
Sweden and Iceland, reported exceptionally low MRSA prevalence rates of less than 
1 %.  Denmark, the Netherlands, Finland, Estonia and Canada had slightly higher 
MRSA prevalence rates of between 1 and 10 %, while Mexico, Morocco, Tunisia and 
much of northern Europe had moderate prevalence rates ranging from 10 to 25 %.  
In comparison, the UK, the USA, Turkey, Algeria, Egypt, Australia, Brazil, Argentina 















Finally, the highest MRSA prevalence rates were reported for countries such as 
Columbia, Iraq, Japan, Singapore, South Korea and Romania and exceeded 50 %. 
 
As indicated by Grundmann et al. (2006), the absence of data from developing 
countries, particularly those in Africa and Asia, makes it challenging to obtain an 
accurate comparison of global MRSA prevalence rates.  As South Africa has 
previously participated in international antimicrobial surveillance studies, it is one of 
the few African countries for which MRSA prevalence data is available.  Zinn et al. 
(2004) detected a 39 % MRSA prevalence rate among isolates obtained during 1996.  
The  SENTRY  study  carried  out  between 1998 and  1999  reported  that  41.5 %  
of S. aureus isolates from South Africa were methicillin-resistant (Bell et al., 2002).  
Similarly, the PEARLS study carried out between 2001 and 2002 reported that the 
MRSA prevalence rate in South Africa was 33.3 % (Bouchillon et al., 2004).  These 
findings should, however, be interpreted cautiously because the data were typically 
representative of only a small number of institutions from certain regions of the 
country, and, as mentioned previously, MRSA prevalence rates may vary markedly 
within a given country (Oliveira et al., 2002).  Antimicrobial surveillance has become 
more common in South Africa in recent years with local studies being initiated in both 
the public and private sectors (Perovic et al., 2006; Shittu and Lin, 2006; Brink et al., 
2007; Groome et al., 2009; Marais et al., 2009).  In perhaps the most comprehensive 
national study carried out to date in this country, the National Antimicrobial 
Surveillance Forum reported that the nationwide prevalence of MRSA from S. aureus 
blood culture isolates was 36 % in the private healthcare sector between January 
and June 2006 (Brink et al., 2007). 
 
1.5.3 The genetic basis and mechanism of methicillin resistance 
In S. aureus, methicillin resistance arises subsequent to the acquisition of a large 
mobile genetic element (approximately 21 – 67kb), which is known as the 
staphylococcal cassette chromosome mec (SCCmec) (Katayama et al., 2000; 
Berglund et al., 2008; Deurenberg and Stobberingh, 2008; Zhang et al., 2009; 
Malachowa and DeLeo, 2010).  The SCCmec element undergoes site-specific 
integration into the S. aureus chromosome (Ito et al., 1999; Katayama et al., 2000; Ito 
et al., 2001).  The site of integration is at the 3 prime end of orfX, an open reading 















between the spa and purA loci (Ito et al., 1999; Ito et al., 2003).  Eleven SCCmec 
types (I – XI), and many subtypes thereof, have been reported to date (Ito et al., 
2009; http://www.sccmec.org/Pages/SCC_TypesEN.html); however, only SCCmec 
types I – VIII have been described in detail to date (Ito et al., 2001; Ma et al., 2002; 
Ito et al., 2004; Oliveira et al., 2006; Berglund et al., 2008; Zhang et al., 2009).  
Studies have shown that SCCmec types I – VIII, with the exception of SCCmec type 
VII, all share a common basic genetic structure (Ito et al., 2009), as illustrated in 
Figure 1.3.   
 
Figure 1.3 Schematic diagram illustrating the basic genetic structure common 
to SCCmec types I – VI and VIII.  The S. aureus chromosome is shown in grey 
and the staphylococcal cassette chromosome mec (SCCmec) element in bold.  
Adapted from de Lencastre et al. (2007). 
 
The basic structure of SCCmec elements I – VI and VIII can be summarised, starting 
from the 3 prime end of orfX, as ―J3 – mec complex – J2 – ccr complex – J1‖, where 
the mec complex encodes the methicillin resistance determinant, the ccr complex 
confers mobility on the element and the joining or J (formerly junkyard) regions 
comprise non-essential components that may carry additional resistance 
determinants (Ito et al., 2003; de Lencastre et al., 2007; Deurenberg and 
Stobberingh, 2008; Ito et al., 2009).  SCCmec type VII deviates from the common 
basic structure as, although it contains the same components, the positions of the 
mec and ccr complexes are reversed [3.1] (Berglund et al., 2008). 
 
In accordance with the guidelines of the International Working Group on the 
Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC), 
SCCmec types are differentiated based on the combination of the class of mec 
complex and ccr allotype present, while differences in the J regions are used to 
define SCCmec subtypes (Ito et al., 2009).  A detailed description of the information 
available on the genetic structure, unique features and epidemiology of SCCmec 
types I – XI, focusing on SCCmec types I – VIII, will be provided in Chapter 3 [3.1].  















components of the mec and ccr complexes that are common to all extant SCCmec 
types. 
 
1.5.3.1 The mec complex 
Six classes of mec complex have been identified to date, and are designated A, B, 
C1, C2, D and E (Hanssen and Ericson Sollid, 2006; Deurenberg and Stobberingh, 
2008).  These mec complexes all contain the methicillin resistance determinant, 
mecA, as well as various regulatory components and insertion sequences (Hanssen 
and Ericson Sollid, 2006; Ito et al., 2009).  The exogenous mecA gene is 2.1kb in 
size and encodes a 78kDa PBP, known as PBP2‘ or PBP2A (Brown and Reynolds, 
1980; Reynolds and Brown, 1985; Beck et al., 1986; Ubukata et al., 1985; Utsui et 
al., 1985; Ito et al., 1999).  PBP2‘ has a very low affinity for methicillin and other β-
lactam antibiotics (Brown and Reynolds, 1980; Hartman and Tomasz, 1981; 
Reynolds and Brown, 1985; Utsui et al., 1985; Ubukata et al., 1989; Lowy, 2003).  
Crystallisation studies indicate that the active site of PBP2‘ is able to retain its 
transpeptidase activity whilst preventing β-lactam binding (Lim and Strynadka, 2002).  
As a result, PBP2‘, in conjunction with the penicillin-insensitive transglycosylase 
domain of the endogenous PBP2, acts as a custodian of transpeptidation, thereby 
maintaining cell wall integrity in the presence of β-lactam antibiotics (Pinho et al., 
2001a; Pinho et al., 2001b; Berger-Bächi and Rohrer, 2002).  It would, however, 
appear that PBP2‘ does not function as effectively as the endogenous S. aureus 
PBPs because the peptidoglycan layer of MRSA isolates is not as extensively cross-
linked in the presence of β-lactams (Berger-Bächi and Rohrer, 2002). 
 
The class A mec complex is thought to be the prototypic mec complex and includes 
mecA as well as intact copies of the mecI and mecR1 regulatory components (Ito et 
al., 2009).  The mecI and mecR1 genes are responsible for the regulation of mecA 
expression, and encode the MecI repressor and MecR1 sensor-transducer, 
respectively (Berger-Bächi and Rohrer, 2002; Lowy, 2003).  In the absence of β-
lactam antibiotics, MecI binds to the operator region of mecA, thereby inhibiting 
transcription.  The presence of β-lactams results in the autocatalytic cleavage of 
MecR1, which activates its cytoplasmic metalloprotease domain.  In turn, the 
metalloprotease domain of MecR1 is responsible for MecI cleavage, thereby 















and Rohrer, 2002).  It has been shown that mutations or deletions in the mecI gene 
result in constitutive rather than inducible methicillin resistance (Berger-Bächi and 
Rohrer, 2002; Lowy, 2003).   
 
Of the six known classes of mec complex, all except A contain remnants of mecI and 
mecR1 due to deletions, or the integration of insertion sequences within that region 
of the mec complex, as illustrated in Figure 1.4 (Hanssen and Ericson Sollid, 2006; 




















Figure 1.4 Schematic representation of the genetic structures of mec 
complexes A – E.  Arrowheads indicate the orientation of certain mec complex 
components.  ΔmecR1*, 976 bp deletion compared to ΔmecR1 in the class D mec 
complex.  Adapted from Hanssen and Ericson Sollid (2006). 
 
All known mec classes, except class D, have been described in SCCmec elements 
isolated from S. aureus strains [3.1] (Ito et al., 2009; 















complex, mecR1 and mecI are located upstream of mecA, while the insertion 
sequence IS431 is located downstream of the methicillin-resistance determinant 
(Figure 1.4).  In comparison, the class B mec complex also includes mecA and the 
downstream copy of IS431, but mecR1 is truncated following the integration of 
insertion sequence IS1272 (Figure 1.4).  The class C1 and C2 mec complexes are 
similar, but distinct: both consist of mecA with a downstream copy of IS431, but 
mecR1 is truncated due to the upstream insertion of an additional copy of IS431 
(Figure 1.4).  The orientation of the second copy of IS431 differentiates classes C1 
and C2.  In mec class C1, both copies of IS431 are in the same orientation, while in 
C2 the upstream copy of IS431 is in the reverse orientation to the downstream copy 
(Figure 1.4) (Ito et al., 2009).  The class D and E mec complexes are also similar as 
they both contain mecA with a downstream copy of IS431, as well as a partial copy of 
mecR1 upstream of the methicillin-resistance determinant (Figure 1.4).  The partial 
copies of the mecR1 genes distinguish these mec complexes as that present in class 
E carries a 976 bp deletion compared to that present in class D (Hanssen and 
Ericson Sollid, 2006; Deurenberg and Stobberingh, 2008).  Variants within the major 
mec classes have been described, and are characterised by the presence of 
additional insertion sequences.  These variants are indicated by subscript numerals 
following the mec class, for example, B2 (Ito et al., 2009).   
 
1.5.3.2 The ccr complex 
The ccr complex consists of the ccr gene(s), as well as any associated ORFs 
(Deurenberg and Stobberingh, 2008; Ito et al., 2009).  In S. aureus, three 
phylogenetically distinct ccr genes have been described: ccrA, ccrB and ccrC (Ito et 
al., 2009).  The ccrA and ccrB genes have been further classified into four and six 
allotypes, respectively; however, only one ccrC allotype has been described to date 
(Ito et al., 2009; http://www.sccmec.org/Pages/SCC_TypesEN.html).  The known ccr 
complexes can be separated into two distinct groups: those that contain adjacent 
copies of ccrA and ccrB, and those that contain ccrC.  The ccr complex allotypes 
most commonly found in S. aureus include type 1 (ccrA1B1), type 2 (ccrA2B2), type 
3 (ccrA3B3), type 4 (ccrA4B4) and type 5 (ccrC) (Ito et al., 2009).  Additionally, the 
IWG-SCC has communicated the identification of ccr allotypes 6 (A5B3), 7 (A1B6) 
and 8 (A1B3) via their website (http://www.sccmec.org/Pages/SCC_TypesEN.html), 

















The ccr genes encode recombinases of the invertase/resolvase family, which confer 
mobility on the SCCmec element (Ito et al., 1999; Katayama et al., 2000; Ito et al., 
2001; Ito et al., 2004; Oliveira et al., 2006).  The recombinases mediate the site-
specific integration and excision of SCCmec at the insertion site sequence (ISS), also 
known as the SCCmec attachment site (attB), which is located at the 3 prime end of 
orfX (Ito et al., 1999; Ito et al., 2001; Ito et al., 2009).  The precise location of the 
integration site within the ISS has been determined to within four nucleotides.  These 
four nucleotides comprise part of a 15 bp direct repeat sequence that is characteristic 
of the ISS with its counterpart situated in the terminal portion of the J3 region of 
SCCmec (Ito et al., 1999; Ito et al., 2001).  The 15 bp direct repeats, in addition to the 
27 bp imperfect inverted repeat sequences that are also present at the terminals of 
the SCCmec element, appear to be targeted by the recombinases mediating 
integration and excision (Ito et al., 1999; Ito et al., 2001; Ito et al., 2009).  Similarly, 
the composition of regions flanking the ISS also appears to affect an isolate‘s ability 
to acquire SCCmec (Noto et al., 2008).  
 
1.5.3.3 The origin of mecA and possible reservoirs of SCCmec 
Early studies showed that there was no allelic equivalent of mecA in MSSA isolates 
(Stewart and Rosenblum, 1980).  Combined with the detection of skewed GC content 
at the third codon position, and atypical codon usage within several SCCmec ORFs, 
this suggested that the methicillin resistance determinant was obtained from another 
organism (Hiramatsu et al., 2001).  Screening different staphylococcal species for the 
presence of mecA resulted in the detection of homologues with 80 and 91 % 
nucleotide identities in Staphylococcus sciuri (Couto et al., 1996) and 
Staphylococcus vitulinus (Schnellmann et al., 2006), respectively; however, these 
homologues were not components of an SCCmec element, or a mec complex. 
 
Based on the available data, it was predicted that the origin of mecA would be traced 
to a close relative of S. sciuri and S. vitulinus.  Staphylococcus fleurettii, an animal 
commensal belonging to the S. sciuri species group, was recently identified as the 
origin of mecA (Tsubakishita et al., 2010).  The nucleotide identities shared by mecA 
homologues detected in S. fleurettii strains and the MRSA strain N315 ranged from 















revealed that the mecA locus in this organism is highly similar to the prototypic class 
A mec complex.  It appears that S. fleurettii, S. sciuri and S. vitulinus acquired mecA 
from a common ancestor, and that the gene underwent molecular differentiation after 
these species diverged, resulting in the three alleles observed today.  At present, the 
origin of the SCCmec element remains unknown, but it seems likely that it arose 
when the S. fleurettii-derived mec complex fused with a mecA-negative SCC 
element.  It is possible that this process occurs frequently, and that novel SCCmec 
elements are produced on a regular basis.  Alternatively, SCCmec may have 
emerged on a limited number of occasions with subsequent genetic diversification 
generating the wide variety of SCCmec elements described to date (Tsubakishita et 
al., 2010).   
 
Although the origins of SCCmec are currently under debate, it is widely accepted that 
the CNS represent a reservoir of SCCmec elements (Hiramatsu et al., 2001; 
Hanssen and Ericson Sollid, 2006; de Lencastre et al., 2007; Garza-González et al., 
2010).  Several observations support this hypothesis, including the fact that SCCmec 
elements are more prevalent, and more diverse, in CNS than S. aureus (Garza-
González et al., 2010).  Other evidence cited in support of the hypothesis includes 
the fact that there has been species-independent conservation of certain ccr genes 
(Garza-González et al., 2010), and also that the insertion sequence IS1272 found in 
the class B mec complex [1.5.3.1] is more commonly described in S. haemolyticus 
and S. epidermidis than in S. aureus, suggesting that these elements may have been 
transferred from the CNS species to S. aureus (Hiramatsu et al., 2001; Hanssen and 
















1.6 S. aureus epidemiology 
It  has  long  been  acknowledged   that,  in   order  to   control  a  pathogen  such  as 
S. aureus, it is prerequisite to obtain an understanding of its epidemiology, population 
genetics and evolution (Aires-de-Sousa and de Lencastre, 2004; Deurenberg and 
Stobberingh, 2008; Robinson et al., 2010).  Given that S. aureus is an important 
pathogen in both hospitals and communities, it is crucial to have accurate and 
reliable epidemiological tools available for use during outbreak investigations 
(Shopsin and Kreiswirth, 2001; Oliveira et al., 2002; Aires-de-Sousa and de 
Lencastre, 2004).  Additionally, epidemiological data is essential for the evaluation 
and modification of existing antibiotic prescription guidelines and infection control 
practices in the pursuit of controlling S. aureus dissemination (van Belkum et al., 
2009). 
 
Early S. aureus epidemiological studies were reliant upon phenotypic typing 
techniques; however, advances in molecular biology have led to the development of 
several new techniques that have revolutionised the field of S. aureus epidemiology 
(Oliveira et al., 2002; Aires-de-Sousa and de Lencastre, 2004).  S. aureus typing is 
no longer based on phenotypic methods, but rather on genotypic methods that are 
able to detect underlying genetic variation (Aires-de-Sousa and de Lencastre, 2004; 
van Belkum et al., 2009).  Over the past few decades, a global emphasis on the 
importance of S. aureus molecular epidemiology has led to the development of 
numerous band- and DNA sequence-based genotypic techniques (Shopsin and 
Kreiswirth, 2001; Aires-de-Sousa and de Lencastre, 2004; Smyth and Robinson, 
2010).  Band-based genotypic techniques require visual comparisons of restriction 
patterns or PCR amplification profiles to determine the relatedness of isolates.  
These methods indirectly detect underlying genetic variation that occurs in the form 
of restriction enzyme recognition sequences or primer-binding sites (Shopsin and 
Kreiswirth, 2001; Smyth and Robinson, 2010).  Due to their shortcomings, the 
popularity of band-based techniques has waned over the years, and these methods 
have largely been replaced by DNA sequence-based techniques (Aires-de-Sousa 
and de Lencastre, 2004; Deurenberg and Stobberingh, 2008).  Reasons for the 
transition from band- to sequence-based typing techniques will be discussed further 
















The inclusion of particular typing techniques in an epidemiological study is primarily 
dependent on the questions to be addressed (Aires-de-Sousa and de Lencastre, 
2004; Cookson et al., 2007; van Belkum et al., 2009).  The available methods have 
varying powers of discrimination as they index genetic variation that accumulates at 
different rates; therefore some techniques are best suited to local or short-term 
epidemiology, while others are better suited to global or long-term epidemiology, 
while others still provide information valuable to either type of study (Deurenberg and 
Stobberingh, 2008; van Belkum et al., 2009).  Additional factors that may be 
considered when selecting molecular typing methods include cost, time to result and 
whether the technique is to be used in a clinical or research laboratory (Aires-de-
Sousa and de Lencastre, 2004).  Molecular typing techniques popular worldwide for 
the characterisation of S. aureus isolates include pulsed-field gel electrophoresis, 
SCCmec typing and subtyping, multilocus sequence typing, and spa typing (Aires-de-
Sousa and de Lencastre, 2004; Deurenberg and Stobberingh, 2008; van Belkum et 
al., 2009).  A brief overview of the major techniques currently used in S. aureus 
molecular epidemiology will be provided here, while more detailed descriptions of the 
methods used in this study will be included in subsequent chapters. 
 
1.6.1 Pulsed-field gel electrophoresis 
Pulsed-field gel electrophoresis (PFGE) is a highly discriminatory band-based typing 
technique, which indexes variation that accumulates rapidly throughout the S. aureus 
genome (Spratt, 1999; Deurenberg and Stobberingh, 2008; van Belkum et al., 2009).  
Briefly, PFGE involves the comparison of macrorestriction patterns that are 
generated after pulsed-field gel electrophoresis is used to separate the large DNA 
fragments produced by restriction enzyme digestion of intact chromosomal DNA 
(Schwartz and Cantor, 1984; Trindade et al., 2003).  A more detailed description of 
the technique is provided in Chapter 2 [2.1].  PFGE is one the oldest genotypic 
techniques, but is still commonly used in studies concerned with local or short-term 
epidemiology (Deurenberg and Stobberingh, 2008).  The method has remained 
popular because of its utility in outbreak investigations, and in studies tracing 
hospital-to-hospital transmission (Struelens et al., 1992; Cookson et al., 2007; 
















1.6.2 SCCmec typing and subtyping 
Information regarding the SCCmec content of MRSA isolates can be valuable in both 
local and global epidemiological studies.  A variety of PCR-based SCCmec typing 
and subtyping assays have been developed, with the choice of method dependent on 
the epidemiological questions to be addressed (Aires-de-Sousa and de Lencastre, 
2004; de Lencastre et al., 2007; Deurenberg and Stobberingh, 2008).  The most 
popular SCCmec typing and subtyping assays are multiplex PCRs, which include 
primers for the detection of SCCmec type- or subtype-specific loci, resulting in 
unique, easily identifiable amplification patterns after the PCR products are 
separated by agarose gel electrophoresis (de Lencastre et al., 2007).  Further 
information on techniques that are currently popular for SCCmec typing and 
subtyping is provided in Chapter 3 [3.1]. 
 
1.6.3 Multilocus sequence typing 
Multilocus enzyme electrophoresis (MLEE) was one of the first molecular typing 
techniques used in studies investigating the global epidemiology of S. aureus (Spratt, 
1999; Smyth and Robinson, 2010).  MLEE indirectly indexes variation that 
accumulates in housekeeping genes by examining the electrophoretic mobilities of 
their products.  Multilocus sequence typing (MLST) represents an extension of MLEE 
that was made possible by advances in DNA sequencing, and catalogues underlying 
genetic variation that accumulates within seven housekeeping genes (Spratt, 1999).  
In MLST, internal fragments of the seven housekeeping genes are amplified by PCR, 
sequenced  directly,  and  compared  to  existing  sequences  present  in  the  online 
S. aureus MLST database (http://saureus.mlst.net/).  The isolate‘s sequence type 
(ST) is then determined, based on the combination of housekeeping alleles present, 
and is identified by a unique number (Maiden et al., 1998; Spratt, 1999; Enright et al., 
2000).  A more comprehensive description of MLST can be found in Chapter 5 [5.1]. 
 
The eBURST algorithm, a revised version of the BURST (based upon related 
sequence types) algorithm, was developed to detect relationships between STs, and 
is freely available on the MLST website (http://saureus.mlst.net/eburst/) (Feil et al., 
2004; Aanensen and Spratt, 2005).  The algorithm groups STs into clonal complexes 
(CCs); a CC includes all strains that share at least six of the seven MLST loci with 















Enright, 2004; Feil et al., 2004).  In most cases, it is possible to assign a putative 
founding genotype to a CC, which is defined as the ST with the most single locus 
variants (SLVs).  The larger CCs commonly contain a number of SLVs and double 
locus variants (DLVs) that have become dominant within particular regions, forming 
subgroups with their own SLVs and DLVs (Feil et al., 2004).  As MLST indexes 
genetic variation that accumulates slowly over time, the technique is useful for the 
detection of underlying relationships between isolates; therefore MLST and the 
eBURST algorithm have proved invaluable in global or long-term epidemiological 
studies, as described later in this chapter [1.7] (Spratt, 1999; Deurenberg and 
Stobberingh, 2008; van Belkum et al., 2009; Lindsay, 2010). 
 
1.6.4 spa typing 
In recent years, spa typing, a single-locus sequence-based method, has become 
increasingly popular for use in S. aureus epidemiological investigations.  It has been 
shown that spa typing has a discriminatory power between that of PFGE and MLST 
and can be used for studying both local and global S. aureus epidemiology [5.1] 
(Deurenberg and Stobberingh, 2008).  The technique also has the advantage of 
being less expensive than MLST and less laborious than either MLST or PFGE.  In 
brief, spa typing entails PCR amplification and direct sequencing of the hypervariable 
X-region of spa, which encodes protein A (Frénay et al., 1996; Shopsin et al., 1999; 
Shopsin and Kreiswirth, 2001; Harmsen et al., 2003).  The X-region is comprised of 
repeats [5.1] and variation arises due to duplications and deletions of these repeats, 
as well as point mutations (Harmsen et al., 2003).  Ridom StaphType, a software 
package for the analysis of spa sequencing data, has become popular worldwide for 
the rapid assignment of spa types [5.1] (Deurenberg and Stobberingh, 2008).  The 
software package is linked to well-curated online database to ensure that the 
universal nomenclature is maintained, and also to facilitate inter-laboratory 
comparisons and data sharing (Harmsen et al., 2003; Deurenberg and Stobberingh, 
2008). Additional details on spa typing and Ridom StaphType are available in 
Chapter 5 [5.1]. 
 
As for MLST, it is possible to carry out cluster analyses to define spa clonal 
complexes (spa-CCs) using the BURP (based upon repeat pattern) algorithm in 















between spa-CCs identified using the BURP algorithm and those identified using 
MLST and the eBURST algorithm (Strommenger et al., 2006a; Cookson et al., 2007; 
Hallin et al., 2007; Mellmann et al., 2008); however, this approach may, at times, lack 
discriminatory power (Deurenberg and Stobberingh, 2008; Strommenger et al., 
2008).  It has been suggested that spa typing be used in conjunction with other 
molecular typing tools in order to obtain the most accurate description of S. aureus 
epidemiology (Hallin et al., 2007; Strommenger et al., 2008). 
 
1.6.5 Other techniques currently available for S. aureus epidemiology 
In addition to the techniques described above for S. aureus typing, many more have 
been developed recently and are increasing in popularity.  One example is dru 
typing, a single-locus sequence-based technique that indexes variation within the 
SCCmec-associated series of imperfect direct repeat units present in most MRSA 
isolates [5.1] (Goering et al., 2008a).  The technique is becoming increasingly 
popular because of its ability to subtype isolates indistinguishable by PFGE, 
providing a degree of resolution that is important during outbreak investigations 
(Goering et al., 2008a; Shore et al., 2010).  There has also been a move to update 
multilocus variable-number tandem repeat analysis (MLVA), a band-based typing 
method (van Belkum et al., 2009).  Groups have updated MLVA by using software 
packages to estimate PCR product size after agarose gel electrophoresis (Pourcel et 
al., 2009), or by using an automated DNA sequencer to determine the sizes of 
fluorescently labelled amplicons (Schouls et al., 2009).  It has been suggested that 
methods based on MLVA will, like dru typing, aid in the differentiation of isolates 
indistinguishable by PFGE (Holmes et al., 2010). 
 
Further advances in DNA sequencing technologies have led to the development of 
new typing methods, which have the potential to once again revolutionise the field of 
S. aureus epidemiology (van Belkum et al., 2009; Lindsay, 2010).  A recent study 
demonstrated the value of whole genome sequencing in S. aureus epidemiological 
studies by examining the fine-scale transmission of a particular MRSA clone within a 
Thai hospital (Harris et al., 2010).  The same study indicated the value of whole 
genome sequencing for global MRSA epidemiology.  The increasing availability of 
whole genome data has also aided the development of multi-strain DNA microarrays 















DNA microarray genotyping remain expensive; therefore these technologies are 















1.7 The population genetics and evolution of S. aureus 
The field of bacterial population genetics is, in part, concerned with describing the 
phylogenies or natural groups or lineages that have descended from a unique 
common ancestor within a particular species.  This information serves as the 
framework for evolutionary hypotheses explaining the patterns of descent and the 
accumulation of genetic variation within the given population (Smyth and Robinson, 
2010).  A detailed understanding of a pathogen‘s population structure and evolution 
is important as it may be used to mitigate the disease burden caused by the 
organism.  For instance, the identification of dominant bacterial lineages and their 
associated pathogenic characteristics and molecular markers may be valuable when 
investigating new therapeutic targets or diagnostic markers.  Similarly, a pathogen‘s 
population structure may provide information regarding its spread that can be used to 
prevent further dissemination.  Additionally, this type of information can be used to 
predict how a pathogen may evolve in the future, thereby providing a tactical 
advantage in the ongoing battle between humans and bacteria (Lyndsay, 2010; 
Smyth and Robinson, 2010; Robinson et al., 2010).   
 
1.7.1 The population structure of S. aureus 
Given the propensity of S. aureus to cause infections in the hospital setting, an 
understanding of its population genetics and evolution has been pursued for decades 
in the hope of controlling thi  pathogen (Smyth and Robinson, 2010).  Progress in the 
field was initially hampered by the lack of appropriate techniques; however, 
remarkable progress has been made in the past decade due to the development of 
molecular typing methods, as well as the advent of whole genome sequencing and 
comparative genomic microarrays (Lindsay, 2010; Smyth and Robinson, 2010). 
 
As mentioned previously, MLST is well-suited to the detection of underlying genetic 
relationships between apparently unrelated isolates obtained over extended time 
periods or great geographical distances (Spratt, 1999; Deurenberg and Stobberingh, 
2008).  Enright et al. (2002) used MLST and the eBURST algorithm to provide the 
first detailed DNA sequence-based description of the S. aureus population structure.  
The strain collection characterised by Enright et al. (2002) included 912 S. aureus 
isolates obtained from 20 countries between 1961 and 1999.  The study has since 















website  (http://saureus.mlst.net/), thus providing a more detailed description of  the 
S. aureus population structure.   As of December 2010, an eBURST analysis of the 
S. aureus MLST database detected forty-two major CCs, as well as eighteen minor 
CCs lacking putative ancestral STs, and two hundred and forty-six singleton STs not 
associated with a CC (http://saureus.mlst.net/eburst/).  Of the known S. aureus CCs, 
CC1, CC5, CC8, CC9, CC12, CC15, CC22, CC25, CC30, CC45 and CC51 have 
been identified as major lineages relevant in humans (Lindsay, 2010; McCarthy and 
Lindsay, 2010). 
 
Subsequent studies have examined the relatedness of S. aureus lineages and have 
shown that the extant CCs can be separated into two groups, both containing 
clinically important and widely disseminated clones (Robinson and Enright, 2003; 
Cooper and Feil, 2006; Smyth and Robinson, 2010).  It has been suggested that 
different evolutionary processes may have moulded these two groups, but further 
studies are required for confirmation (Smyth and Robinson, 2010).  Also of interest in 
these studies were two CCs that did not fall into either subgroup: CC152 and CC75 
(Smyth and Robinson, 2010).  CC152 represents a divergent lineage predominant in 
Mali (Ruimy et al., 2008), while CC75 is thought to represent an ancestral S. aureus 
lineage confined to Australia (Ng et al., 2009; Smyth and Robinson, 2010). 
 
1.7.2 The   population   structure    and    evolution   of   methicillin-resistant 
S. aureus: focusing on healthcare-associated lineages 
In 1993 it was proposed that all extant MRSA arose from a single MSSA ancestor 
that had acquired SCCmec (Kreiswirth et al., 1993).  Almost ten years later, the 
MLST-based study carried out by Enright et al. (2002) overturned the single-clone 
hypothesis.  This study, and that of Robinson and Enright (2003), provided the first 
detailed description of the population structure and evolution of hospital-associated 
MRSA (HA-MRSA) lineages.  Robinson and Enright (2003) supplemented MLST with 
sas typing (a multilocus sequence typing method that indexes variation within seven 
S. aureus surface associated proteins) and spa typing to show that SCCmec had 
been acquired, and in some cases re-acquired, on at least twenty occasions by a 
limited number of S. aureus lineages, namely CC5, CC8, CC22, CC30 and CC45.  
Further support for the multi-clone hypothesis was provided by Fitzgerald et al. 















least five occasions by different lineages.  Early studies also showed that SCCmec 
was typically acquired by MSSA lineages already successful in the hospital setting 
(Gomes et al., 2006).  These lineages appeared to possess some genetic advantage 
prior to the acquisition of the methicillin resistance determinant; however, certain 
lineages, such as ST239 of CC8, have become increasingly successful subsequent 
to the acquisition of SCCmec (Lyndsay, 2010). 
 
Enright et al. (2002) found that, although epidemic MRSA (EMRSA) clones dominant 
in distant regions over a period of nearly forty years were distinguishable by PFGE, 
several clones in fact shared the same ST and SCCmec type, suggesting underlying 
genetic relationships.  These findings, supported by the work of Robinson and 
Enright (2003), suggested that several major EMRSA clones arose from a common 
ancestor, and have since been disseminated worldwide.  Table 1.2 provides an 
overview of important pandemic HA-MRSA clones, indicating those that are thought 
















Table 1.2 An overview of important hospital-associated methicillin-resistant 








Common names Geographical distribution
c
 
ST5-MRSA-I 5 UK-EMRSA-3 
Arg, Den, Ger, Jap, Nor, Par, Pol, 





Ast, Bel, Can, Chn, Den, Fin, Fra, 
Ger, Hun, Ire, Isr, Jap, Kor, Mex, 
Nor, Por, SA, Sin, Swe, Swi, Tai, 




Alg, Arg, Ast, Aus, Bra, Col, Den, 
Fin, Fra, Ger, Gre, Kor, Nor, Pol, 




Aus, Bel, Den, Fin, Ger, Hun, Ita, 
Pol, Slo, Spa, Swi  





Ast, Aus, Bel, Can, Den, Fin, Fra, 
Ger, Hun, Ire, Isr, Jap, Net, Nor, 








Alg, Arg, Ast, Aus, Bra, Can, Chi, 
Chn, Cze, Den, Fin, Ger, Gre, Hun, 
Ind, Ids, Kor, Mon, Net, Nor, Par, 
Pol, Por, RoG, Rus, SA, Sin, Slo, 
Spa, Sri, Swe, Tai, Tha, UK, Uru, 
USA, Vie 
ST247-MRSA-I 8 Iberian 
Aus, Bel, Cro, Cze, Den, Fin, Fra, 
Ger, Hun, Isr, Ita, Net, Nor, Pol, 
Por, Slo, Spa, Swe, Swi, UK, USA 
ST250-MRSA-I 8 Archaic 





Ast, Aus, Bel, Can, Chn, Cze, Den, 
Fin, Ger, Hun, Ire, Kuw, Mal, NZ, 




Arm, Ast, Aus, Bel, Chn, Den, Fin 





Ast, Aus, Bel, Can, Den, Fin, Ger, 
Gre, Ire, Mex, Nor, Por, Spa, Swe, 
Swi, UK, USA 
a
 Adapted from Deurenberg and Stobberingh (2008); Gordon and Lowy (2008); Witte et al. (2008). 
b
 Clone name as determined using the universal nomenclature proposed by Enright et al. (2002) 
following the form (Sequence Type-methicillin resistance phenotype-SCCmec type). 
c
 Alg, Algeria; Arg, Argentina; Arm, Armenia; Ast, Australia; Aus, Austria; Bel, Belgium; Bra, Brazil; 
Can, Canada; Chi, Chile; Chn, China; Col, Columbia; Cro, Croatia; Cze, Czech Repubic; Den, 
Denmark; Fin, Finland; Fra, France; Ger, Germany; Gre, Greece; Hun, Hungary; Ind, India; Ids, 
Indonesia; Ire, Ireland; Isr, Israel; Jap, Japan; Kor, Korea; Kuw, Kuwait; Mal, Malta; Mon, Mongolia; 
Net, Netherlands; NZ, New Zealand; Nor, Norway; Par, Paraguay; Pol, Poland; Por, Portugal; RoG, 
Republic of Georgia; Rus, Russia; SA, Saudi Arabia; Sin, Singapore; Slo, Slovenia; Spa, Spain; Sri, 
Sri Lanka; Swe, Sweden; Swi, Switzerland; Tai, Taiwan; Tha, Thailand; Tur, Turkey; Uga, Uganda; 















Historically, EMRSA clones were named according to their geographical origins.  
Given that many EMRSA clones appear to share common ancestors, this somewhat 
arbitrary system has been replaced with a universal nomenclature (Enright et al., 
2002).  The revised nomenclature is based on an isolate‘s ST and SCCmec type, 
and also indicates whether the isolate is MSSA, MRSA or glycopeptide intermediate 
S. aureus (GISA).  For example, the Archaic clone, which corresponds to ST250 and 
carries SCCmec type I, is described as ST250-MRSA-I using the universal 
nomenclature.  Table 1.2 includes the revised universal nomenclature, as well as the 
common names, of important HA-MRSA clones.  The universal nomenclature is now 
widely used, making underlying relationships between clones more apparent.  This is 
well illustrated by the ST239-MRSA-III clone, which corresponds to the former 
Brazilian, Hungarian and Portuguese clones.  These clones were responsible for 
MRSA epidemics in their respective countries and have certain distinguishing 
molecular characteristics, but in fact share a common ancestor (Enright et al., 2002; 
Robinson and Enright, 2003; Harris et al., 2010).   
 
The results of the studies discussed above suggested that the worldwide prevalence 
of MRSA is due to the dissemination of a limited number of highly successful 
pandemic clones.  MLST does, however, only monitor genetic diversity within a very 
small portion of the S. aureus genome (approximately 3.2kb) (Enright et al., 2000).  A 
more recent study examining variation within a larger proportion of the genome 
(46kb) has suggested that MRSA evolution may be more complex than MLST-based 
studies suggested (Nübel et al., 2008).  Nübel et al. (2008) showed that, in the case 
of ST5, the frequency of SCCmec acquisition has been underestimated, and ST5-
MRSA lineages have emerged on numerous occasions in distinct geographical 
locations.  Further studies are required to determine whether the same is true of 
other MRSA lineages but, if this is the case, it may be necessary to revise the 
existing nomenclature to include the region of origin in to distinguish different 
subpopulations within a given clonal type.   
 
Although the results reported by Nübel et al. (2008) are interesting, the contribution 
of dissemination to the global prevalence of MRSA cannot be dismissed.  Recent 
studies investigating the population structure of ST239-MRSA-III have indicated that 















prevalence (Smyth et al., 2009; Gray et al., 2010; Harris et al., 2010).  As mutation 
discovery and comparative genomics become more accessible, the relative 
contributions of dissemination and local emergence to the global MRSA population 
structure will gradually be resolved. 
 
1.7.3 The evolution of community-associated methicillin-resistant S. aureus 
(MRSA) and companion animal- and livestock-associated MRSA 
Although MRSA first emerged in the hospital setting, there have been increasingly 
frequent reports of CA-MRSA since the 1990s (Deurenberg and Stobberingh, 2008; 
DeLeo et al., 2010).  CA-MRSA tends to infect previously healthy individuals without 
prior healthcare exposure or other risk factors for MRSA infection and outbreaks 
commonly occur among individuals in the military, prisoners, athletes involved in 
contact sports, certain indigenous populations (Native Americans, Pacific Islanders 
and Aborigines), men who have sex with men, children in day-care centres and 
intravenous drug users (Millar et al., 2007; Deurenberg and Stobberingh, 2008; 
DeLeo et al., 2010).  CA-MRSA isolates are typically distinguished by distinctive 
molecular characteristics: they are generally susceptible to non-β-lactam antibiotics, 
carry SCCmec types IV, V and VII, are often associated with the PVL toxin, and 
generally belong to genetic lineages distinct from HA-MRSA clones [4.1] (Millar et al., 
2007; Deurenberg and Stobberingh, 2008).  These strains have gradually been 
introduced into hospitals and, similarly, HA-MRSA clones have been introduced into 
communities [4.1].  As a result, HA-MRSA and CA-MRSA can now be acquired in the 
hospital or community settings (Millar et al., 2007; Deurenberg and Stobberingh, 
2008; Elston and Barlow, 2009; Witte, 2009). 
 
As mentioned previously in this chapter, S. aureus is also a major veterinary 
pathogen (Witte et al., 2008; Ben Zakour et al., 2008; Witte, 2009).  Companion 
animals are commonly colonised or infected with MRSA, and these strains typically 
belong to the major human HA-MRSA lineages previously mentioned in this chapter 
[1.7.2], suggesting transmission within the household setting (Strommenger et al., 
2006b; Pantosti and Venditti, 2009; van Belkum et al., 2009).  Given their zoonotic 
potential and economic importance, there is also an increasing emphasis on the 
study of the evolution of livestock-associated MRSA (LA-MRSA) (Ben Zakour et al., 















ST5, which has been isolated from poultry (McCarthy and Lindsay, 2010), while other 
genotypes appear to be restricted to certain hosts, such as the bovine lineages 
CC97, CC130, CC151, CC188 and CC771, or the ST398 genotype, which represents 
a major coloniser of pigs, but is seldom detected in humans (Witte et al., 2008; Witte, 
2009; Lindsay, 2010; McCarthy and Lindsay, 2010; Smyth and Robinson, 2010).  In 
this context, host adaptation, and the effects of recent changes in agricultural 
practices and animal husbandry on the evolution and population structure of LA-
MRSA, is of ongoing interest. 
 
CA- and LA-MRSA strains both represent an emerging threat to public health with 
potential for major economic repercussions; therefore, it is important to attempt to 
obtain a greater understanding of the evolution of and population structure of these 
MRSA subgroups, as different strategic approaches may be required for their control 
(van Belkum et al., 2009). 
 
1.8 Study relevance, aims and objectives 
As emphasised above, comprehensive local epidemiological data are prerequisite for 
the development of effective antibi tic prescription policies and infection control 
guidelines that will ultimately result in the control of MRSA within the hospital setting.  
In the global context, studies on S. aureus molecular epidemiology have provided 
valuable preliminary data that have served as a foundation for more extensive 
studies on the evolution and population structure of certain clones.  It is envisioned 
that   an  improved  understanding  of  the  population  structure  and  evolution   of 
S. aureus, particularly MRSA, will alleviate the global disease burden caused by this 
organism. 
 
At the onset of this study, a limited number of studies investigating the epidemiology 
of MRSA from Africa had been carried out, and the field was in its infancy in South 
Africa.  To the best of the author‘s knowledge, the only molecular epidemiological 
data on MRSA from South Africa available at the time was presented at the 17th 
European Congress of Clinical Microbiology and Infectious Diseases in Munich, 
Germany, in 2007.  That study included only spa typing and SCCmec typing, but no 















communities (Oosthuysen et al., 2007).  The field has, however, grown during the 
course of the current study as evidenced by the publication of a number of reports 
describing aspects of the molecular epidemiology of MRSA from South Africa (Essa 
et al., 2009; Shittu et al., 2009; Makgotlho et al., 2009; Moodley et al., 2010), which 
will be discussed in detail later in this thesis.  Nevertheless, there remained a paucity 
of data on MRSA circulating in hospitals in Cape Town, in the Western Cape 
province of South Africa. 
 
1.8.1 Study aim 
The primary aim of this study was to describe the epidemiology of MRSA circulating 
in Cape Town hospitals by performing a molecular characterisation of one hundred 
isolates obtained from local hospitals between January 2007 and December 2008. 
 
1.8.2 Study objectives 
 Describe the local epidemiology of MRSA from hospitals in Cape Town using 
PFGE, SCCmec typing and subtyping, and analyse the data in conjunction 
with the laboratory data provided by the National Health Laboratory Service. 
 Describe the epidemiology of MRSA from hospitals in Cape Town within the 
context of global MRSA epidemiology using a combination of multilocus 
















The Epidemiology of Methicillin-Resistant S. aureus from 
Hospitals in Cape Town 
 
2.1 Introduction 
Between  January  2004  and  June  2010,   MRSA  was  responsible  for  42.16 %  
of S. aureus bacteremias identified by the National Health Laboratory Service 
(NHLS) microbiology laboratory based at Groote Schuur Hospital, which serves five 
public hospitals in Cape Town (A. Whitelaw, unpublished data).  In comparison to 
previous  reports from South Africa  (Bell et al., 2002; Bouchillon et al., 2004;  Zinn  
et al., 2004; Perovic et al., 2006; Shittu and Lin, 2006; Brink et al., 2007) and other 
countries worldwide (Grundmann et al., 2006), this figure suggests a relatively high 
prevalence of MRSA in hospitals in Cape Town; therefore, the aim of this study was 
to obtain a comprehensive understanding of the epidemiology of MRSA from local 
hospitals.  One of the methods employed to achieve this was pulsed-field gel 
electrophoresis (PFGE).  PFGE is a highly discriminatory molecular typing technique 
that is currently considered the gold standard for S. aureus epidemiological 
investigations, particularly for those concerned with local epidemiology (Spratt, 1999; 
Deurenberg and Stobberingh, 2008; Struelens et al., 2009; van Belkum et al., 2009). 
 
PFGE was developed by Schwartz and Cantor (1984), and has since been adapted 
for many organisms, including S. aureus (Ichiyama et al., 1991).  The method entails 
the lysis of bacteria within an agarose plug in order to obtain intact chromosomal 
DNA.  The DNA is digested with a restriction enzyme that cleaves the bacterial 
chromosome infrequently, generating between twelve and twenty high molecular 
weight fragments, which are separated on an agarose gel by pulsed-field gel 
electrophoresis (Schwartz and Cantor, 1984; Ichiyama et al., 1991; Trindade et al., 
2003).  The resulting macrorestriction profiles are visualised and the levels of 
similarity between isolates can be assessed manually using the Tenover criteria 
(Tenover et al., 1995), or with a software package, such as GelCompar II by Applied 
















Despite developments in DNA sequence-based typing techniques, PFGE remains 
the method of choice for MRSA outbreak investigations worldwide (Deurenberg and 
Stobberingh, 2008).  Since 2005, PFGE has been used to investigate nosocomial 
outbreaks in neonatal and paediatric units in France (El Helali et al., 2005), Italy 
(Bertini et al., 2006) and Taiwan (Lin et al., 2007).  In all three cases, PFGE 
confirmed a nosocomial outbreak and the epidemiological data were used to inform 
intervention strategies.  This approach has also been used in community-based 
epidemiological investigations, as was reported after outbreaks of an epidemic 
MRSA clone, known as USA300, among prisoners and professional athletes in the 
USA during 2002 and 2003, respectively (Kazakova et al., 2005; Turabelidze et al., 
2006). 
 
In addition to being widely used for outbreak investigations, PFGE has also been 
used to monitor the composition of MRSA clones within a particular hospital, country 
or region (Struelens et al., 2009).  Using PFGE, Trzciński et al. (1997) showed that 
two MRSA clones were dominant across four hospitals in Warsaw, Poland, between 
1991 and 1994.  In a similar study, Teixeira et al. (1995) used PFGE to show that 
one particular MRSA clone had become dominant across six distant Brazilian 
hospitals during the 1990s.  PFGE also proved useful for marking changes in the 
composition of MRSA clones in Portugal during the 1990s when the technique was 
used to document the emergence of the Brazilian clone in three Portuguese hospitals 
(Aires-de-Sousa et al., 1998).  On a larger scale, PFGE was used to show that the 
Iberian, EMRSA-15 and EMRSA-16 clones were present throughout Europe 
















2.2 Experimental Protocol 
2.2.1 Bacterial isolates and collection data 
One hundred clinical MRSA isolates, collected between January 2007 and December 
2008, were included in this study.  These isolates represented 13.6 % of all MRSA 
isolated during the collection period by the NHLS microbiology laboratory based at 
Groote Schuur Hospital.  The isolates were collected randomly, without duplication, 
from patients at 5 hospitals linked to the University of Cape Town (UCT) academic 
complex, namely Groote Schuur Hospital (GSH, n = 51), Red Cross War Memorial 
Children‘s Hospital (RCCH, n = 21), Mowbray Maternity Hospital (MMH, n = 19), UCT 
Private Academic Hospital (UCTPH, n = 5) and Victoria Hospital (VH, n = 4).  The 
available laboratory data for all study isolates can be found in Appendix A. 
 
The isolates were obtained from patients in various wards, including intensive care 
units  (n  =  23),  surgical (n  =  23), medical (n  =  16), obstetrics  and  gynaecology 
(n = 16), outpatient clinics (n = 15), and emergency services (n = 4).  The clinical 
request form did not specify a ward for 3 of the isolates.  The proportions of isolates 
from the included hospitals reflected the proportions of MRSA isolated from patients 
at each hospital.  The isolates were cultured from a variety of specimens including 
pus and pus swabs (n  =  64), respiratory tract specimens  (n  =  13), urine (n = 9), 
central venous catheter tips (n = 7) and blood (n = 7).  These proportions of 
specimen types were representative of those from which all MRSA was cultured 
during the collection period. 
 
2.2.2 Isolate identification and antimicrobial susceptibility testing 
Isolate identification and antimicrobial susceptibility testing was carried out by the 
staff  of  the  NHLS  microbiology  laboratory  at  GSH.    Isolates  were  identified  as 
S. aureus either by the VITEK 2 (BioMerieux, Marcy l‘Etoile, France) or by a positive 
DNase test. Antimicrobial susceptibility testing was carried out by disc diffusion 
(Oxoid Ltd, Basingstoke, UK), E-test strips (AB Biodisk, Solna, Sweden), or on the 
VITEK 2 for the following antimicrobial agents: penicillin, cloxacillin, erythromycin, 
clindamycin, rifampicin, co-trimoxazole, ciprofloxacin, gentamicin, fusidic acid and 
vancomycin.  The choice of method was determined by the standard operating 















were interpreted according to Clinical Laboratory Standards Institute guidelines 
(Clinical Laboratory Standards Institute, 2007; Clinical Laboratory Standards Institute, 
2008). 
 
2.2.3 Pulsed-field gel electrophoresis 
The method described by Reed et al. (2007) was optimised for use in this study. 
 
2.2.3.1 Isolate sub-culture 
All isolates were sub-cultured from 25 % glycerol stocks.  An inoculum was streaked 
for single colonies on a BBA plate (NHLS, Cape Town, South Africa) and incubated 
aerobically at 37°C overnight. 
 
2.2.3.2 Preparation of agarose plugs 
Cell suspensions were prepared by re-suspending a sweep of colonies in 2 ml of 
TEN Buffer (Appendix B).  One millilitre of cell suspension was standardised to an 
OD600 reading that ranged between 0.825 and 0.875 using a Biomate 5 
spectrophotometer (Thermo Scientific, Waltham, MA, USA).  Standardisation of the 
bacterial suspensions ensured that a uniform amount of DNA was obtained for each 
isolate, thereby increasing the accuracy of the final comparison of macrorestriction 
profiles. 
 
To weaken the bacterial cell wall, 5 µl of lysostaphin (1 mg/ml) (Sigma Aldrich, Inc., 
St Louis, MO, USA) was added to a 250 µl aliquot of standardised cell suspension, 
followed by 250 µl of molten 2 % SeaKem Gold agarose (Cambrex Bio Science 
Rockland, Inc., Rockland, ME), which had been equilibrated at 60°C for 10 min.  The 
mixture was then transferred into sealed plug moulds and the plugs were allowed to 
solidify at 4°C for 10 min.  Any excess agarose was removed using a surgical blade, 















2.2.3.3 Bacterial lysis 
In order to obtain intact chromosomal DNA, in situ lysis of S. aureus was carried out 
as follows: two millilitres of EC Buffer (Appendix B), pre-warmed to 37°C, was added 
to cover the agarose plugs, which were incubated at 37°C for 4 h to allow digestion 
of the cell wall and membrane to proceed.  The EC Buffer was replaced with an 
equal volume of ESP Buffer (Appendix B), and the disruption of the cell wall and 
membrane, as well as the degradation of cellular proteins, was facilitated by 
incubation at 55°C for 16 h.   
 
After the 16 h incubation period, the plugs were transferred to sterile universal 
bottles.  A volume (10 ml) of TE Buffer (Appendix B) was added and the plugs were 
washed on a compact rocker CR300t (FINEPCR, Gunpo-si, South Korea) for 30 min 
at 35 rpm.  The TE buffer was decanted and the wash was repeated 4 times with 
fresh TE buffer.  After the fourth wash, the protocol was either stopped by storing the 
plugs in TE Buffer at 4°C, or was continued by proceeding with the restriction 
enzyme digest. 
 
2.2.3.4. SmaI restriction enzyme digest 
The intact chromosomal DNA obtained after bacterial lysis was digested with the 
restriction enzyme SmaI, which cleaves the S. aureus chromosome infrequently, 
producing  between 12 and 20 fragments,  which is ideal for comparison  (Ichyama  
et al., 1991; Reed et al., 2007).   
 
A section (width, 5mm; height, 2mm; depth, 1mm) was trimmed from each agarose 
plug in preparation for the restriction enzyme digest.  The chromosomal DNA was 
digested with 30U SmaI (Roche Diagnostics GmbH, Mannheim, Germany) in a final 
volume of 125 µl, with 1 µl BSA (Roche Diagnostics GmbH, Mannheim, Germany), 
using the buffer supplied by the manufacturer at a 1X final concentration.  The digest 















2.2.3.5 Preparation of the agarose gel and electrophoresis buffer 
A volume (150 ml) of 1 % pulsed-field certified ultra pure DNA grade agarose 
(BioRad Laboratories, Inc, Hercules, CA, USA) was prepared with 0.5X TBE buffer 
(Appendix B) and equilibrated at 60°C for 10 min.  The agarose was poured into the 
gel mould and allowed to set at room temperature for 2.5 h.  Two and a half litres of 
0.5X TBE buffer was poured into the chamber of the electrophoresis apparatus.  The 
cooling unit was set to 14°C and the pump was turned on to allow the buffer to 
circulate and cool for 2 h prior to electrophoresis. 
 
2.2.3.6 Sample loading 
The first and last 3 lanes of each gel were not used due to poor migration in these 
regions.  The Lambda Ladder PFG Marker (New England BioLabs, Inc, Ipswich, MA, 
USA)  (Appendix  C)  was loaded into the first and last wells used  in  each  gel.   The 
S. aureus strain NCTC8325, used as a PFGE reference strain, was loaded in every 
fifth lane.  The plugs were inserted against the front of the wells using a sealed 
Pasteur pipette.  The wells were sealed using excess molten 2 % SeaKem Gold plug 
agarose and, once the agarose had set, the gel platform was placed into the 
electrophoresis chamber.   
 
2.2.3.7 Pulsed-field gel electrophoresis 
PFGE was used to separate the DNA fragments obtained after SmaI digestion.  In 
PFGE, the direction of the electrical field is changed or ―switched‖ periodically to 
facilitate size-dependent migration of the large DNA fragments.  In this study, 
electrophoresis was carried out using a CHEF-DRII GeneNavigator (Amersham 
Biosciences, Fairfield, CT, USA), with an initial switch time of 5 s, and a final switch 
time of 60 s.  The duration of the run was 22 h at 200V with the circulating buffer at a 
constant temperature of 14°C.   
 
2.2.3.8 Visualisation of macrorestriction profiles 
After electrophoresis, the gel was transferred to a plastic container to which 500 ml of 
0.5X TBE buffer was added.  Ethidium bromide (Fluka, Sigma Aldrich, Inc., St Louis, 















compact rocker CR300t (FINEPCR, Gunpo-si, South Korea) set at 15rpm for 30 min.  
The gel was destained in 400 ml of distilled water for 20 min.  The macrorestriction 
profiles were visualised using UV transillumination and photographed with a UVIpro 
Silver (UVItec Ltd, Cambridge, UK) or a G:BOX (Syngene, Frederick, MD, USA), and 
the digital image was converted to TIFF file format for use in the computer-assisted 
comparison of macrorestriction profiles. 
 
2.2.3.9 Analysis of macrorestriction profiles 
The digital images were analysed using GelCompar II (version 4.6) by Applied Maths 
(BVBA, Sint-Martens-Latem, Belgium).  The guidelines supplied by Applied Maths 
and the method described by Reed et al. (2007) were followed.  Once the image had 
been cropped and converted to greyscale, each lane was defined manually, and 
background noise was reduced by carrying out a background subtraction.  The 
NCTC8325 control strains loaded in every fifth lane were then used to normalise the 
gel to correct for any inconsistencies in migration.  The molecular weights of the 
SmaI restriction fragments for NCTC8325 are known and the first 11 fragments were 
used for normalisation in this study (Appendix D).  Distortion bars were used to 
confirm the accuracy of the normalisation as described in the GelCompar II manual.  
After normalisation, bands were assigned using the automatic search function and 
were then checked manually.  Only DNA fragments within the normalised region of 
the gel, that is between the first (674kb) and eleventh (76kb) NCTC8325 SmaI 
fragments, were included in the analysis (Murchan et al., 2003).  Processing was 
completed by linking the macrorestriction profiles to the database. 
 
Once all gel images had been processed, a composite comparison of 
macrorestriction profiles obtained for the 100 MRSA isolates was carried out.  The 
NCTC8325 strains were used as global references to enable inter-gel comparisons.  
A dendrogram indicating the levels of similarity between the isolates was created with 
the unweighted pair-group method using arithmetic averages (UPGMA) using the 
Dice  similarity coefficient.   The optimisation and band tolerance settings were  at  
0.5 %  and  1 %, respectively (Reed et al., 2007).  Due to the highly clonal nature of 
S. aureus, a higher similarity threshold is used to define clusters compared to other 
bacteria.  A similarity threshold of 80 % was used to define PFGE clusters in this 
















2.3.1 Comparison of PFGE macrorestriction profiles 
Using the 80 % similarity threshold, the 100 MRSA isolates were separated into 6 
PFGE clusters (A – F), and 8 sporadic isolates, which were designated S1 – S8 
(Figure 2.1).  Clusters C (n = 35) and E (n = 33) were the largest clusters identified, 
and collectively accounted for 68 % of the isolates.  The outstanding isolates 
assigned  to  PFGE  clusters  were distributed across clusters  A  (n = 4),  B  (n = 2), 
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Figure 2.1. Pulsed-field gel electrophoresis macrorestriction profiles obtained for 
100 methicillin-resistant S. aureus from 5 hospitals in Cape Town, and the 
dendrogram showing the levels of similarity between the isolates.  The PFGE data 
were analysed using GelCompar II version 4.6 (Applied Maths), and the dendrogram 
was created using the unweighted pair-group method using arithmetic averages 
(UPGMA) with the Dice similarity coefficient.  Scale bars above and below the 
dendrogram indicate the levels of similarity (%) between isolates.  Using a similarity 
threshold of 80 %, six clusters (A – F), and 8 sporadic isolates, were identified.  Cluster 
names are indicated adjacent to the macrorestriction profiles, and similarity levels (%) 
are shown on the dendrogram adjacent to the relevant nodes.  The second column 
indicates strain designations used throughout this thesis.  The hospitals of origin are 
shown in the final column (GSH, Groote Schuur Hospital; RCCH, Red Cross War 
Memorial Children‘s Hospital; MMH, Mowbray Maternity Hospital; UCTPH, University of 















The PFGE results were analysed in conjunction with the available laboratory data, 
including hospital and ward of origin, as well as date of isolation.  The laboratory and 
experimental data for individual isolates are available in Appendix A.  When the 
isolates were stratified according to hospital of origin, clusters A, B and F included 
isolates from 2 hospitals, clusters C and D contained isolates from 3 hospitals, and 
cluster E included isolates from all 5 hospitals, as summarised in Table 2.1.   
 
Table 2.1 Stratification of pulsed-field gel electrophoresis clusters by hospital 
of origin a   
PFGE cluster 
(no. isolates) 
Distribution of strains across hospitals (no. isolates (%)) 
GSH RCCH MMH UCTPH VH 
A (4) 2 (50.00) 2 (50.00) - - - 
B (2) 1 (50.00) - - 1 (50.00) - 
C (35) 13 (37.14) 4 (11.43) 18 (51.43) - - 
D (7) 4 (57.14) 2 (28.57) - - 1 (14.29) 
E (33) 19 (57.58) 9 (27.27) 1   (3.03) 1  (3.03) 3  (9.09) 
F (11) 8 (72.73) - - 3 (27.27) - 
a 
GSH, Groote Schuur Hospital; RCCH, Red Cross War Memorial Children‘s Hospital; MMH, Mowbray 
Maternity Hospital; UCTPH, University of Cape Town Private Academic Hospital ; VH, Victoria 
Hospital 
 
Since sample sizes from individual wards were small, it was difficult to detect 
clustering by ward of origin.  There was generally no clustering according to date of 
isolation; however, th re were a few minor exceptions, and these isolates are 
indicated in Appendix A.  A noteworthy exception in both of the previously described 
analyses was cluster C. 
 
Scrutiny of cluster C (35 isolates) detected several groups of highly similar MRSA 
with similarity levels ranging from 88.57 to 100 % (Figure 2.2).  These MRSA isolates 
were obtained within short periods of time from patients in gynaecology and 
obstetrics wards and neonatal units at MMH and GSH (Figures 2.2).  Significantly, 18 
out of 19 MRSA from MMH were included in cluster C, with the remaining isolate 
assigned to cluster E (Figure 2.1; Appendix A).  While isolates from MMH comprised 
the majority of MRSA from cluster C (n = 18, 51.43 %), an additional 7 (20.00 %) of 















and neonatal units at GSH.  Therefore 71.43 % of isolates from cluster C was 
obtained from patients in the maternity services at MMH and GSH.  Additionally, 3 
groups of indistinguishable isolates were identified in cluster C, each including 

















Figure 2.2 Clustering of methicillin-resistant S. aureus isolates from the 
maternity and neonatal services within pulsed-field gel electrophoresis 
cluster C.  An enlarged portion of the PFGE dendrogram showing only cluster C is 
shown on the left, with similarity levels (%) indicated at the nodes.  Strain 
designations used in the text are indicated adjacent to the dendrogram, and isolates 
obtained from patients in the maternity and neonatal services at MMH and GSH are 
highlighted in grey.  The hospital and ward of origin, as well as the date of isolation, 
is shown for each isolate.  In the column indicating dates of isolation, groups of 
MRSA isolates obtained within 3 weeks of each other are demarcated with a black 















2.3.2 Comparison of antimicrobial susceptibility profiles across PFGE 
clusters 
Antimicrobial susceptibility profiles were examined within and across PFGE clusters.  
By definition, all of the study isolates were resistant to the β-lactam antibiotics tested 
(penicillin and cloxacillin); all isolates were also susceptible to vancomycin.  The 
antimicrobial susceptibility profiles of isolates within the same PFGE cluster were 























 (no. isolates (%) resistant) 
PEN OXA ERY CLI RIF SXT CIP GEN FUS VAN 







































































































 PEN, penicillin; OXA, cloxacillin; ERY, erythromycin; CLI, clindamycin; RIF, rifampicin; SXT, co-trimoxazole; CIP, ciprofloxacin; GEN, gentamicin; FUS, fusidic 
acid; VAN, vancomycin. 
b















The predominant PFGE clusters, C and E, had notably disparate antimicrobial 
susceptibility profiles.  Isolates from cluster C were typically susceptible to rifampicin, 
co-trimoxazole, ciprofloxacin, gentamicin and fusidic acid, but a large proportion 
(91.43 %) was resistant to erythromycin and clindamycin (Table 2.2).  In contrast, 
isolates from cluster E were typically resistant to several classes of antimicrobial 
agents with 32 out of 33 (96.97 %) isolates classified as multidrug-resistant (resistant 
to 3 or more classes of antimicrobial agents in addition to the β-lactam antibiotics).  
These isolates were universally resistant to rifampicin and almost universally 
resistant to co-trimoxazole (n = 31, 93.94 %) with a large proportion also resistant to 
the other antimicrobial agents, with the exception of erythromycin and clindamycin 
(Table 2.2).  It was noted that all MRSA isolates from cluster D had similar multidrug-
resistant profiles.  These isolates were also resistant to rifampicin and co-
trimoxazole, but a smaller proportion was resistant to ciprofloxacin compared to 
isolates from cluster E (Table 2.2). 
 
Four sporadic isolates (S1, S4, S5 and S6) were also multidrug-resistant with 
antimicrobial susceptibility profiles similar to those observed for isolates from clusters 
D and E (Table 2.3).  This contrasted sharply with the antimicrobial susceptibility 
profile of isolate S8 that was pan-susceptible to the non-β-lactam antimicrobial 
agents (Table 2.3), and was also defined as the PFGE outlier as it shared the lowest 
similarity level with all other study isolates (54.12 %) (Figure 2.1). 
 
Table 2.3 Antimicrobial resistance profiles of sporadic isolates 





Antimicrobial resistance profile 
b
 
S1 PEN, OXA, RIF, SXT, CIP, GEN 
S2 PEN, OXA, ERY, CLI 
S3 PEN, OXA, ERY, CLI, CIP, GEN 
S4 PEN, OXA, ERY, CLI, RIF, SXT, CIP, GEN 
S5 PEN, OXA, RIF, SXT, GEN 
S6 PEN, OXA, RIF, SXT, GEN 
S7 PEN, OXA, ERY, CLI, CIP, FUS 
c
 
S8 PEN, OXA 
a
 Strain designations as used in the text and indicated in Figure 2.1. 
b
 PEN, penicillin; OXA, cloxacillin; ERY, erythromycin; CLI, clindamycin; RIF, 
rifampicin; SXT, co-trimoxazole; CIP, ciprofloxacin; GEN, gentamicin; FUS, 
fusidic acid. 
c
















Six clusters of closely related MRSA and eight sporadic isolates were identified 
among the hundred isolates obtained from hospitals in Cape Town.  The two 
dominant clusters, C and E, contained thirty-five and thirty-three isolates, 
respectively.  Similar levels of homogeneity have recently been reported in other 
studies that have used PFGE to investigate the molecular epidemiology of MRSA 
from South Africa.  Shittu et al. (2009) showed that sixty-one MRSA obtained from 
thirteen healthcare institutions between 2001 and 2003 in the KwaZulu-Natal 
province were assigned to seven PFGE clusters, with the predominant cluster 
containing 62.3 % of the isolates.  More recently, Moodley et al. (2010) reported that 
82 % of three hundred and twenty MRSA isolates, obtained from state and private 
diagnostic microbiology laboratories throughout South Africa between 2005 and 
2006, were distributed across five major PFGE clusters.  On the other hand, far 
greater levels of genetic diversity among nosocomial MRSA have also been reported.  
For instance, twenty-three distinct clusters were identified among fifty-four MRSA 
isolates from a teaching hospital in Portugal (Couto et al., 1995). 
 
Stratification of PFGE clusters according to hospital showed that all clusters 
contained isolates from at least tw  hospitals, suggesting transmission of MRSA 
between hospitals in Cape Town during the collection period.  Previous studies have 
shown that staff and patient transfer plays a major role in the dissemination of MRSA 
between healthcare institutions (Murchan et al., 2004; Henderson, 2006; Lin et al., 
2007).  A noteworthy example was the transmission of the EMRSA-16 clone across 
the United Kingdom (UK) during the 1990s.  It was reported that the transfer of 
infected patients and colonised staff led to the dissemination of EMRSA-16 from 
Northamptonshire, England, initially to neighbouring counties, and then to further 
regions of the UK (Murchan et al., 2004).  It has also been shown that overcrowding 
and understaffing in hospitals leads to decreased infection control compliance, as 
well as increased movement of staff and patients between wards, resulting in 
increased transmission of MRSA (Bertini et al., 2006; Clements et al., 2008).  In 
Cape Town, it is common practice for healthcare workers to rotate through multiple 
hospitals within the UCT academic complex, which represents one possible route of 
transmission of MRSA within and between local hospitals.  Healthcare workers also 















frequently transferred between the included hospitals, representing a second 
possible mode of dissemination of MRSA between hospitals in Cape Town.   
 
Although it was not possible to detect any trends in clustering by ward of origin, the 
fact that closely related isolates within each cluster were obtained from a large 
number of wards and floors in each hospital was of concern.  This pattern of 
dissemination may have been due to a combination of environment-to-person or 
person-to-person transmission of MRSA, and may be indicative of poor adherence to 
infection control guidelines.  Previous studies showed that MRSA isolated from 
healthcare workers and their patients belonged to the same PFGE cluster, confirming 
that MRSA can be transmitted from patient to healthcare worker and vice versa (El 
Helali et al., 2005; Bertini et al., 2006; Lin et al., 2007).  Many hospitals in the USA, 
Canada, Europe and New Zealand screen asymptomatic healthcare workers and 
high-risk patients for MRSA (Herwaldt, 1999; Gavaldà et al., 2006; Humphreys, 2007; 
Albrich and Harbarth, 2008).  Colonised healthcare workers are typically treated with 
antibiotics and, in some cases, are restricted to MRSA-dedicated wards, or are 
removed from duty and are only permitted to return once the bacteria have been 
eradicated.  Likewise, colonised patients are generally treated with antibiotics, or 
cohorted in MRSA-dedicated wards, or depending on local policies, both 
interventions may be utilised (Albrich and Harbarth, 2008; Struelens et al., 2009).  
These policies are not implemented in the included hospitals, primarily due to 
resource constraints.  While it is likely that poor adherence to infection control 
guidelines contributed to the dissemination of MRSA observed in this study, it is also 
possible that colonisation of healthcare workers and patients may have played a role 
in the transmission of these isolates. 
 
Based on the findings of this study, infection control practices in all five hospitals are 
of concern, but dissemination of MRSA within the maternity and neonatal services is 
particularly worrying.  As shown in PFGE cluster C (Figure 2.2), several groups of 
highly similar, if not indistinguishable, MRSA were identified, including isolates 
obtained within short time periods from patients in the maternity and neonatal 
services at GSH and MMH.  The remaining isolates from cluster C were obtained 
from patients at RCCH.  Staff and patient movements between the three hospitals 
are common, representing likely modes of transmission of MRSA within the maternity 















poor adherence to infection control guidelines, which merits further investigation and 
surveillance.  A study is currently underway to investigate the association of cluster C 
isolates with maternity and neonatal services. 
 
A comparison of antimicrobial susceptibility profiles across the six PFGE clusters and 
eight sporadic isolates indicated that, with the exception of the PFGE outlier, S8, the 
isolates tended to be resistant to β- and non-β-lactam antibiotics.  These 
antimicrobial susceptibility profiles are typical of HA-MRSA clones which, historically, 
have been resistant to non-β-lactam antibiotics (Deurenberg and Stobberingh, 2008; 
Ratnaraja and Hawkey, 2008).  There were marked similarities in antimicrobial 
susceptibility profiles among isolates from the same PFGE cluster.  This is not 
always the case, as illustrated by Laplana et al. (2007) who identified differences in 
antimicrobial susceptibility profiles among isolates from the same PFGE cluster.   
 
Multidrug-resistant MRSA is currently problematic worldwide (Levy and Marshall, 
2004) and South Africa is no exception, as shown by Marais et al. (2009) who found 
that 81.5 % of MRSA obtained from patients at public and private healthcare 
institutions throughout South Africa were multidrug-resistant.  Nevertheless, it was 
cause for concern that multidrug-resistant isolates were identified in all six PFGE 
clusters.  It was particularly worrying that 96.97 and 100 % of isolates from clusters D 
and E were multidrug-resistant, and were observed in all five local hospitals 
(Appendix A).  Isolates from both of these clusters were universally resistant to 
rifampicin, and all but two were resistant to co-trimoxazole; however, resistance to 
these particular antimicrobial agents was largely absent among the remaining 
isolates (Appendix A). 
 
High proportions of MRSA resistant to rifampicin and co-trimoxazole have also been 
reported in studies carried out in the KwaZulu-Natal and Gauteng provinces (Shittu et 
al., 2009; Groome et al., 2009).  In this context, rifampicin is commonly prescribed in 
South Africa for the treatment of Mycobacterium tuberculosis infections (South 
African Department of Health, 2004), while co-trimoxazole is prescribed for the 
prophylaxis or treatment of Pneumocystis infections in HIV-positive persons (South 
African Department of Health, 2010).  A study carried out in Japan suggested that the 















antimicrobial agent (Sekiguchi et al., 2006).  Further, it has been suggested that the 
use of co-trimoxazole in HIV-positive persons selects for co-trimoxazole-resistant, 
and multidrug-resistant, S. aureus strains (Martin et al., 1999).  It is quite possible 
that frequent use of these antibiotics in hospitals in Cape Town and other regions in 
South Africa has selected for rifampicin- and co-trimoxazole-resistant MRSA, which 
are best fitted to the local environment.  
 
In summary, PFGE provided data regarding the epidemiology of MRSA from 
hospitals in Cape Town.  These data suggested the transmission of multidrug-
resistant MRSA within and between local hospitals.  This approach also provided an 
overview of the relatedness of the isolates, which served as a starting point for the 
complete molecular characterisation of the MRSA, as described in subsequent 
















SCCmec Content of Local Methicillin-Resistant S. aureus: 
The Devil is in the Detail 
 
3.1 Introduction 
Characterisation of the staphylococcal cassette chromosome mec (SCCmec) content 
of MRSA isolates is essential for a complete description of their molecular 
epidemiology (Enright et al., 2002; Cookson et al., 2007).  The role of SCCmec in 
methicillin resistance, common structural components of the known SCCmec types, 
and the site-specific integration and excision of the element were described in 
Chapter 1 [1.5.3].  The focus of this chapter will be the classification of SCCmec 
types, and the strategies used to differentiate these elements.  Additionally, details 
regarding the global distribution and structural components of individual SCCmec 
types will be provided here. 
 
In December 2009, the IWG-SCC published a comprehensive set of guidelines 
regarding the classification of SCCmec elements (Ito et al., 2009).  In accordance 
with the IWG-SCC guidelines, SCCmec types are defined by the combination of mec 
class and ccr allotype present, while subtypes are defined by differences in their 
respective J regions, as will be discussed later in this chapter.  The IWG-SCC also 
recommended that the existing SCCmec nomenclature be revised to make the 
system more informative.  It was suggested that the Roman numerals should be 
retained, but ccr allotype (currently 1 – 5, 7 and 8 in SCCmec elements in S. aureus) 
and mec class (currently A, B, C1, C2 and E in SCCmec elements in S. aureus) 
should also be indicated, in that order, in parentheses (Ito et al., 2009; 
http://www.sccmec.org/Pages/SCC_TypesEN.html).  The revised names for 
SCCmec types I – XI are, therefore, I (1B), II (2A), III (3A), IV (2B), V (5C2), VI (4B), 
VII (5C1), VIII (4A), IX (1C2), X (7C1) and XI (8E), respectively.  The only information 
currently available on the most recently reported SCCmec types IX – XI is the 
combination of mec and ccr complexes that they contain 
(http://www.sccmec.org/Pages/SCC_TypesEN.html); therefore only SCCmec types I 















nomenclature is not yet commonly used and, for ease of reading, only Roman 
numerals will be used in the remainder of this thesis. 
 
Although, with the exception of SCCmec type VII, the genetic organisation of 
SCCmec types I – VIII is identical [1.5.3], there are numerous differences in the 
underlying sequences of the basic structural components present in these elements, 
as shown in Figure 3.1 (Ito et al., 2009).  Additionally, differences in the epidemiology 
of SCCmec types I – VIII have also been described.  SCCmec type I (34.3kb) was 
isolated from the first MRSA strain reported in England in 1961, and is defined by the 
presence of a class B mec complex and type 1 ccr allotype (Figure 3.1) (Ito et al., 
2001).  In general, SCCmec type I does not carry additional antibiotic resistance 
genes within its J regions; therefore this mobile genetic element typically does not 
confer resistance to antimicrobial agents besides the β-lactam antibiotics (Ito et al., 




















Figure 3.1 Schematic representation of SCCmec types I – VIII.   The basic structure of 
SCCmec is shown at the top.  Regions corresponding to the mec and ccr complexes are 
highlighted  in pink  and yellow,  respectively.  J1, J2,  and  J3  indicate  the  joining  regions. 
The S. aureus chromosome is shown in grey.  The revised nomenclature for SCCmec types I – 
VIII is shown on the left (ccr allotype and class of mec complex indicated, in order, in 
parentheses).  Arrowheads indicate orientation.  IS, insertion sequence; p, linearised plasmid; 
Tn, transposon; SCCHg, staphylococcal cassette chromosome mercury. Adapted from Chen et 















On the other hand, SCCmec types II and III, which both carry the class A mec 
complex but contain ccr allotypes 2 and 3, respectively, commonly carry additional 
resistance determinants within their J regions (Figure 3.1) (Ito et al., 2001; Ito et al., 
2003; Ito et al., 2009).  In SCCmec type II (53kb), these regions contain plasmid 
pUB110, which encodes resistance to several aminoglycosides, including 
tobramycin, kanamycin and bleomycin, as well as a copy of transposon Tn554, which 
confers resistance to the macrolides, lincosamides and streptogramins (Ito et al., 
2003).  The genetic organisation of SCCmec type III (66.9kb) is more complex in that 
it is a composite element consisting of two smaller SCC elements: SCCHg (formerly 
SCCmercury), and the SCCmec III element, which contains a class A mec complex 
and ccr allotype 3 (Figure 3.1) (Ito et al., 2009).  The SCCHg component carries 
Tn554, as well as p1258, which contains the mer operon, conferring resistance to 
mercury (Ito et al., 2003).  The SCCmec III component of the composite element 
includes ψTn554, which confers cadmium resistance, and pT181, which encodes 
resistance to tetracycline (Ito et al., 2001; Ito et al., 2003).  SCCmec types II and III 
were first described in strains isolated in Japan and New Zealand, respectively (Ito et 
al., 2001), and, as with SCCmec type I, have since been described frequently 
worldwide, particularly in association with HA-MRSA isolates (Deurenberg and 
Stobberingh, 2008; Ratnaraja and Hawkey, 2008).   
 
SCCmec type IV is defined by the presence of the class B mec complex and ccr 
allotype 2 (Figure 3.1) (Ma et al., 2002).  This element typically does not include 
additional antibiotic resistance determinants (Ma et al., 2002; Deurenberg and 
Stobbering, 2008).  Ranging from 20.9kb to 24.3kb, SCCmec type IV is one of the 
smallest SCCmec elements, which may explain why it is the most frequently 
transferred SCCmec type and is prevalent worldwide (Ma et al., 2002; Okuma et al., 
2002; Robinson and Enright, 2003; Deurenberg and Stobberingh, 2008).  SCCmec 
type IV was first described in CA-MRSA (Daum et al., 2002) and has been commonly 
associated with these lineages, although there have also been reports of HA-MRSA 
strains carrying this element (de Lencastre et al., 2007; Ratnaraja and Hawkey, 
2008).  A number of variants of SCCmec types I – III have been described based on 
differences in the J regions of elements carrying the same mec-ccr combination 
(Deurenberg and Stobberingh et al., 2008; Ito et al., 2009); however, SCCmec type 
IV has been shown to be most variable with ten subtypes (IVa – d, IVE, IVF and IVg 















et al., 2005; de Lencastre et al., 2007; Berglund et al., 2009).  It is thought the 
frequent horizontal transfer of SCCmec type IV, and the genetic background of the 
MRSA lineages carrying this element, have contributed to the highly polymorphic 
nature of this SCCmec type (Ma et al., 2002; Okuma et al., 2002; Robinson and 
Enright, 2003; Jansen et al., 2006).   
 
The current nomenclature systems used for describing SCCmec subtypes are 
relatively unwieldy: lowercase letters denote differences in the J1 region (eg. IVa), 
uppercase  letters  indicate the presence or absence of mobile genetic  elements  
(eg. IA), and Arabic numerals denote differences in each J region (eg. II.1.1.1, 
II.1.1.2 and II.2.1.1).  Unsurprisingly, there has been a move to simplify and improve 
subtype nomenclature through the creation of a website dedicated to identifying 
molecular markers within the J regions (http://www.SCCmec.org), which will be used 
to differentiate subtypes and assign subtype numbers in a more informative manner 
(Ito et al., 2009). 
 
SCCmec types V and VI are two of the smaller SCCmec elements at 28kb (Ito et al., 
2004) and 20.9kb (Oliveira et al., 2006), respectively, and also typically only confer 
resistance to β-lactam antibiotics (Figure 3.1) (Deurenberg and Stobberingh, 2008).  
SCCmec type V (class C2 mec complex, ccr allotype 5) has commonly been reported 
in CA-MRSA strains (Ito et al., 2004; de Lencastre et al., 2007; Deurenberg and 
Stobberingh, 2008), while the distribution of SCCmec type VI (class B mec complex, 
ccr allotype 4) appears more limited with the element reported in continental Portugal 
and its island territories, and also in France (Oliveria et al., 2006; Dauwalder et al., 
2008; Conceiçao et al., 2010).   
 
SCCmec types VII and VIII represent the most recently reported SCCmec elements 
that have been described in full in the literature (Berglund et al., 2008; Zhang et al., 
2009; Ito et al., 2009).  SCCmec type VII (35.9kb) is defined by the presence of a 
class C1 mec complex and ccr allotype 5, and deviates from the common structural 
organisation observed for all other SCCmec types as the ccr complex precedes the 
mec complex (Figure 3.1).  This element only confers resistance to β-lactam 
antibiotics and was described in a putative CA-MRSA isolate from Sweden (Berglund 















represents the SCCmec element most recently described in full (Zhang et al., 2009).  
SCCmec type VIII contains the class A mec complex and ccr allotype 4, and includes 
Tn554 in the J2 region (Figure 3.1), which, as in SCCmec types II and III, confers 
resistance to the macrolides, lincosamides and streptogramins, (Ito et al., 2009; 
Zhang et al., 2009). 
 
The classification of SCCmec types is most commonly carried out using PCR-based 
assays (de Lencastre et al., 2007; Deurenberg and Stobberingh, 2008).  Techniques 
used for the identification of SCCmec type and subtype commonly include multiplex 
PCR assays such as those described by Milheiriço et al. (2007a and 2007b), which 
are currently among the most frequently used SCCmec typing and SCCmec type IV 
subtyping strategies.  The SCCmec typing multiplex PCR assay is used for the 
detection of SCCmec types I – VI (Milheiriço et al,. 2007a), while the SCCmec type 
IV subtyping assay is used for the detection of subtypes IVa – IVh (Milheiriço et al., 
2007b).  These strategies were used in the current study to characterise the 
SCCmec content of the MRSA described in Chapter 2.  SCCmec types VII – XI, and 
subtypes IVi and IVj, were identified after these typing strategies were developed by 
Milheiriço et al. (2007a and 2007b), which illustrates how existing assays constantly 
need to be updated to include novel SCCmec types and subtypes.  The most 
recently developed SCCmec typing strategy is a Real-Time multiplex PCR assay for 
the detection of SCCmec types I – VI and VIII (Chen et al., 2009); however, a 















3.2 Experimental Protocol 
3.2.1 The isolation of S. aureus genomic DNA 
S. aureus was sub-cultured from 25 % glycerol stocks as described in Chapter 2 
[2.2.3.3], and genomic DNA was isolated using the QIAamp DNA Mini Kit (QIAGEN, 
Valencia, CA, USA).  The protocol provided by the manufacturer required minor 
modifications.  An extra initial incubation step was included, prior to the addition of 
Buffer ATL, to weaken the bacterial cell wall; a sweep of pure colonies was added to 
200 µl of pre-treatment solution containing 25 µg/ml of lysostaphin (Sigma Aldrich, 
Inc., St Louis, MO, USA), 2 mM EDTA and 20 mM Tris-Cl, and incubated at 37°C in a 
ThermoMixer Compact (Eppendorf, Hamburg, Germany), with shaking at 800rpm, for 
30 min, which was found to be optimal in our laboratory.  After the initial incubation 
step, the bacteria were harvested by centrifugation at 7500rpm at room temperature 
for 15 min in an Eppendorf 5417 C bench-top centrifuge (Eppendorf, Hamburg, 
Germany), the supernatant was discarded and the manufacturer‘s protocol resumed 
with the addition of 180 µl of Buffer ATL.  In the final elution step, 50 µl of Buffer AE 
was applied to the MiniSpin column, which was incubated at room temperature for 5 
min prior to centrifugation to increase the final yield of genomic DNA.  The 
concentration of the genomic DNA was determined using a NanoDrop 1000 
Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). 
 
3.2.2 Agarose gel electrophoresis 
The integrity of the S. aureus genomic DNA was confirmed by conventional 
electrophoresis using 1 % agarose gels.  The SeaKem LE agarose (Lonza Biologics 
Plc, Slough, UK) was dissolved in 1X TAE buffer (Appendix B) with ethidium bromide 
(Fluka, Sigma Aldrich, Inc., St Louis, MO, USA) at a final concentration of 0.5 µg/ml.  
Five microlitres each of genomic DNA and 5X loading buffer (Bioline, London, UK) 
were  loaded  into the wells.   An electrical field (5V/cm) was applied to the gel  for  
1.5 h, causing negatively charged DNA molecules to migrate towards the positive 
terminal of the electrophoresis chamber with the rate of migration dependent on the 
molecular weights of the fragments.  A molecular weight marker, Hyperladder I 
(Bioline, London, UK) (Appendix C), was included to facilitate the estimation of DNA 
fragment sizes.  DNA was visualised by UV transillumination and photographed using 
a UVIpro Silver (UVItec Ltd, Cambridge, UK) or a CHEMI-Genius Bioimaging System 















3.2.3 Methods used for the characterisation of SCCmec content of MRSA 
isolates 
The characterisation of the SCCmec content of the 100 MRSA isolates required 
several methodological approaches that were carried out sequentially, as depicted in 
Figure 3.2. 
 
Figure 3.2 Flow-diagram depicting methods used to characterise the SCCmec 















3.2.3.1. Multiplex PCR assay for the detection of SCCmec Types I – VI  
The multiplex PCR assay developed by Oliveira and de Lencastre (2002) and 
updated by Milheiriço et al. (2007a), for the detection of SCCmec types I – VI, was 
initially used for SCCmec typing.  The assay was optimised by Dr Eliya Madikane 
and Mkunde Chachage, and carried out on 41 of the 100 MRSA isolates prior to the 
start of this study.  The SCCmec types of the remaining 59 isolates were determined 
by the author.  SCCmec types VII – XI had not been described at the onset of this 
study; therefore primers for the detection of these SCCmec elements were not 
included in the assay.   
 
The multiplex PCR assay was carried out in a volume of 50 µl, which contained a 
final concentration of 1X Super-Therm PCR buffer and 1.5 mM MgCl2 (JMR 
Holdings, London, UK), with 160 µM deoxynucleotide triphosphate (dNTP) mix 
(Thermo Scientific, Wilmington, DE, USA).  Five nanograms of genomic DNA [3.2.1] 
and 1.25 U of Super-Therm Taq polymerase (JMR Holdings, London, UK) were 
added to each reaction.  The primers CIF2 F2, CIF2 R2, RIF5 F10 and RIF R13 were 
included at a final concentration of 0.6 µM, while primers kdp F1, kdp R1, dcs F2,  
dcs R1, mecI P2, mecI P3, ccrC F2, ccrC R2, ccrB2 F2, ccrB2 R2, SCCmec III J1F, 
SCCmec III J1R, SCCmec V J1F and SCCmec V J1R were included at a final 
concentration of 0.8 µM.  For the amplification of mecA, the internal control, primers 
mecA P4 and mecA P7 were included at a final concentration of 0.2 µM.  All primers 
were synthesised at the Synthetic DNA Laboratory at the University of Cape Town 
(Cape Town, South Africa), and the primer sequences and corresponding control 
strains are shown in Appendix E.  Table 3.1 summarises the primer target 
sequences, the SCCmec types detected by each primer pair, and also indicates the 
expected PCR product sizes.  Where necessary, individual primer pairs were used in 
separate PCR assays to confirm the origin of additional PCR products identified in 


























SCCmec types containing complementary sequence Expected 
product size 
(bp) I II III IV V VI 
CIF2 F2 
CIF2 R2 
Sequence downstream of pls 
(J1) 
      495 
ccrC F2 
ccrC R2 
Internal to ccrC  
(ccr complex) 
      449 
RIF5 F10 
RIF5 R13 
Region between Tn554 and orfX 
(SCCHg) 
      414 
SCCmec V J1F 
SCCmec V J1R 
Not specified  
(J1) 
      377 
dcs F2 
dcs R1 
Internal to dcs gene  
(J3) 
      342 
ccrB2 F2 
ccrB2 R2 
Internal to ccrB allotype 2  
(ccr complex) 
      311 
kdp F1 
kdp R1 
Internal to kdp operon  
(J1) 
      284 
SCCmec III J1F 
SCCmec III J1R 
Not specified  
(J1) 
      243 
mecI P2 
mecI P3 
Internal region of mecI  
(mec complex) 
      209 
mecA P4 
mecA P7 




      162 
a
 Milheiriço et al. (2007a) (primer sequences available in Appendix E). 
b
 SCCmec, staphylococcal cassette chromosome mec; J1, joining region 1; SCCHg, staphylococcal cassette chromosome mercury; J3, joining region 3.  
c
















PCR amplification was carried out using an Applied Biosystems 2720 Thermocycler 
(Applied Biosystems, Carlsbad, CA, USA), including an initial denaturation step at 
94°C for 3 min, followed by 30 cycles of 30 s at 94°C, 30 s at 53°C, and 30 s at 72°C, 
with a final extension step of 3 min at 72°C.  The following prototypic S. aureus 
strains containing SCCmec types I – VI were included in each experiment: COL (I), 
BK2464 (II), ANS46 (III), MW2 (IV), WIS (V) and HDE288 (VI) (Oliveira and de 
Lencastre, 2002; Milheiriço et al., 2007a).  These control strains were obtained from 
Professor Hermínia de Lencastre (Instituto de Tecnologia Química e Biológica, 
Universidade Nova de Lisboa, Oeiras, Portugal) with the exception of WIS, which 
was obtained from Professor Keiichi Hiramatsu (Department of Bacteriology, 
Juntendo University, Tokyo, Japan). 
 
The PCR products were separated by conventional electrophoresis on 2 % gels that 
were prepared by dissolving SeaKem LE agarose (Lonza Biologics Plc, Slough, UK) 
in 0.5X TBE buffer (Appendix B), with 0.5 µg/ml ethidium bromide (Fluka, Sigma 
Aldrich, Inc., St Louis, MO, USA).  The electrophoresis and visualisation of PCR 
products was carried out as previously described [3.2.2], except that 10 µl of the final 
volume (50 µl) of PCR product and 2 µl of 5X loading buffer (Bioline, London, UK) 
were loaded into the wells.  Hyperladder IV (Bioline, London, UK) (Appendix C) was 
included as the molecular weight marker and electrophoresis proceeded at 5V/cm for 
2.5 h.   
 
3.2.3.2. DNA sequencing of PCR products 
When necessary, PCR products obtained in multiplex PCR assays, or in reactions 
containing individual primer pairs, were sequenced to confirm their identities.  Twenty 
microlitres of PCR product, and 4 µl of 5 X loading buffer (Bioline, London, UK), were 
loaded into the wells of a 2 % agarose gel prepared as for the visualisation of these 
products.  The products were separated by electrophoresis at 3V/cm for 3 h.  The 
DNA was visualised using a UV lightbox (FotoDyne Inc, Hartland, WI, USA) and PCR 
products of interest were identified with the aid of the included molecular weight 
marker.  Using a surgical blade, the fragments of interest were carefully excised from 
the agarose gel so as to avoid carry-over of non-specific products.  The DNA was 
purified for direct sequencing using the MinElute Gel Extraction Kit (QIAGEN, 















eluted in 10 µl of molecular grade water (Fluka, Sigma Aldrich, Inc., St Louis, MO, 
USA) and quantified using a NanoDrop 1000 Spectrophotometer (Thermo Scientific, 
Wilmington, DE, USA). 
 
The purified PCR products and corresponding primers were sent to the Central 
Analytical Facility at the University of Stellenbosch where both strands were 
sequenced using the Sanger or dideoxy method.  The Sanger method includes a 
cycle sequencing reaction in which dNTPs and dideoxynucleotide triphosphates 
(ddNTPs) are available for incorporation into the growing DNA strand.  Each of the 4 
ddNTPs has a specific fluorescent tag, and lacks a 3 prime hydroxyl group; therefore, 
elongation is terminated upon addition of a ddNTP, thereby generating sequencing 
products that vary in size depending on where the ddNTP was incorporated (Hartwell 
et al., 2004).  At the Central Analytical Facility, automated sequencing was carried 
out on an ABI3730xl DNA analyser, which uses capillary electrophoresis for the fine-
scale size-dependent separation of the resulting sequencing products.  As a product 
exits the capillary, a UV laser excites the fluorescent tag of the terminal ddNTP, and 
in this way the full sequence of the amplicon of interest is gradually determined 
(Hartwell et al., 2004). 
 
The chromatograms provided by the Central Analytical Facility were viewed and 
sequences edited in BioEdit Sequence Alignment Editor (version 7.0.5.2) (Hall, 
1999).  A nucleotide-BLAST query of the nucleotide collection database was carried 
out for the sequences of interest, using the default settings 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 
3.2.3.3 Characterisation of the SCCmec content of MRSA isolates with atypical 
multiplex PCR profiles 
Thirty-seven of the 100 study isolates had amplification patterns that did not 
correspond to those of the control strains and were, therefore, non-typable by the 
SCCmec typing multiplex PCR assay of Milheiriço et al. (2007a).  The SCCmec 
typing strategy described by Kondo et al. (2007) was modified for use in this study to 
resolve the identities of the non-typable isolates.  The strategy of Kondo et al. (2007) 
includes individual multiplex PCR assays for the detection of class A, B, C1 and C2 















mec and ccr complexes present in an isolate in order to determine its SCCmec type. 
The primer pairs described for the detection of class A, B and C2 mec complexes, 
and ccr allotypes 1 and 5, were used individually in separate assays as necessary to 
confirm the SCCmec content of the non-typable isolates (Figure 3.2).  
 
For the detection of mec classes A, B and C2, all reactions were carried out in a 
volume of 50 µl with 1X SuperTherm PCR buffer, 2 mM MgCl2 (JMR Holdings, 
London, UK), 200 µM of each dNTP (Thermo Scientific, Wilmington, DE, USA), 20 ng 
of template DNA [3.2.1] and 2.5 U of Taq polymerase (JMR Holdings, London, UK).  
Each primer from the pairs mA7/ mI6, mA7/ IS7, and mA7/ IS2 (iS-2) (Synthetic DNA 
Laboratory, University of Cape Town, Cape Town, South Africa) was added at a final 
concentration of 0.1 µM.  The common primer, mA7, is specific for mecA, while 
primers mI6, IS7 and IS2 (iS-2) are specific for regions upstream of the methicillin-
resistance determinant that are unique to mec classes A, B and C2, respectively, as 
summarised in Table 3.2 (Appendix E).  S. aureus control strains ANS46 (class A 
mec complex), COL (class B mec complex) and WIS (class C2 mec complex) were 
included as appropriate.  The PCRs were carried out in an Applied Biosystems 2720 
Thermocycler (Applied Biosystems, Carlsbad, CA, USA) with the cycling conditions 
for each assay including an initial denaturation step of 2 min at 94°C followed by 30 
cycles of denaturation for 2 min at 94°C, annealing for 1 min at 57°C and extension 
















Table 3.2 Primers for the classification of SCCmec types based on the combination of mec class and ccr allotype present 
Primer pair 
a






SCCmec types containing mec class/ccr complex Expected 
product size 
(bp) I II III IV V VI VII VIII 
mA7 
mI6 
mecA – mecI  mec class A         1963 
mA7 
IS7 
mecA – IS1272 mec class B         2872 
mA7 
IS2(iS-2) 
mecA – IS431  
(copy inserted upstream of mecA) 
mec class C2         804 
α1 
βc 





 ccr type 5         518 
a
 Kondo et al. (2007) (primer sequences available in Appendix E). 
b
















For the detection of ccr allotypes 1 and 5, reaction volumes of 50 µl were used with 
all components at the same final concentrations as those described for the mec 
complex detection assays, except for MgCl2 (JMR Holdings, London, UK), which was 
included at 3.2 mM, and the template DNA [3.2.1], 10 ng of which was added.  The 
degenerate primer βc, specific for ccrB allotypes 1 – 3, and primer α1 and the primer 
pair γF/ γR were included for the detection of ccr allotypes 1 and 5, respectively. All 
primers were synthesised at the Synthetic DNA Laboratory at the University of Cape 
Town (Cape Town, South Africa).  Table 3.2 includes a summary of primer target 
sequences and expected product sizes, while the primer sequences are shown in 
Appendix E.  S. aureus control strains COL (ccr allotype 1) and WIS (ccr allotype 5) 
were included in the individual assays as appropriate.  The PCR amplification 
parameters were the same as those described for the mec complex detection 
assays, except that an annealing temperature of 60°C was used.   
 
PCR products obtained from these assays were separated by conventional 
electrophoresis on 1.5 % agarose gels as previously described [3.2.2], except that  
10 µl of the final volume (50 µl) of PCR product and 2 µl of 5X loading buffer (Bioline, 
London, UK) were loaded into the wells.  Hyperladders I and IV were included as 
appropriate based on expected PCR product sizes (Table 3.2; Appendix C).  
Selected PCR products were purified for direct sequencing as previously described 
[3.2.3.2], except that amplicons of interest were separated on a 1.5 % agarose gel 
prior to purification. 
 
3.2.4 Multiplex PCR assay for the subtyping of SCCmec type IV elements 
The SCCmec type IV subtyping multiplex PCR assay developed by Milheiriço et al. 
(2007b) was used to further characterise the SCCmec content of local SCCmec type 
IV isolates.  The assay includes primers for the detection of subtypes IVa – IVh 
based on differences in their respective J1 regions.  Subtypes IVi and IVj had not 
been detected when the assay was developed; therefore, primers for the detection of 
these subtypes were not included.  The subtypes detected by the multiplex assay, 
IVa – IVh, include 5 unique J1 regions as those of IVb and IVF, and IVc and IVE, are 
identical.  Subtypes IVb and IVF differ in the J3 region: the J3 region of subtype IVb 
includes the dcs locus, whereas this locus is absent in subtype IVF.  Similarly, 















Additional individual PCR assays including primers for the detection of dcs and 
Tn4001 are recommended for the differentiation of subtypes IVb and IVF, and IVc 
and IVE, respectively. 
 
Each PCR was carried out in a volume of 50 µl containing a final concentration of 1X 
PCR buffer, 1.5 mM MgCl2 and 1.25 U of SuperTherm Taq polymerase (JMR 
Holdings, London, UK), as well as 160 µM dNTP mix (Thermo Scientific, Wilmington, 
DE, USA) and 5 ng of template DNA [3.2.1].  All primers were synthesised at the 
Synthetic DNA Laboratory at the University of Cape Town (Cape Town, South Africa) 
with the recommended final primer concentrations modified and added as presented 
in Table 3.3.  The target sequences and expected product sizes of the primer pairs 
are also shown in Table 3.3, while the primer sequences are shown in full in 
Appendix E. 
 
Table 3.3 Primers used in the multiplex PCR assay for the detection of 





Final concentration of 
each primer used in the 
assay (µM) 
Subtypes detected  







J IVa F 
J IVa R 
0.4 IVa (J1) 278 
J IVb F 
J IVb R 
0.8 IVb and IVF (J1) 336 
J IVc F 
J IVc R 
0.6 IVc and IVE (J1) 483 
J IVd F 
J IVd R 
0.8 IVd (J1) 575 
J IVg F 
J IVg R 
0.9 IVg (J1) 792 
J IVh F 
J IVh R 










 Milheiriço et al. (2007b) (primer sequences available in Appendix E). 
b
 J1, joining region 1. 
c
















Amplification was carried out using an Applied Biosystems 2720 Thermocycler 
(Applied Biosystems, Carlsbad, CA, USA), including denaturation for 4 min at 94°C, 
followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 48°C for 30 s and 
extension at 72°C for 2 min, with a final extension step of 4 min at 72°C.  Prototypic 
S. aureus strains JCSC4744 (IVa), JCSC2172 (IVb), DEN2949 (IVc), BK2529 (IVd), 
AR43/3330.1 (IVE), M03-68 (IVg) and HAR22 (IVh) were included in each assay.  
Control strains JCSC4744 and JCSC2172 were obtained from Professor Teruyo Ito 
(Department of Bacteriology, Juntendo University, Tokyo, Japan), while the 
remaining strains were obtained from Professor Hermínia de Lencastre (Instituto de 
Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal).  It 
should be noted that, in the case of strain M03-68, a genomic DNA preparation 
sufficient for only a single reaction was provided; therefore, a PCR assay was carried 
out as for the multiplex PCR but included only the subtype IVg specific primers.  In 
subsequent assays, 1 µl of PCR product was included as template DNA to control for 
the detection of the J1 region of subtype IVg.  It was not possible to obtain a subtype 
IVF control strain; however, this was not essential given that the J1 region of subtype 
IVF is identical to that of IVb. 
 
The PCR products were separated and visualised on 2 % agarose gels as described 
for the SCCmec typing multiplex PCR assay [3.2.3.1], except that the gels were 
prepared using 1X TAE buffer, and 20 µl PCR product and 4 µl of 5X loading buffer 

















3.3.1 The classification of SCCmec types of local MRSA isolates  
Using the SCCmec typing multiplex PCR described by Milheiriço et al. (2007a), PCR 
profiles were obtained for all of the MRSA isolates described in Chapter 2.  A comparison 
of these profiles with the amplification patterns obtained from S. aureus control strains 
COL, BK2464, ANS46, MW2, WIS and HDE288, containing SCCmec types I – VI, 
respectively, determined the SCCmec types of 63 of the 100 MRSA isolates.  Forty-six 
isolates had multiplex PCR profiles consistent with SCCmec type IV.  SCCmec type II 
was detected in 12 isolates, while 4 and 1 isolates contained SCCmec types III and I, 
respectively.  The PCR profiles obtained for the control strains and a subset of typable 
isolates are shown in Figure 3.3. 
 
 
Figure 3.3 SCCmec typing multiplex PCR profiles obtained for methicillin-resistant 
S. aureus (MRSA) control strains and a representative selection of MRSA from 
hospitals in Cape Town. Lanes 2 – 7 contain MRSA control strains carrying SCCmec 
types I – VI; lanes 9 – 18 contain a selection of MRSA from hospitals in Cape Town.  
Lane 1, Hyperladder IV molecular weight marker; lane 2, COL (SCCmec type I); lane 3, 
BK2464 (SCCmec type II); lane 4, ANS46 (SCCmec type III); lane 5, MW2 (SCCmec 
type IV); lane 6, WIS (SCCmec type V); lane 7, HDE288 (SCCmec type VI); lane 8, 
Hyperladder IV molecular weight marker; lane 9, A1 (III); lane 10, S2 (unique atypical 
profile: 495 bp, 449 bp, 414 bp, 162 bp); lane 11, B1 (I); lane 12, C17 (atypical profile 
detected in 36 MRSA: 495 bp, 449 bp, 414 bp, 342 bp, 162 bp); lane 13, D4 (IV); lane 
14, E4 (IV); lane 15, E5 (IV); lane 16, E32 (IV); lane 17, F8 (II) ; lane 18, S8 (IV); lane 19, 















Atypical amplification patterns were obtained for 37 of the 100 isolates, necessitating 
additional investigations to determine the SCCmec content of these MRSA.  The 
experimental approaches used in these investigations, and the results obtained, are 















Figure 3.4 Flow-diagram representing the characterisation of the SCCmec 
content of 100 methicillin-resistant S. aureus isolates.  Prototypic S. aureus strains 
containing SCCmec types I – VI were used to control the SCCmec typing multiplex 
PCR assay:  COL (SCCmec type I (1B)) BK2464 (SCCmec type II (2A)) ANS46 
(SCCmec type III (3A)) MW2 (SCCmec type IV (2B)) WIS (SCCmec type V (5C2)) 
HDE288 (SCCmec type VI (4B)) (Oliveira and de Lencastre, 2002; Milheiriço et al., 
2007a).  PCR assays for the detection of class A, B and C2 mec complexes were 
controlled using ANS46, COL and WIS, respectively; those for the detection of ccr 
allotypes 1 and 5 were controlled using COL and WIS, respectively.    , result 
















3.3.1.1 Characterisation of the SCCmec content of 36 MRSA isolates with atypical 
multiplex PCR profiles 
Thirty-seven MRSA isolates had atypical multiplex PCR profiles, 36 of which were 
similar to, but distinct from, the multiplex PCR profile observed for the SCCmec type I 
control strain, COL (Figure 3.3).  Given the SCCmec type I-like profiles of the 
isolates, primer pairs described by Kondo et al.(2007) for the detection of the class B 
mec complex and ccr allotype 1 (the combination of mec and ccr complexes 
characteristic of SCCmec type I) were used in separate PCR assays to confirm the 
SCCmec content of these isolates (Figure 3.4).  Products corresponding to 2827 bp 
and 695 bp regions of the class B mec complex and ccr allotype 1, respectively, were 
detected in all 36 MRSA, as shown for a selection of isolates in Figure 3.5.  These 
products were also detected in isolate B1, the only local MRSA isolate with a typical 
SCCmec type I multiplex PCR profile, and in COL, the SCCmec type I control strain 
(Figure 3.5).  Based on the detection of the class B mec complex and ccr allotype I, 
the 36 isolates with identical SCCmec type I-like multiplex PCR profiles were 












Figure 3.5 PCR products obtained following assays for the detection of the 
class B mec complex and ccr allotype 1 in SCCmec type I-like isolates.  (A)  
PCR products detected following the amplification of a 2827 bp region of the class B 
mec complex.  Lane 1, Hyperladder I molecular weight marker; lane 2, control strain 
COL (SCCmec type I; class B mec complex); lane 3, B2 (SCCmec type I-like); lane 
4, B1 (SCCmec type I); lane 5, C17 (SCCmec type I-like).  (B)  PCR products 
detected following the amplification of a 695 bp region of ccr allotype 1.  Lane 1, 
Hyperladder IV molecular weight marker; lane 2, control strain COL (SCCmec type 
I; ccr allotype 1); lane 3, B1 (SCCmec type I); lane 4, C2, (SCCmec type I-like); lane 















Inspection of the atypical multiplex PCR profiles obtained for the 36 SCCmec type I 
isolates revealed products of 495 bp, 342 bp and 162 bp that were consistent with those 
typical of SCCmec type I.  Two additional products that were inconsistent with the 
multiplex PCR profile of SCCmec type I were also detected (Figure 3.3).  The sizes of 
these products equated with the 449 bp and 414 bp amplicons emanating from primer 
pairs ccrC F2/ccrC R2 (for the detection of SCCmec type V) and RIF5 F10/RIF5 R13 
(for the detection of SCCmec type III), respectively, as summarised in Figure 3.6 and 
Table 3.1. 
Figure 3.6 Schematic diagram representing SCCmec typing multiplex PCR 
profiles detected for SCCmec type I control strain COL and 36 atypical SCCmec 
type I isolates.  Additional products detected for 36 SCCmec type I-like isolates 
equated with sizes of amplicons typically detected in SCCmec elements other than 
SCCmec type I.  PCR a says including primer pairs for the amplification of the 
corresponding fragments, followed by sequencing where necessary, confirmed the 
identities of atypical products.  J1, joining region 1; J3, joining region 3.  *Emanating 
from primer pair ccrC2 F2/ccrC2 R2 (cross-complementary to ccrC present in SCCmec 
type V  and  in  the  SCCHg  component  of  SCCmec  type  III).   **Emanating  from  
RIF5 F10/RIF5 R13 (complementary to ccrC present in the SCCHg component of 
SCCmec type III).  
 
To investigate the possibility that ccrC F2/ccrC R2 and RIF5 F10/RIF5 were extended in 
the amplification of the additional products, PCR assays were carried out as for the 
SCCmec typing multiplex PCR assay, except that only the primer pair of interest was 
included in each individual assay.  DNA from one of the 36 MRSA (isolate C17) and the 
local typical SCCmec type I isolate (isolate B1) was included in these assays, which 
were controlled using COL (SCCmec type I), WIS (SCCmec type V) and ANS46 















In the PCR assay including only primer pair ccrC F2/ccrC R2, a 449 bp product 
corresponding to that amplified from WIS and ANS46 was detected in isolate C17, 










Figure 3.7 Agarose gel electrophoresis of amplicons obtained using the 
primer pair ccrC F2/ccrC R2 in PCR assays for the detection of ccrC in 
methicillin-resistant S. aureus control strains and local SCCmec type I 
isolates with typical and atypical multiplex PCR profiles.  Lane 1, Hyperladder 
IV molecular weight marker; lane 2, control strain COL (SCCmec type I; ccrC-
negative); lane 3, control strain ANS46 (SCCmec type III; ccrC-positive (SCCHg 
component)); lane 4, control strain WIS (SCCmec type V; ccrC-positive (ccr 
complex)); lane 5, B2 (atypical SCCmec type I multiplex profile); lane 6, B1 (typical 
SCCmec type I multiplex profile); lane 7, C17 (atypical SCCmec type I multiplex 
profile). 
 
The product detected in ANS46, the SCCmec type III control strain (Figure 3.7), was 
unexpected as Milheiriço et al. (2007a) described ccrC F2/ccrC R2 as 
complementary to only SCCmec type V.  A BLAST query indicated that the copy of 
ccrC present in WIS (accession number AB121219) was in fact 91 % similar to a 
copy of ccrC present in the SCCHg component of the prototypic SCCmec type III 
strain 85/2082 (accession number AB037671), which was used to develop the 
multiplex PCR assay.  Subsequent analyses revealed that the primer pair ccrC2 
F2/ccrC2 R2 is cross-complementary to ccrC sequences present in both SCCmec 
types V and III (Figure 3.6).  Re-examination of the multiplex PCR profiles obtained 















corresponding to 449 bp due to the cross-complementarity of this primer pair (Figure 
3.3).  The 449 bp product amplified from isolate C17 was sequenced, and a BLAST 
query indicated that it was 96 % similar to the ccrC sequence present in WIS 
(Appendix F).  The ccrC gene is not typically present in SCCmec type I strains; 
therefore an individual PCR assay with the primer pair ccrC F2/ccrC R2 was carried 
out for all local SCCmec type I MRSA.  The ccrC gene was detected in all of these 
isolates, but not in isolate B1. 
 
In the PCR assay including primer pair RIF5 F10/RIF5 R13, a 414 bp product 
corresponding to that amplified from ANS46 was detected in isolate C17, but not in 












Figure 3.8 Agarose gel electrophoresis of PCR products obtained using the 
primer pair RIF5 F10/RIF5 R13 in PCR assays for the detection of a 414 bp 
product, described as unique to SCCmec type III isolates, in methicillin-
resistant S. aureus control strains and local SCCmec type I isolates with 
typical and atypical multiplex PCR profiles.  Lane 1, Hyperladder IV molecular 
weight marker; lane 2, control strain COL (SCCmec type I); lane 3, control strain 
ANS46 (SCCmec type III); lane 4, control strain WIS (SCCmec type V); lane 5, B2 
(atypical SCCmec type I multiplex profile); lane 6, B1 (typical SCCmec type I 
multiplex profile); lane 7, C17 (atypical SCCmec type I multiplex profile).  
 
The precise region of SCCmec type III amplified by RIF5 F10/RIF5 R13 was not 
specified by Oliveira and de Lencastre (2002) or Milheiriço et al. (2007a); however, 
examination of the nucleotide sequence of S. aureus strain 85/2082 (accession 















RIF5 F10/RIF5 R13 target a copy of ccrC present in the SCCHg component of 
SCCmec type III.  Although the ccrC genes in ANS46 and WIS are 91 % identical, 
alignment of RIF5 F10 and RIF5 R13 with the nucleotide sequences of WIS identified 
several mismatches between each of the primers and their complementary 
sequences.  This explains the absence of a 414 bp product for the SCCmec type V 
control strain, WIS, in the individual PCR assay including RIF5 F10/RIF5 R13 (Figure 
3.8).   
 
3.3.1.2 Characterisation of the SCCmec content of the remaining MRSA isolate 
with an atypical multiplex PCR profile 
The multiplex PCR profile of the remaining non-typable isolate, designated isolate S2 
(Appendix A), was similar to, but distinct from, the 36 MRSA isolates described 
above.  Four PCR products, including a 162 bp product corresponding to the mecA 
internal control, were detected in the multiplex PCR profile of S2 (Figure 3.3).  As for 
the 36 atypical SCCmec type I isolates, 495 bp, 449 bp, 414 bp and 162 bp products 
were detected in S2; however, the 342 bp product, corresponding to the dcs locus 
present in the J3 region of SCCmec types I, II, IV and VI (Table 3.1), was absent in 
this isolate (Figure 3.3).  Given the overall similarities between the multiplex profiles 
of the 36 SCCmec type I isolates and that of S2, PCR assays including primer pairs 
for the detection of the class B mec complex and ccr allotype 1 were also carried out 
for this isolate (Figure 3.4); however, products were only detected for the control 




























Figure 3.9 PCR products obtained following assays for the detection of the 
class B mec complex and ccr allotype 1, characteristic of SCCmec type I, in 
sporadic isolate S2 with a unique atypical multiplex PCR profile.  (A)  
Amplicons obtained following PCR assay for the detection of a 2827 bp region of 
the class B mec complex.  Lane 1, Hyperladder I molecular weight marker; lane 2, 
control strain COL (SCCmec type I; class B mec complex); lane 3, S2. (B)  
Amplicons obtained following PCR assay for the detection of a 695 bp region of ccr 
allotype 1.  Lane 1, Hyperladder IV molecular weight marker; lane 2, control strain 
COL (SCCmec type I; ccr allotype 1); lane 3, S2. 
 
In order to determine the SCCmec type of isolate S2, additional individual PCR 
assays, derived from the strategy described by Kondo et al. (2007), were carried out 
for the detection of the class A and C2 mec complexes.  Based on the detection of an 
804 bp region of the class C2 mec complex (Figure 3.10), an additional PCR assay 
for the detection of ccr allotype 5 was carried out using primers described by Kondo 
et al. (2007), as this mec-ccr combination is characteristic of SCCmec type V (Figure 
3.4).  The appropriate control strains were included in each assay (Figure 3.4).  A 
PCR product corresponding to a 518 bp region of ccr allotype 5 (ccrC), was amplified 















Figure 3.10 PCR products obtained following assays for the detection of the 
class C2 mec complex and ccr allotype 5, characteristic of SCCmec type V, in 
the sporadic isolate S2.  (A) Amplicons detected following a PCR assay for the 
amplification of an 804 bp region of the class C2 mec complex.  Lane 1, 
Hyperladder IV molecular weight marker; lane 2, control strain WIS (SCCmec type 
V; class C2 mec complex); lane 3, S2. (B) Amplicons detected following a PCR 
assay for the amplification of a 518 bp region of ccr allotype 5 (ccrC).  Lane 1, 
Hyperladder IV molecular weight marker; lane 2, control strain ANS46 (SCCmec 
type III; ccrC-positive); lane 3, control strain WIS (SCCmec type V, ccrC-positive); 
lane 4, control strain HDE228 (SCCmec type VI, ccrC-negative); lane 5, isolate S2. 
 
As the multiplex PCR profile of S2 was not consistent with that of WIS, the SCCmec 
type V control strain (Figure 3.3), the 804 bp and 518 bp putative mec class C2 and 
ccrC PCR products were sequenced directly.  Analysis of the sequencing data 
obtained for the 804 bp class C2 mec complex product showed that it was 99 % 
similar to that present in WIS (Appendix F); however, the sequencing data obtained 
for the 518 bp product were inconclusive.  The identities of nucleotide bases were 
ambiguous at several identical positions on both the forward and reverse sequences, 


















Figure 3.11 Nucleotide sequences of a portion of ccrC from sporadic isolate 
S2.  (A) Trimmed nucleotide sequence generated from an alignment of the forward 
and reverse sequences of the 518 bp PCR product amplified from S2 using ccrC-
specific primer pair γF/ γR.  Identical ambiguous bases were detected on both the 
forward and reverse sequences (Y/K/R/M/W; shown in bold and underlined). (B)  
Ambiguous bases identified in (A) corresponded to identical double peaks at a 
single nucleotide position in the chromatograms of the forward and reverse 
sequences.  This is illustrated for the portion of the sequence highlighted in orange 















Scrutiny of the chromatograms revealed identical double peaks at corresponding 
nucleotide positions in the forward and reverse sequences, suggesting that the purified 
PCR products included at least two ccrC alleles (Figure 3.11).  The detection of a class 
C2 mec complex in conjunction with ccrC suggested that S2 contained SCCmec type V; 
however, the assignment was tentative based on the detection of multiple copies of ccrC 
(Figure 3.4). 
 
The typical multiplex PCR profile of SCCmec type V strains includes 449 bp, 377 bp and 
162 bp products (Table 3.1); however, the amplification profile of S2 included only 2 of 
these products (449 bp and 162 bp), as well as 2 additional products (495 bp and 414 bp) 
not typically associated with SCCmec type V, as shown in Figures 3.3 and 3.12. 
 
Figure 3.12 Schematic diagram depicting the atypical SCCmec typing multiplex 
PCR profile obtained for the putative SCCmec type V isolate, S2.  The 377 bp 
amplicon typical of SCCmec type V was not detected in S2, and 2 additional amplicons 
that equated with the sizes of products typically amplified from SCCmec types other than 
V were present.  Individual PCR assays including primers for the amplification of these 
corresponding products, followed by sequencing where necessary, confirmed the 
identities of atypical products, and also failed to detect a 377 bp fragment.  *Emanating 
from primer pair ccrC2 F2/ccrC2 R2 (cross-complementary to ccrC present in SCCmec 
type V and in the SCCHg component of SCCmec type III).  **Emanating from RIF5 
















Given its atypical PCR profile, the amplicons generated for S2 during the SCCmec 
typing multiplex PCR were characterised further.  Based on the detection of at least 
two ccrC alleles in S2, it was suspected that the 449 bp and 414 bp products 
emanated  from  the ccrC-specific primer pairs ccrC F2/ccrC R2  and  RIF5 F10/RIF5 
R13, respectively.  This was confirmed using individual PCR assays that included 













Figure 3.13 Agarose gel electrophoresis of amplicons obtained following PCR 
assays with the primer pair ccrC F2/ccrC R2 to confirm the origin of the 449 
bp product detected in the multiplex PCR profile of the putative SCCmec type 
V isolate, S2.  Lane 1, Hyperladder IV molecular weight marker; lane 2, COL 




























Figure 3.14 Agarose gel electrophoresis of amplicons obtained following PCR 
assays with the primer pair RIF5 F10/RIF5 R13 to confirm the origin of the 414 
bp product detected in the multiplex PCR profile of the putative SCCmec type 
V isolate, S2.  Lane 1, Hyperladder IV molecular weight marker; lane 2, ANS46 
(SCCmec type III; ccrC-positive, detected by RIF5 F10/RIF5 R13); lane3, WIS 
















The 377 bp product typically amplified from the J1 region of SCCmec type V strains 
(Table 3.1; Figure 3.12) was not detected in the multiplex PCR profile of S2 (Figure 
3.3).  An individual PCR assay including only primer pair SCCmec V J1 F/SCCmec 
J1 R for the amplification of the 377 bp product was carried out; however, the 377 bp 
product was only amplified from the control strain, WIS, as indicated in Figure 3.15, 














Figure 3.15 Agarose gel electrophoresis of amplicons obtained following PCR 
assays for the detection of a 377 bp portion of the SCCmec type V J1 region 
in the putative SCCmec type V isolate, S2.  Lane 1, Hyperladder IV molecular 
weight marker; lane 2, control strain COL (SCCmec type I); lane 3, control strain 
WIS (SCCmec type V); lane 4, S2 (putative SCCmec type V).  
 
The atypical 495 bp product detected in S2 corresponded to the expected size of the 
product amplified from the region downstream of pls in the J1 region of SCCmec type 
I (Figure 3.12; Table 3.1).  An individual PCR assay including the primer pair CIF2 
F2/CIF2 R2 complementary to this locus confirmed that the 495 bp product was 
indeed amplified from S2, but not from WIS, the SCCmec type V control strain 
(Figure 3.16).  A BLAST query of the DNA sequence of the 495 bp product indicated 
a 96 – 100 % nucleotide identity with SCCmec-associated pls loci, suggesting the 




























Figure 3.16 Agarose gel electrophoresis of amplicons obtained following PCR 
assays for the amplification of a 495 bp product, described as unique to 
SCCmec type I, in the putative SCCmec type V isolate, S2.  Lane 1, Hyperladder 
IV molecular weight marker; lane 2, control strain COL (SCCmec type I); lane 3, 
control strain WIS (SCCmec type V); lane 4, S2.  
 
In conclusion, using a number of PCR assays, including the multiplex method 
described by Milheiriço et al. (2007a) and the typing strategy of Kondo et al. (2007), 
SCCmec types were assigned to the 100 MRSA isolates.  Forty-six isolates carried 
SCCmec type IV, 37 SCCmec type I, 12 SCCmec type II, 4 SCCmec type III and 1 
















3.3.2 Subtyping of SCCmec type IV isolates 
The multiplex PCR assay described by Milheiriço et al. (2007b) was used to subtype all 
SCCmec type IV isolates.  The PCR profiles obtained for control strains IVa – IVE, IVg and IVh, 
and for a subset of local SCCmec type IV isolates, are shown in Figure 3.17.  Forty-four of the 
46 SCCmec type IV isolates contained subtype IVd.  One of the two remaining MRSA isolates 
contained subtype IVh, while the PCR profile of the other isolate suggested the presence of 
subtype IVb or IVF.  Based on the detection of the dcs locus in the SCCmec typing multiplex 
PCR, the subtype of the outstanding isolate was confirmed as IVb.   
 
Figure 3.17 SCCmec type IV subtyping multiplex PCR profiles obtained for SCCmec type 
IV control strains and a representative selection of SCCmec type IV isolates from 
hospitals in Cape Town. Lanes 2 – 8 contain MRSA control strains with SCCmec type IV 
subtypes IVa – IVE, IVg and IVh; lanes 10 – 24 contain a selection of SCCmec type IV isolates 
obtained from hospitals in Cape Town. Lane 1, Hyperladder IV molecular weight marker; lane 
2, JCSC4744 (subtype IVa); lane 3, JCSC2172 (subtype IVb); lane 4, DEN2949 (subtype IVc); 
lane 5, BK2529 (subtype IVd); lane 6, AR43/3330.1 (subtype IVE); lane 7, M03-68 (subtype 
IVg; 203 bp internal control amplicon absent because the 792 bp amplicon corresponding to a 
portion of the J1 region of IVg was used as template DNA); lane 8, HAR22 (subtype IVh); lane 
9, Hyperladder IV molecular weight marker; lane 10, S1 (IVd); lane 11, S4 (IVd); lane 12, S5 
(IVd); lane 13, S6 (IVd); lane 14, S7 (IVh); lane 15, S8 (IVb); lane 16, D1(IVd); lane 17, D2 
(IVd) ; lane 18, D3 (IVd); lane 19, D4 (IVd); lane 20, D5 (IVd); lane 21, D6 (IVd); lane 22, D7 
















Multiplex PCR assays are popular worldwide for SCCmec typing because they 
enable the rapid determination of SCCmec types in both the diagnostic and research 
environments (de Lencastre et al., 2007); however, these assays are not without their 
pitfalls (Deurenberg and Stobberingh, 2008).  Previous studies have incorrectly 
classified SCCmec elements due to primer cross-complementarity (Jansen et al., 
2009), which was also problematic in the current study, and the identification of 
atypical amplification patterns frequently forces researchers to report isolates as non-
typable.  The investigations required to resolve atypical multiplex PCR profiles are 
intricate, often necessitating long-range PCR or the creation of cosmid or fosmid 
libraries in order to determine the underlying genetic structure of the element (Shore 
et al., 2005; Heusser et al., 2007; Berglund et al., 2008; Berglund et al., 2009).   
 
A further shortcoming of the majority of existing SCCmec typing methods is that they 
lack the capacity to characterise novel SCCmec types and subtypes.  The most 
comprehensive typing strategy currently available is that of Kondo et al. (2007), 
which allows for the detection of novel combinations of mec complex and ccr 
allotype.  The method includes six multiplex PCR assays, and, as a result, it is not 
practical for routine use (de Lencastre et al., 2007; Deurenberg and Stobberingh, 
2008); however, as shown in the current study, the method has value in the research 
setting.  While multiplex strategies such as that of Kondo et al. (2007) may detect 
new combinations of mec complex and ccr allotype, the IWG-SCC does not deem 
this sufficient for the description of novel SCCmec types.  The IWG-SCC currently 
recommends complete nucleotide sequencing of any putative novel SCCmec type or 
subtype inferred from multiplex profiles because PCR products represent only a 
small portion of the element, and are not absolute indicators of underlying nucleotide 
sequence identities (Ito et al., 2009). 
 
In the current study the SCCmec types of the 100 MRSA isolates were determined 
using two popular multiplex PCR assays (Kondo et al., 2007; Milheiriço et al., 2007a) 
and DNA sequencing.  SCCmec types IV and I were most prevalent among local 
MRSA, accounting for forty-six and thirty-seven isolates, respectively.  Twelve and 
four isolates contained SCCmec types II and III, respectively, while the remaining 















types I, II and III collectively accounted for the majority of the isolates given that 
these elements have frequently been described in association with HA-MRSA 
isolates worldwide (de Lencastre et al., 2007; Deurenberg and Stobberingh, 2008; 
Ratnaraja and Hawkey, 2008).  Similarly, SCCmec types I, II and III also accounted 
for the collective majority of isolates included in the recent molecular characterisation 
of MRSA from public and private microbiology laboratories from throughout South 
Africa (Moodley et al., 2010). 
 
Examination of the SCCmec content of the MRSA in conjunction with the PFGE data 
indicated an absolute correlation between PFGE cluster and SCCmec type 
(Appendix A).  The SCCmec type IV isolates were distributed across clusters D and 
E, and also included six sporadic isolates (S1, S4, S5, S6, S7 and S8).  Clusters B 
and C contained all SCCmec type I isolates, while SCCmec type II and III isolates 
were assigned to clusters F and A, respectively (Appendix A).  The remaining 
sporadic isolates, S2 and S3, contained the putative SCCmec type V element and 
SCCmec type II, respectively.  Associations betwe n PFGE clusters and particular 
SCCmec types were also reported by Moodley et al. (2010) following their recent 
study on the molecular epidemiology of MRSA from South Africa.  In contrast, 
multiple SCCmec types have previously been reported within a single PFGE cluster 
(Laplana et al., 2007).  In the local context, a recent study on the molecular 
characterisation of MRSA from the KwaZulu-Natal province of South Africa reported 
up to four SCCmec types within a single PFGE profile (Shittu et al., 2009).  Whether 
these differences in associations between PFGE clusters and SCCmec types are 
due to the excision and subsequent replacement of SCCmec elements within 
particular MRSA lineages, or to variations in PFGE protocols and methods of data 
analysis remains to be determined. 
 
Since the first description of SCCmec type IV in CA-MRSA isolated from children in a 
Chicago hospital (Daum et al., 2002; Ma et al., 2002), this SCCmec type has been 
described frequently in both communities and hospitals worldwide (McDougal et al., 
2003; Donnio et al., 2004; Ma et al., 2006; Taneike et al., 2006; de Lencastre et al., 
2007; Laplana et al., 2007; Mimica et al., 2009; Shittu et al., 2009; Strandén et al., 
2009).  Perhaps unsurprisingly, therefore, SCCmec type IV was the dominant 
SCCmec element identified in the current study accounting for 46 % of the isolates, 















reported that the national prevalence of SCCmec type IV was 38 %, and showed that 
the element was distributed throughout the country, while Shittu et al. (2009) and 
Essa et al. (2009) reported a prevalence of 62.3 % and 79 %, respectively, among 
MRSA  from  the KwaZulu-Natal province.   The low frequency of SCCmec type  IV  
(4 %) among MRSA from the Steve Biko Academic Hospital in Pretoria, in the 
Gauteng province of South Africa, was the only inconsistency in the literature 
(Makgotlho et al., 2009).   
 
SCCmec type IVd accounted for forty-four of the forty-six SCCmec type IV isolates 
(Appendix A), which included all isolates from PFGE clusters D and E.  
Internationally, SCCmec type IVd was common among MRSA obtained from 
Japanese hospitals during the early 1980s (Ma et al., 2006), and has since been 
described in the epidemic USA500 clone (Zhang et al., 2008), at a low frequency in 
MRSA from Israel (Maor et al., 2009), in association with CC22 isolates from England 
and Wales (Boakes et al., 2010), and also in MRSA isolated from horses and 
veterinary staff in the UK and Europe (Cuny et al., 2006; Williams, 2008; Clegg, 
2010).  In South Africa, SCCmec type IV subtyping remains uncommon, with only the 
report of Makgotlho et al. (2009) including information obtained using this technique.  
Interestingly, that study reported that all four SCCmec type IV isolates detected 
among MRSA from the Steve Biko Academic Hospital, Pretoria, contained subtype 
IVd.  The four isolates were classified as CA-MRSA based on the presence of 
SCCmec type IV and pvl, both of which are currently considered molecular markers 
of CA-MRSA (Millar et al., 2007).  This raised the question whether or not the 
SCCmec type IV isolates from Cape Town might also carry pvl, and may have 
originated in the community, which will be considered further in Chapter 4. 
 
The two remaining SCCmec type IV isolates, S7 and S8 (Appendix A), contained 
subtypes IVh and IVb, respectively.  Subtype IVb was first described in CA-MRSA 
from the USA (Ma et al., 2002), but has rarely been reported since.  In addition to 
containing the uncommon SCCmec type IVb, S8 was also the PFGE outlier and the 
only isolate pan-susceptible to non-β-lactam antibiotics, which collectively suggested 
that this isolate may have had a different origin to the other study isolates.  The same 
may be true of S7, which contained subtype IVh.  This subtype has been commonly 
described in association with the pandemic clone EMRSA-15 (Milheiriço et al., 















several countries in HA-MRSA, CA-MRSA and MRSA from companion animals 
(Faria et al., 2005; Moodley et al., 2006; Strommenger et al., 2006b; de Lencastre et 
al., 2007; Boakes et al., 2010). 
 
The reasons for the prevalence of MRSA isolates carrying SCCmec type IV in Cape 
Town and other regions of South Africa are likely to be complex.  It is possible that 
the prevalence of this element is related to the fact that SCCmec type IV is the most 
frequently transferred SCCmec element, and is thought to be associated with a lower 
fitness cost than the larger SCCmec elements (Ma et al., 2002; Okuma et al., 2002; 
Robinson and Enright, 2003).  In light of the fact that 65.32 % of SCCmec type IV 
isolates obtained from public and private microbiology laboratories across South 
Africa belonged to two PFGE clusters (Moodley et al., 2010), it is interesting to 
consider the possibility that the SCCmec type IV isolates from Cape Town may be 
related to those from other regions of the country; however, a complete molecular 
characterisation, incorporating sequence-based typing techniques, is required to 
resolve this issue, as will be discussed further in subsequent chapters of this thesis. 
 
In terms of SCCmec epidemiology, one of the major differences observed in the 
present study was the relatively low prevalence of isolates containing SCCmec types 
II (12 %) and III (4 %) in hospitals in Cape Town compared to the nationwide 
prevalence rates of 25.94 % and 25.00 %, respectively (Moodley et al., 2010).  
Closer examination of two regional studies indicated that, although SCCmec type II 
comprised a small proportion of MRSA from healthcare institutions in KwaZulu-Natal 
(Essa et al., 2009; Shittu et al.; 2009), SCCmec type III was more prevalent in that 
province than in Cape Town, accounting for 26.5 % (Shittu et al., 2009) and 13 % 
(Essa et al., 2009) of the isolates.  In contrast, SCCmec type II accounted for the 
majority (67 %) of the MRSA from the Steve Biko Academic Hospital in Pretoria, 
while SCCmec type III was second-most prevalent accounting for 14 % of the 
isolates (Makgotlho et al. 2009). 
 
Perhaps the most striking difference between SCCmec epidemiology in Cape Town 
and the remainder of South Africa was the markedly varied frequencies of SCCmec 
type I isolates throughout the country.  SCCmec type I was the second-most 















for 37 % of the isolates.  This contrasted sharply with the work of Essa et al. (2009) 
and Makgotlho et al. (2009) who did not detect SCCmec type I isolates among MRSA 
from KwaZulu-Natal and Pretoria, respectively.  Similarly, Shittu et al. (2009) only 
detected a single SCCmec type I isolate comprising 1.6 % of MRSA from healthcare 
institutions in KwaZulu-Natal.  Based on the recent report by Moodley et al. (2010), 
the nationwide prevalence of SCCmec type I was only 10.3 %.  Additionally, that 
study showed an uneven geographical distribution of isolates from PFGE clusters 
associated with SCCmec type I.  Isolates carrying this SCCmec type were obtained 
from laboratories in all provinces except Gauteng and the Northern Cape, hinting at 
regional differences in SCCmec epidemiology (see Appendix G for a provincial map 
of South Africa).  It should be noted that Moodley et al. (2010) did not indicate the 
proportion of isolates obtained from each province, and it is possible that the uneven 
distribution of MRSA clones observed in that study may reflect uneven provincial 
contributions.  However, assuming that the contributions from each province were 
equal, these findings may suggest that MRSA lineages carrying SCCmec type I have 
not have been disseminated throughout South Africa.  Alternatively, these lineages 
may have enjoyed a limited success, or may have been usurped by other clones in 
certain regions of the country.   
 
The amplification of ccrC in thirty-six of the otherwise typical SCCmec type I isolates 
was unexpected as the gene is not commonly described in strains carrying this 
SCCmec element.  A portion of the gene was amplified with primers specific for the 
ccrC allele present in SCCHg of SCCmec type III, but not that present in SCCmec 
type V; therefore, it is possible to suggest that the ccrC allele present in local 
SCCmec type I isolates may be more similar to that present in SCCHg.  To the best 
of the author‘s knowledge this is the first report of SCCmec type I isolates carrying 
ccrC in South Africa as previous studies have not detected the gene, or reported 
SCCmec type I isolates with atypical multiplex PCR profiles.  In the global context, to 
the best of the author‘s knowledge, the amplification of ccrC from SCCmec type I 
strains has only been reported in two isolates, one each from England and Egypt 
(Kondo et al., 2007); however mosaic or composite elements including multiple ccr 
complexes are being described with increasing frequency in S. aureus and CNS 
(Heusser et al., 2007; Higuchi et al., 2008; Ito et al., 2009; Chlebowicz et al., 2010; 
















Mosaic or composite SCCmec types consist of combinations of SCC(mec) elements, 
and occur in two similar but distinct forms.  In the first, two SCC elements, both 
carrying ccr complexes, but typically only one carrying a mec complex, integrate in 
tandem into the S. aureus chromosome.  These composite elements are defined by 
the presence of the characteristic 15 bp terminal direct repeat sequence at their 
internal junction, as illustrated by SCCmec type III, which consists of tandem copies 
of SCCHg and SCCmec III.  Alternatively, the two SCC elements may fuse to form a 
composite element in which no direct repeat sequence can be detected at the 
internal junction, as seen in SCCmec type VII (Ito et al., 2009).  It is possible that 
local SCCmec type I isolates in fact contain one of these two types of composite 
elements including SCCmec type I, and another ccrC-driven SCC element; however, 
the possibility that ccrC is located elsewhere on the bacterial chromosome cannot be 
excluded at present.   
 
It is interesting to speculate on the absence of ccrC in isolate B1, the only typical 
SCCmec type I isolate, in the context of its relatedn ss to ccrC-positive B2.  Isolates 
B1 and B2 were defined as a two-member PFGE cluster due to their similarity level 
of 80.01 %.  It is possible that B1, or its recent ancestors, contained ccrC, but 
subsequently lost the region, which would explain the presence of ccrC in isolate B2.  
On the other hand, the similarity level defining cluster B is only marginally higher than 
the recommended 80 % cluster threshold (Murchan et al., 2003), and there are 
marked differences between the macrorestriction profiles of B1 and B2; therefore, it 
is interesting to consider the possibility that these isolates may in fact be less similar 
than estimated by PFGE.  Although it is unusual to overestimate the relatedness of 
isolates using PFGE, it is possible that the similarities in the macrorestriction profiles 
of B1 and B2 did not reveal underlying diversity in the DNA sequences.  If this is the 
case, ccrC may only have been acquired after B1 and the ccrC-positive SCCmec 
type I isolates diverged from a common ancestor.  The additional investigations 
required to determine the precise location of ccrC, characterise the potential 
composite element, and explain the absence of a corresponding amplicon in isolate 
B1 would necessitate sequencing of the entire SCCmec element and its flanking 
chromosomal regions, which was not possible given the time and funding available 
















One isolate, S2, was tentatively classified as containing SCCmec type V, based on 
the detection of the class C2 mec complex in conjunction with ccr allotype 5 (ccrC).  
SCCmec type V is commonly associated with CA-MRSA (de Lencastre et al., 2007; 
Tristan et al., 2007b; Deurenberg and Stobberingh, 2008; Ratnaraja and Hawkey, 
2008), and, to the best of the author‘s knowledge, has not been previously described 
in South Africa (Essa et al., 2009; Shittu et al., 2009; Makgotlho et al., 2009; Moodley 
et al., 2010).  The detection of at least two copies of ccrC in S2 was not wholly 
unexpected as there have recently been several reports of SCCmec type V isolates 
carrying multiple ccrC alleles (Higuchi et al., 2008; Chlebowicz et al., 2010; Coombs 
et al., 2010).  On the other hand, it is also possible that S2 may contain a novel 
composite SCCmec element with multiple ccrC alleles.   
 
As recommended by the IWG-SCC (Ito et al., 2009), S2 was classified based on the 
combination of mec complex and ccr allotype detected, but queries regarding the 
composition and identity of this SCCmec element were raised based on the results of 
investigations into its atypical multiplex PCR profile.  Additional PCR assays for the 
detection of a portion of the SCCmec type V J1 region did not detect this region in 
S2; therefore, it is possible to suggest that S2 contains a variant of SCCmec type V 
with a modified J1 region.  Alternatively, it is possible that the SCCmec element 
present in S2 does not correspond to SCCmec type V.  The detection of the pls 
locus, characteristic of SCCmec type I, was also unexpected (Oliveira and de 
Lencastre, 2002; Milheiriço et al., 2007a; Werbick et al., 2007); this locus has been 
detected in an SCCmec type IV isolate (Werbick et al., 2007), and also in SCCmec 
type II and III isolates (Deschamps et al., 2003) but, to the best of the author‘s 
knowledge, has not been described in association with SCCmec type V.  As 
recommended by the IWG-SCC (Ito et al., 2009), sequencing of the entire SCCmec 
element and its flanking regions is necessary to definitively determine the type of the 
SCCmec element present in isolate S2 and, as previously discussed, these 
















The Identification of Community- and Hospital-Acquired 
Methicillin-Resistant S. aureus 
 
4.1 Introduction 
Community-associated MRSA (CA-MRSA) was first reported in the early 1990s in 
Western Australia.  Those infected were previously healthy members of indigenous 
populations living in remote communities who had no known risk factors for MRSA 
infection (DeLeo et al., 2010).  In the past decade, there have been increasingly 
frequent reports of CA-MRSA infections worldwide, particularly in the USA, Europe 
and Oceania (Millar et al., 2007; Deurenberg and Stobberingh, 2008; Witte, 2009; 
DeLeo et al., 2010).  CA-MRSA primarily tends to cause skin and soft tissue 
infections, but has also been implicated in more severe systemic infections such as 
sepsis, pneumonia and necrotising fasciitis (Millar et al., 2007; Witte, 2009; Cooke 
and Brown, 2010).  The additional virulence factors present in many CA-MRSA 
lineages cause these strains to be more virulent than their HA-MRSA counterparts, 
resulting in severe disease (Deurenberg and Stobberingh, 2008; DeLeo et al., 2010). 
 
Studies on the molecular evolution of CA-MRSA have indicated that these lineages 
are distinct from HA-MRSA lineages, and are also more diverse (Groom et al., 2001; 
Naimi et al., 2001; Enright et al., 2002; Okuma et al., 2002; Vandenesch et al., 2003; 
Tristan et al., 2007b; Deurenberg and Stobberingh, 2008; Elston and Barlow, 2009).  
Certain CA-MRSA clones belong to unique lineages which have not given rise to HA-
MRSA, such as ST59, ST152 and ST80, while others appear to have emerged 
independently in lineages known to contain HA-MRSA clones, such as ST1, ST5, 
ST8, ST22 and ST30 (Deurenberg and Stobberingh, 2008; Witte, 2009; Lindsay, 
2010).  Table 4.1 provides an overview of the major CA-MRSA clones and their 

















Table 4.1 An overview of important community-associated methicillin-






















Ast, Can, Fin, Fra, Ger, 
Sin, Swi, Uru, USA 
ST8-MRSA-IV 8 Positive USA300 
Ast, Can, Fin, Fra, Ger, 
Sin, Swi, Uru, USA 




Ast, Aus, Bel, Bra, Chn, 
Den, Fin, Egy, Ger, Ire, 
Jap, Lat, Net, Nor, NZ, 
Rus, Sin, Spa, Swe, 
Swi, UK, Uru, USA 
ST59-MRSA-IV/V 59 Positive USA1000 
Ast, Chn, Fra, Ger, Net, 
Nor, Sin, Swe, Tai, 
USA 
ST80-MRSA-IV 80 Positive European 
Alg, Ast, Aus, Bel, Bul, 
Cro, Den, Fin, Fra, Ger, 
Gre, Ire, Lib, Net, Nor, 
Rom, Sin, Slo, Spa, 
Swe, Swi, Tun, UK, 
Yug 
a
 Adapted from Deurenberg and Stobberingh (2008); Elston and Barlow (2009); DeLeo et al. 
(2010). 
b
 Clone name as determined using the universal nomenclature proposed by Enright et al. (2002) 
following the form (Sequence Type-methicillin resistance phenotype-SCCmec type). 
c
 Alg, Algeria; Ast, Australia; Aus, Austria; Bel, Belgium; Bra, Brazil; Bul, Bulgaria; Can, Canada; 
Chn, China; Cro, Croatia; Den, Denmark; Egy, Egypt; Fin, Finland; Fra, France; Ger, Germany; 
Gre, Greece; Ire, Ireland; Isr, Israel; Jap, Japan; Kor, Korea; Lat, Latvia; Lib, Libya; Net, 
Netherlands; NZ, New Zealand; Nor, Norway; Rom, Romania; Rus, Russia; Sin, Singapore; Spa, 
Spain; Swe, Sweden; Swi, Switzerland; Tai, Taiwan; Tun, Tunisia; UK, United Kingdom; Uru, 
Uruguay; USA, United States of America; Yug, Yugoslavia. 
 
Several molecular markers have traditionally been associated with CA-MRSA, and 
have been used to distinguish these strains from their HA-MRSA counterparts (Millar 
et al., 2007).  CA-MRSA have typically been associated with the smaller SCCmec 
elements, such as SCCmec types IV, V and VII, while HA-MRSA generally carry 
SCCmec types I – III (Table 4.1) (Deurenberg and Stobbering, 2008; Cooke and 
Brown, 2010; DeLeo et al., 2010; Nastaly et al., 2010).  CA-MRSA isolates have 
frequently been described as susceptible to non-β-lactam antibiotics, while HA-
MRSA isolates are often resistant to several classes of antimicrobial agents (Millar et 
al., 2007; Deurenberg and Stobbering, 2008; Cooke and Brown, 2010; Nastaly et al., 
2010).  Additionally, the Panton-Valentine leukocidin (PVL) toxin has been described 















2003; Millar et al., 2007; Tristan et al., 2007a; Tristan et al., 2007b; Deurenberg and 
Stobbering, 2008; Diep and Otto, 2008; Cooke and Brown, 2010; DeLeo et al., 2010). 
 
PVL is encoded by the lukPV operon (also known as pvl), which is carried by several 
prophages (Diep and Otto, 2008; Malachowa and DeLeo, 2010).  The pvl operon 
consists of the co-transcribed lukS-PV and lukF-PV genes, which encode the two 
subunits of the pore-forming toxin (Boyle-Vavra and Daum, 2007; Nastaly et al., 
2010).  The LukS-PV and LukF-PV subunits are secreted by the bacterial cell, bind to 
each other, and then assemble into heptamers, which localise to the membranes of 
polymorphonuclear leukocytes (PMNs) (Nastaly et al., 2010).  Once bound to the cell 
membrane, PVL induces pore formation which, at low PVL concentrations, causes 
apoptosis or, at high PVL concentrations, cell lysis (Boyle-Vavra and Daum, 2007; 
Nastaly et al., 2010).  It is thought that PVL-mediated apoptosis and lysis of PMNs, 
enables CA-MRSA to evade the host‘s innate immune response; however, the 
precise role of PVL in the pathogenesis of CA-MRSA infections is not yet fully 
understood (Boyle-Vavra and Daum, 2007).  It has been suggested that sepsis and 
tissue necrosis are indirectly mediated either by an inflammatory cascade induced by 
apoptosis or lysis of immune cells, or by cytotoxic elements released by lysed 
components of the immune system (Kaneko and Kamio, 2004). 
 
The contribution of PVL to S. aureus pathogenesis remains controversial as several 
studies have reported conflicting results (Deurenberg and Stobberingh, 2008).  A 
study carried out using isogenic pvl MRSA strains in an acute pneumonia mouse 
model showed that only mice infected with pvl-positive MRSA developed necrotising 
pneumonia (Labandeira-Rey, 2007).  This contrasted with studies reported by Saïd-
Salim et al. (2005) and Voyich et al. (2006). Saïd-Salim et al. (2005) found no 
difference in the ability of pvl-positive and pvl-negative clinical CA-MRSA to lyse 
human PMNs.  Similarly, Voyich et al. (2006) found no difference in the survival of 
mice infected with pvl-positive and pvl-negative MRSA in a mouse sepsis model, 
and, in a mouse abscess model, abscesses caused by pvl-negative strains were in 
fact slightly larger than those caused by pvl-positive strains.  In the same study, the 
authors reported no difference in the ability of isogenic pvl strains of the epidemic 
CA-MRSA clones USA300 and USA400 to lyse PMNs.  Studies have also provided 
evidence that the virulence of CA-MRSA can be attributed to factors other than pvl 















include the arginine catabolic mobile element (ACME), other toxins such as the α-
toxin, and secreted phenol-soluble modulins able to lyse human neutrophils, which 
have been found in epidemic CA-MRSA clones such as USA300 and USA400 
(Deurenberg and Stobberingh, 2008; Gordon and Lowy, 2008).  It has also been 
suggested that differential expression of virulence determinants may play a role in 
the pathogenesis of certain CA-MRSA strains (Li et al., 2009).  
 
While the contribution of PVL to the virulence of CA-MRSA is currently under debate, 
numerous studies have provided epidemiological data suggesting an association 
between PVL and CA-MRSA.  Diep and Otto (2008) carried out a PubMed search for 
articles on pvl published between 2002 and 2007, and found over 250 articles 
describing an association between pvl and CA-MRSA outbreaks.  Although there is 
strong epidemiological evidence supporting an association between CA-MRSA and 
pvl, recent reports suggest that the association is not universal as was initially 
assumed, with pvl-negative CA-MRSA described in Australia, Japan, Korea, 
Madagascar and parts of Europe (Coombs t al., 2004; Deurenberg and 
Stobberingh, 2008; Nimmo and Coombs, 2008; DeLeo et al., 2010). 
 
It is currently recommended that isolates be defined as CA- or HA-MRSA based on a 
combination of their epidemiological origin, which is most commonly ascertained 
using criteria developed by the Centers for Disease Control and Prevention (CDC) 
(Figure 4.1), and the presence of distinguishing molecular characteristics typical of 
these two groups (Millar et al., 2007; Elston and Barlow, 2009).  The classification of 
CA- and HA-MRSA has become increasingly complicated in recent years as the 
distinctions between these groups have started to blur (Millar et al., 2007; 
Deurenberg and Stobberingh, 2008).  Strains with molecular characteristics 
associated with CA-MRSA have been reported in the healthcare setting, and, 
conversely, strains with characteristics typical of HA-MRSA have become prevalent 
in communities, revealing inadequacies in the existing terminology (Millar et al., 
2007; Deurenberg and Stobberingh, 2008; Nimmo and Coombs, 2008; Ratnaraja and 
Hawkey, 2008; Elston and Barlow, 2009; Witte, 2009).  In this thesis, CA-MRSA and 
HA-MRSA will only be used to denote strains known to have evolved in the 
community and healthcare settings, respectively.  As described by Witte (2009) and 
summarised in Figure 4.1, an additional set of abbreviations may be used to indicate 















For the purposes of this thesis, ca- and ha-MRSA will denote community- and 
hospital-acquired MRSA, respectively, regardless of their molecular characteristics.  
In this context, ha-MRSA will be used to describe nosocomial infections, as well as 
community-onset infections in patients with one or more of the risk factors for 
nosocomial infection.   
 
Figure 4.1 Definitions and Centers for Disease Control and Prevention (CDC) 
criteria used to distinguish methicillin-resistant S. aureus (MRSA) with 
different epidemiological origins.  In this thesis, the term ha-MRSA will be used 
to indicate both nosocomial MRSA and community-onset MRSA isolated from 
patients with one or more of the traditional risk factors for healthcare-acquired 
MRSA.  Adapted from Millar et al. (2007) and Witte (2009). 
 
The SCCmec types detected in Chapter 3 raised questions regarding the origins of 
several isolates.  Of particular interest was the large number of isolates with SCCmec 
type IV, given that this SCCmec element is considered a common molecular marker 
of CA-MRSA (Millar et al., 2007).  SCCmec type IVd accounted for the majority of the 















to date in South Africa have contained pvl, (Makgotlho et al., 2009), which is also 
considered a common molecular marker of CA-MRSA (Millar et al., 2007).  Although 
drawing epidemiological distinctions between local ca- and ha-MRSA was not the 
focus of this study, available admissions data were used to classify the MRSA 
isolates as ca-MRSA or ha-MRSA.  Additionally, all isolates were screened for the 















4.2 Experimental Protocol 
4.2.1 Identification of community- and hospital-acquired MRSA based on 
admissions data 
The CDC defines ca-MRSA as MRSA isolated within 48 hours of admission to 
hospital, or in an outpatient setting, from patients who have not been hospitalised, 
admitted to a nursing home or hospice, or undergone dialysis within the previous 12 
months.  Additionally, the patient should not have a medical history of MRSA 
infection or colonisation, and should not have permanent medical devices that pass 
through the skin (Millar et al., 2007).  As indicated, it was not the aim of this study to 
compare ca- and ha-MRSA; nevertheless a rudimentary approach was used to 
define isolates based on electronic admission records.   
 
The electronic admission records were reviewed and isolates defined as either ca- or 
ha-MRSA by Dr Andrew Whitelaw (consultant microbiologist in the NHLS laboratory, 
GSH).  In accordance with the CDC definition, MRSA isolated within 48 hours of 
hospital admission from patients who had not been hospitalised or treated in an 
outpatient clinic within the previous 12 months, was classified as ca-MRSA, and all 
other isolates were classified as ha-MRSA.  It should be noted that the electronic 
admission records only detail admission data and outpatient visits related to state 
healthcare facilities in Cape Town, and thus do not include a history of admission to 
private healthcare facilities, nursing homes or healthcare facilities outside of Cape 
Town.  Likewise, data regarding the presence of indwelling medical devices was not 
available; however, one can assume that a patient with no admissions or outpatient 
visits within the previous 12 months was probably unlikely to have had an indwelling 
medical device.  Additionally, patients should not have been colonised with MRSA 
but, as patients are not screened on admission to hospitals in Cape Town, a history 
of colonisation would not have been detected. 
 
4.2.2 Detection of pvl 
The PCR assay for the detection of pvl described by Lina et al. (1999) was used in 
this study.  The method was optimised by Dr Sumayya Haffejee who screened 45 of 
the study isolates.  The remaining MRSA isolates were screened by the author.  The 















buffer, 1.5 mM MgCl2, 1.25 U of SuperTherm Taq polymerase (JMR Holdings, 
London, UK), and  200 µM  dNTP  mix  (Thermo  Scientific,  Wilmington,  DE,  USA).   
The primers luk-PV-1 and luk-PV-2 (Appendix E) were included at a final 
concentration of 0.8 µM each for the co-amplification of lukS-PV and lukF-PV.  
Thereafter, 5 ng of template DNA were added to the reaction volume.  PCR 
amplification was carried out in an Applied Biosystems 2720 Thermocycler (Applied 
Biosystems, Carlsbad, CA, USA) and the parameters were as follows: an initial 
denaturation step for 3 min at 94°C, followed by 35 cycles of 30 s at 94°C, 30 s at 
55°C, and 30 s at 72°C, and a final extension step of 1 min at 72°C.  The S. aureus 
control strains ATCC49775 and ATCC43300 were included in each experiment as 
positive and negative controls respectively.  PCR products were visualised using UV 


















4.3.1 Identification of community- and hospital-acquired MRSA based on 
admissions data 
Using the criteria described in section 4.2.1, 10 isolates were identified as putative 
ca-MRSA (Table 4.2).  These isolates were obtained from patients at RCCH (n = 6), 
GSH (n = 3) and MMH (n = 1) and were cultured from pus and pus swabs (n = 6), 
urine (n = 3) and sputum (n = 1).  Available collection data for the putative ca-MRSA 
isolates are shown in Table 4.2, with full details shown in Appendix A.  
 
Table 4.2. Molecular typing and laboratory data for putative community-












C12 C (I) RCCH Data not provided Pus Swab 




C17 C (I) RCCH Outpatient Clinic Urine 
D3 D (IVd) GSH Medical Pus Swab 
D4 D (IVd) GSH Emergency Services Sputum 
D7 D (IVd) GSH Medical Pus Swab 
E1 E (IVd) RCCH ICU Pus Swab 
E6 E (IVd) RCCH ICU Pus 
E22 E (IVd) RCCH Emergency Services Urine 
E25 E (IVd) RCCH Surgical Pus Swab 
a
 Strain designations as introduced in Chapter 2. 
b
 PFGE, pulsed-field gel electrophoresis; SCCmec, staphylococcal cassette chromosome mec. 
 
The  ca-MRSA isolates were assigned to PFGE clusters C (n = 3), D (n = 3) and E  
(n = 4), and the distribution of these MRSA across PFGE clusters is indicated in 
Figure 4.2.  It was noted that all ca-MRSA isolates assigned to cluster D were 
obtained from patients at GSH, and were susceptible to ciprofloxacin, whereas those 
assigned to cluster E were from patients at RCCH, and all but one were 
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Figure 4.2 Dendrogram indicating the levels of genetic similarity between 
putative community- and healthcare-acquired methicillin-resistant S. aureus 
identified among 100 MRSA isolated from patients in hospitals in Cape Town.  
Nodes and similarity levels of PFGE clusters A – F are marked on the dendrogram, 
and sporadic isolates are marked using strain designations introduced in Chapter 2.  
Scale bars above and below the dendrogram indicate levels of similarity (%) 
between isolates.  Strain designations of the 10 putative community-acquired MRSA 















4.3.2 Detection of pvl 
The 433 bp region of the pvl locus was not detected in any of the 100 isolates.  A  
433 bp product was obtained from the pvl-positive control strain but not from the pvl-
negative control strain.  The integrity of the template DNA was confirmed by the PCR 
amplification of SCCmec components [Chapter 3].  These controls served to 
















It was not the aim of this study to investigate the differences between local ca- and 
ha-MRSA; however, the fact that SCCmec types IV and V are considered molecular 
markers of CA-MRSA suggested that a large proportion of the study isolates may 
have been acquired in the community (Millar et al., 2007).  Alternatively, if the 
isolates were true ha-MRSA, a CA-MRSA clone may have taken hold in local 
hospitals.  The classification of isolates as ca- or ha-MRSA, albeit rudimentary, 
identified only ten putative ca-MRSA isolates, suggesting that most of the study 
isolates were in fact ha-MRSA. 
 
The pvl gene was not detected in any of the study isolates, including the ca-MRSA.  
While there have been few studies describing the molecular characteristics of MRSA 
from South Africa and the rest of Africa, this gene has been described in ca-MRSA 
from Algeria (Tristan et al., 2007b), Nigeria (Ghebremedhin et al., 2009) and Egypt 
(Enany et al., 2010), in ca- and ha-MRSA from Senegal (Breurec et al., 2010), and 
also infrequently in MRSA of unknown epidemiological origins from South Africa 
(Makgotlho et al., 2009; Moodley et al., 2010).  Although the presence of pvl, 
SCCmec type IV and a multiply-susceptible antimicrobial profile have been used as 
markers of CA-MRSA, studies suggest that they are at best only guides to the origins 
of MRSA isolates.  Firstly, there have been reports of pvl-negative CA-MRSA 
(O‘Brien et al., 2004; Park et al., 2007a; Rossney et al., 2007; DeLeo et al., 2010) 
and, to further dispute the definition, there have been reports of pvl-positive HA-
MRSA (Taneike et al., 2006; Deurenberg and Stobberingh, 2008; Ratnaraja and 
Hawkey, 2008).  The larger SCCmec elements, including SCCmec type I, identified 
in three local putative ca-MRSA isolates (Table 4.2), and SCCmec types II and III, 
were considered markers of HA-MRSA; however they have also been described in 
CA-MRSA (Deurenberg and Stobberingh, 2008).  Conversely, SCCmec type IV, 
identified in seven of the local putative ca-MRSA isolates (Table 4.2), does not 
appear restricted to CA-MRSA as it has also been reported in the hospital setting 
(Donnio et al., 2004; Ma et al., 2006; Taneike et al., 2006; de Lencastre et al., 2007; 
Mimica et al., 2009; Shittu et al., 2009; Strandén et al., 2009).  Studies have also 
shown that antimicrobial susceptibility profiles of CA-MRSA may vary according to 
geographic origin (Millar et al., 2007).  These data indicate that the distinctions 
between HA- and CA-MRSA have started to blur (Deurenberg and Stobberingh, 















classified on the basis of molecular characteristics alone, but in conjunction with 
epidemiological criteria, which stresses the importance of a comprehensive clinical 
history. 
 
It was perhaps surprising that the ten putative CA-MRSA isolates did not include any 
of the sporadic isolates (Figure 4.2).  The relatively low levels of genetic similarity 
between the sporadic and clustered isolates suggested that the sporadic isolates 
may have had a different origin, possibly in the community.  S8 and S2 were the 
obvious examples.  S8 was the PFGE outlier, contained SCCmec type IV and was 
pan-susceptible to non-β-lactam antibiotics; S2 contained a putative SCCmec type V 
element, which is commonly associated with CA-MRSA and, with the exception of 
erythromycin and clindamycin, was susceptible to the non-β-lactam antibiotics.  
Taken together, these characteristics suggested that S8 and S2 might well have 
been acquired in the community.  Rather, the designated community-acquired 
isolates were distributed across PFGE clusters C, D and E, suggesting that ca- and 
ha-MRSA from Cape Town are highly similar with respect to SCCmec content and 
overall genetic identity.  The mathematical modeling study of D‘Agata et al. (2009) 
predicted that CA-MRSA will gradually replace HA-MRSA in hospitals in the USA, 
and this will likely also prove true in other countries.  This prediction seems to be 
supported by recent studies that have reported the introduction of CA-MRSA clones 
into healthcare facilities (Seybold et al., 2006; Millar et al., 2007; Nimmo and 
Coombs, 2008; Popovich et al., 2008; Elston and Barlow, 2009; Witte, 2009); 
similarly, HA-MRSA clones have also been reported in the community (Coombs et 
al., 2004; Elston and Barlow, 2009; Witte, 2009).  It is possible that ―cross-pollination‖ 
of MRSA betwee  hospitals and communities in Cape Town may have resulted in the 
high levels of genetic similarity observed between ca- and ha-MRSA isolates in this 
study. 
 
In spite of the possible equivocal classification of the ca-MRSA, it was instructive to 
analyse the PFGE results in conjunction with the collection data.  With respect to the 
seven ca-MRSA containing SCCmec type IV, three belonged to cluster D and were 
isolated from adult patients at GSH, whereas the remaining four belonged to cluster 
E and were isolated from children at RCCH (Table 4.2).  The cluster D isolates were 
susceptible to ciprofloxacin, while those from cluster E were resistant to this antibiotic 















differences in epidemiology of ca-MRSA from adults and children but, in one such 
study, David et al. (2006) described differences in antimicrobial susceptibility profiles 
of adult and paediatric ca-MRSA, showing that paediatric isolates were more likely to 
be susceptible to non-β-lactam antibiotics.  The results of the current study may hint 
at differences in the epidemiology of adult and paediatric ca-MRSA from Cape Town, 
but should be interpreted with caution given that only a few ca-MRSA isolates were 
characterised. 
 
This study was not designed to investigate the differences between local ca- and ha-
MRSA, or to describe the differences in molecular epidemiology and evolution of CA- 
and HA-MRSA in this setting; therefore, future larger prospective studies are required 
to provide more accurate information regarding the epidemiology of ca-MRSA from 
Cape Town.  This information may clarify the differences between local CA- and HA-
MRSA clones, which could prove informative when identifying molecular markers 
suitable for the differentiation of ca- and ha-MRSA in the local setting.  Additionally, 
future studies should further the investigation of any possible differences in 
















Local Methicillin-Resistant S. aureus in the Global Context 
 
5.1 Introduction 
While PFGE remains the gold standard for S. aureus typing, the method has been 
criticised for being too discriminatory, failing to detect underlying relationships 
between distantly related isolates (Maiden et al., 1998; Spratt, 1999).  As a result, 
PFGE is not well suited to studying the epidemiology of isolates obtained over long 
periods of time or geographical distances (Spratt, 1999; Cookson et al., 2007; van 
Belkum et al., 2009).  Aside from being labour intensive and technically demanding, a 
major drawback of PFGE has been its limited portability between laboratories (Spratt 
et al., 1999; Cookson et al., 2007; Hallin et al., 2007).  By the late 1990s, the 
shortcomings of PFGE and other band-based typing strategies left epidemiologists 
wanting techniques suited to global epidemiology that were also less subjective and 
more portable between laboratories than the existing typing methods.  Over the past 
decade, a combination of advances in molecular biology, the development of 
software packages for data analysis, and the dawn of the Internet era has led to the 
development of several sequence-based typing techniques, including multilocus 
sequence typing, spa typing and dru typing (Deurenberg and Stobberingh, 2008; 
Goering et al., 2008a).   
 
Multilocus sequence typing (MLST) was developed for the identification of hyper-
virulent Neisseria meningitidis clones (Maiden et al., 1998), and has since been 
adapted for many other pathogens, including S. aureus (Enright et al., 2000; Feil and 
Enright, 2004).  As depicted in Figure 5.1, MLST for S. aureus entails the PCR 
amplification and direct sequencing of internal fragments of seven housekeeping 
genes.  The sequence of each fragment is then compared to the corresponding 
sequences present in the online S. aureus MLST database (http://www.mlst.net) and, 
for each locus, each unique allele is assigned a particular number.  The series of 
numbers representing the seven loci, corresponding to the housekeeping genes 
taken in alphabetical order, comprises the isolate‘s allelic profile, which can be 















ST, that ‗marks‘ that particular S. aureus clone (Figure 5.1) (Enright et al., 2000; Feil 
and Enright, 2004; Aanensen and Spratt, 2005). 
 
Figure 5.1 Multilocus sequence typing workflow. arcC, carbamate kinase; aroE, 
shikimate dehydrogenase; glpF, glycerol kinase; gmk, guanlyate kinase; pta, 
phosphate acetyltransferase; tpi, triosephosphate isomerase; yqiL, acetyl co-















As MLST detects genetic variation that accumulates slowly in housekeeping genes, it 
is able to detect genetic relationships between isolates obtained over extended 
periods of time and geographical distances (Spratt, 1999; Enright et al., 2000).  As a 
result, the method is widely used to describe the global epidemiology of S. aureus 
(Deurenberg and Stobberingh, 2008).  As described in Chapter 1 [1.6.3; 1.7], MLST 
and the eBURST algorithm have been used to provide a preliminary overview of the 
S. aureus population structure that is gradually being refined as studies examining 
larger proportions of the genome become routine (Enright et al., 2002; Robinson and 
Enright, 2003; Feil et al., 2004; Robinson and Enright, 2004b; Nübel et al., 2008; 
Smyth et al., 2009; Harris et al., 2010; Nübel et al., 2010). 
 
Several seminal studies on the evolution of MRSA were facilitated by MLST used in 
conjunction with the eBURST algorithm.  Enright et al. (2002) used these tools to 
dispel the single clone theory, showing that MRSA lineages emerged from successful 
MSSA clones on several occasions [1.7.2].  Further, the fact that extant MRSA 
isolates were assigned to a limited number of S. aureus CCs suggested that not all 
S. aureus lineages have the capacity to acquire methicillin-resistance (Enright et al., 
2002; Katayama et al., 2005).  MLST-based studies also provided insights into the 
underlying relationships between major epidemic clones prevalent in distinct 
geographical regions, often over extended time periods, which provided the basis for 
the development of a more informative universal nomenclature [1.7.2] (Enright et al., 
2002; Robinson and Enright, 2003; Robinson and Enright, 2004b).  
 
A shortcoming of MLST is that it is less than ideal for routine surveillance because it 
is relatively time consuming and expensive (Deurenberg and Stobberingh, 2008; 
Cookson et al., 2007).  Instead, spa typing has become increasingly popular for 
routine surveillance (Hallin et al., 2007; Deurenberg and Stobbering, 2008; 
Strommenger et al., 2008; van Belkum et al., 2009).  Frénay et al. (1996) developed 
spa typing as an alternative to the phenotypic or band-based typing methods that 
were in use at the time.  This technique indexes variation that arises within spa, 
which is located on the S. aureus chromosome.  The spa gene encodes protein A, 
which binds to the Fc region of immunoglobulin G to prevent opsonisation, thereby 
















As presented in Figure 5.2, the basic structure of spa includes a hyper-variable 
region, known as the X-region, which is comprised of 24 bp repeats flanked by 
conserved sequences (Frénay et al., 1996; Shopsin et al., 1999).  For spa typing, the 
X-region is amplified by PCR using primers complementary to the 3 prime and 5 
prime conserved flanking sequences; the resulting amplicons are sequenced and 
these data determine the spa type of the isolate (Harmsen et al., 2003).  Although 
relatively simple compared to MLST, the technique was initially not widely used, 
primarily because it was not a portable typing tool as there was no uniform system for 
the classification of novel repeats and spa types (Harmsen et al., 2003; Deurenberg 
and Stobberingh, 2008).  The method was also further hampered by the lack of 
software packages for data analysis (Harmsen et al., 2003). 
 
 
Figure 5.2 Schematic representation of the structure of spa.  The hyper-
variable X-region is shown in dark grey.  Conserved flanking sequences are shown 
in light grey.  A – D encode immunoglobulin G-binding regions; E is homologous to 
A – D; S encodes the signal sequence; and Att encodes the cell wall attachment 
sequence.  The positions of sequences complementary to the forward (1113f) and 
reverse (1514r) primers used to amplify and sequence the X-region are indicated.  
Adapted from Shopsin et al. (1999) and Harmsen et al. (2003). 
 
In 2003, the introduction of Ridom StaphType, a novel software package for the 
analysis of spa sequences, contributed to an increase in the popularity of spa typing 
(Harmsen et al., 2003; Deurenberg and Stobberingh, 2008).  Ridom StaphType has 
simplified spa typing as the program automatically assesses the quality of the DNA 
sequences, identifies repeats in the X-region, and determines the corresponding spa 
type.  A numeric code is used to define spa repeats (prefixed by ―r‖) and types 
(prefixed by ―t‖) and, when a novel repeat or type is identified, it is classified through 
the online spa server (http://spaserver.ridom.de/), which ensures that the universal 
nomenclature is maintained (Harmsen et al., 2003).  As described in Chapter 1 
[1.6.4], the BURP algorithm available in Ridom StaphType can be used to assess the 
relatedness of different spa types (Mellmann et al., 2008).  Ridom StaphType 
dramatically reduces the time taken to characterise an isolate, adding to its appeal as 















the spa server can also be converted to the older Kreiswirth nomenclature, which is 
useful when comparing spa types determined using Ridom StaphType to those 
previously described in the literature (Harmsen et al., 2003). 
 
Although a licence is required for Ridom StaphType, the data deposited in the spa 
server (spa repeats and types, global spa type frequencies, and any additional 
epidemiological data provided by users) are freely available.  The creation of a 
bespoke spa typing software package that encourages data sharing through the 
online spa server has resulted in the development of one of the largest S. aureus 
databases: as of December 2010, the spa server included 7589 spa types identified 
in over 150 000 S. aureus strains from 78 countries (http://spaserver.ridom.de/). 
 
Research has indicated that spa typing has a discriminatory power between that of 
PFGE and MLST and, as a result, is useful for both local and global epidemiology 
(Deurenberg and Stobberingh, 2008).  Several studies have demonstrated the utility 
of spa typing for investigating the local epidemiology of S. aureus, particularly when 
used in conjunction with additional techniques such as PFGE, SCCmec typing, 
antimicrobial susceptibility testing and virulence gene profiling (Shopsin et al., 1999; 
Harmsen et al., 2003; Aires-de-Sousa et al., 2006; Strommenger et al., 2006a; 
Cookson et al., 2007; Hallin et al., 2007; Faria et al., 2008; Strommenger et al., 2008; 
Khandavilli et al., 2009).  Ridom GmbH has also incorporated an electronic advanced 
warning  system  into  Ridom  StaphType,  which  can  be  used  to  detect  potential 
S. aureus outbreaks in regions where spa typing forms part of routine surveillance 
strategies (Mellmann et al., 2006).  In the context of S. aureus global epidemiology 
and evolution, Robinson and Enright (2003) used spa typing to further delineate the 
CCs identified by Enright et al. (2002).  The study detailed the acquisition of SCCmec 
by CC5, CC8, CC22, CC30 and CC45, and was the first to suggest multiple 
acquisitions of certain SCCmec types within particular STs, highlighting the 
transmissibility of SCCmec type IV.  More recently, Grundmann et al. (2010) detected 
regional clustering of MRSA lineages based on spa typing data collected by 
laboratories across Europe, thereby providing a greater understanding of patterns of 
















Even when using a combination of MLST, spa typing and PFGE, it can be impossible 
to differentiate MRSA belonging to certain highly homogeneous clones. This is well 
illustrated by ST22-MRSA-IV and ST36-MRSA-II isolates from hospitals in Scotland 
and Ireland, large proportions of which are indistinguishable by PFGE (Goering et al., 
2008a; Shore et al., 2010).  The differentiation of isolates belonging to homogeneous 
clones is vital when investigating nosocomial outbreaks and tracing the dissemination 
of MRSA within and between hospitals (Shore et al., 2010).  The need for additional 
high-resolution sequence-based typing techniques has renewed interests in variable-
number tandem repeat methods, one of which is dru typing (Goering et al., 2008a; 
Pourcel et al., 2009; Schouls et al., 2009).  
 
The dru locus is present in most MRSA isolates and consists of a series of SCCmec-
associated direct repeat units (dru) (Ryffel et al., 1991).  When present, the dru 
region is stable and found adjacent to the copy of IS431 that is situated on the border 
of the mec gene complex and the J3 region, regardless of SCCmec type (Figure 5.3) 
[1.5.3.1] (Ryffel et al., 1991; Goering et al., 2008a).  The imperfect direct repeat units 
are 40 bp in length and, as in the X-region in spa, variation at the dru locus 
accumulates due to point mutations, as well as duplications and deletions of repeats 
(Goering et al., 2008a). 
 
Figure 5.3 Schematic representation of the basic structure of SCCmec 
indicating the position of the dru locus.   
 
For dru typing, the dru locus is amplified by PCR, and sequenced directly using 
primers complementary to the conserved 5 prime and 3 prime flanking sequences 
(Goering et al., 2008a).  In order to determine the isolate‘s dru type, the sequencing 
data are analysed using DruID, an application developed by Dr Davida Smyth and 
Mal McKay that is freely available from the dru typing website (http://www.dru-
typing.org/).  The universal dru typing nomenclature is based on a numeric code 















and types, respectively (Goering et al., 2008a).  The dru typing website is currently 
under construction, but the database is functional and is updated when users submit 
new dru repeats or types.  The dru-typing database has the potential to develop and 
expand over time, providing the scientific community with useful epidemiological data 
in much the same way that the spa server has. 
 
Although still in its infancy, dru typing appears to have potential as a tool for 
subtyping homogeneous isolates that are indistinguishable by PFGE.  The technique 
has been used successfully to subtype isolates belonging to the ST36-MRSA-II and 
ST22-MRSA-IV clones that were submitted to Scottish MRSA Reference 
Laboratories over an eight year period (Goering et al., 2008a), as well as isolates 
belonging to the latter clone that were obtained from a single hospital in Ireland over 
one year (Shore et al., 2010).  The results of Shore et al. (2010) suggested that dru 
typing, in conjunction with spa typing and PFGE, may prove useful for investigating 
outbreaks and tracing intra- and inter-hospital dissemination of homogeneous MRSA 
clones.  Interestingly, although dru typing has been used for short-term or local 
epidemiology to date, a recent study on the population structure of ST239-MRSA-III 
indicated that dru typing was phylogenetically informative for that clone, most likely 
due to the stability of SCCmec type III within the lineage (Smyth et al., 2009); 
therefore, it is possible that dru typing may prove phylogenetically informative for 
other MRSA clones with stable SCCmec content. 
 
MLST,  spa  typing  and  dru typing are suited to investigating  different  aspects  of 
S. aureus epidemiology and, when used in conjunction with techniques such as 
SCCmec typing and PFGE, they provide information pertinent to both global and 
local epidemiology (Deurenberg and Stobberingh, 2008; Goering et al., 2008a; van 
Belkum et al., 2009; Shore et al., 2010).  While the three sequence-based techniques 
examine different aspects of S. aureus epidemiology, they have a number of 
common features that have resulted in their widespread use:  
i) they provide unbiased sequence-based data  
ii) due to the development of software packages and web-based 
applications, data analysis is rapid and accurate 















iv) universal nomenclatures have been developed 
v) they are all associated with freely available online databases, which 
enables users from around the world to compare data   
In this study, MLST, spa typing and dru typing were used to obtain an understanding 
of the relatedness of isolates belonging to the six PFGE clusters, and to investigate 
















5.2 Experimental Approach 
5.2.1 Selection of representative isolates for spa typing, multilocus sequence 
typing and dru typing 
As PFGE can, at times, fail to detect underlying relationships between S. aureus 
isolates (Spratt, 1999), spa typing was included in this study to further investigate the 
relatedness of MRSA from hospitals in Cape Town.  Twenty-six isolates were 
selected for spa typing and included 18 representatives of PFGE clusters A – F, 
while the remaining MRSA corresponded to the 8 sporadic isolates.  The distribution 
of the representative isolates across the PFGE clusters can be seen in Appendix A.  
Multiple isolates were selected from the larger clusters in order to include MRSA with 
varying levels of genetic similarity and different antimicrobial susceptibility profiles.  
Accordingly, 3 isolates were selected from clusters C (C5, C16 and C31) and D (D2, 
D4, D6), while 7 isolates were selected from cluster E (E3, E4, E5, E8, E19 and 
E32).  The 3 isolates from cluster C were selected to include a representative of each 
of the 3 subgroups containing MRSA indistinguishable by PFGE [2.3].  The remaining 
representative isolates corresponded to 2 indistinguishable MRSA from cluster F (F8 
and F9), both members of cluster B (B1 and B2), and a single member of cluster A 
(A1). 
 
Although spa typing provided insights into aspects of the local and global 
epidemiology of MRSA from hospitals in Cape Town, in accordance with current 
international conventions, MLST was required, in conjunction with SCCmec typing, to 
determine the identities of local clones (Enright et al., 2002).  Given the costs 
associated with this technique, it was necessary to select a subset of the 26 isolates 
described above for characterisation by MLST.  Nineteen of the 26 isolates were 
selected after reviewing the PFGE dendrogram, antimicrobial susceptibility profiles 
and spa typing data.  These isolates included 11 diverse representatives of PFGE 
clusters A – F: A1; B1 and B2; C5, C16 and C31; D4; E3, E4 and E32; and F8 
















A number of isolates were indistinguishable by spa typing and MLST, or by PFGE; 
therefore dru typing, which appears promising for the differentiation of isolates 
belonging to homogeneous MRSA clones (Goering et al., 2008a; Shore et al., 2010), 
was used to further characterise the 26 isolates selected for spa typing.   
 
5.2.2 spa typing 
The revised spa typing protocol of Shopsin et al. (1999) and Harmsen et al. (2003) 
available on the Ridom GmbH website (version 1.1, June 2004) was followed in this 
study (http://www3.ridom.de/doc/Ridom_spa_sequencing.pdf).  The PCR for the 
amplification of the X-region was carried out as described in the Ridom StaphType 
protocol.  Reactions were carried out in a final volume of 50 µl with a final 
concentration of 1X PCR buffer, 1.5 mM MgCl2, 1.25 U of Taq polymerase (JMR 
Holdings, London, UK), 400 µM dNTP mix (Thermo Scientific, Wilmington, DE, USA), 
and 10 pmol each of the primers spa-1113f and spa-1514r (Synthetic DNA 
Laboratory, University of Cape Town, Cape Town, South Africa) (Appendix E).  Five 
microlitres of template DNA [3.2.1] was added to each reaction.  Amplification was 
carried out in an Applied Biosystems 2720 Thermocycler (Applied Biosystems, 
Carlsbad, CA, USA).  The PCR amplification parameters included an initial 
denaturation step at 80°C for 5 min, followed by 35 cycles of denaturation at 94°C for 
45 s, annealing at 60°C for 45 s and extension at 72°C for 90 s, with a final extension 
step of 10 min at 72°C. 
 
The PCR products were visualised on 2 % agarose gels as described in Chapter 3 
[3.2.2].  The PCR products were separated on 2 % agarose gels and purified as 
previously described [3.2.3.2].  Direct sequencing of both strands of the purified 
products was carried out at the Central Analytical Facility at the University of 
Stellenbosch using the cycle sequencing parameters recommended by Ridom GmbH 
(http://www3.ridom.de/doc/Ridom_spa_sequencing.pdf).  The resulting sequences 
were analysed using Ridom StaphType (version 2.1.1) (Ridom GmbH, Würzburg, 
Germany).  Novel spa types were assigned by submitting the data to the spa server 
















The BURP algorithm available in Ridom StaphType was used to detect clustering 
among the isolates selected for spa typing.  When using the BURP algorithm, the 
user may define the clustering cost, which represents the number of genetic 
differences between spa types that will be included in a particular cluster (Mellmann 
et al., 2008).  As recommended in the Ridom StaphType user-guide (version 2.1.1), a 
cost of 6 was applied.  Additionally, given that the evolutionary history of spa types 
with less than 5 repeats cannot be reliably deduced, spa types containing 4 repeats 
or less were excluded from the analysis (Mellmann et al., 2008).   
 
5.2.3 Multilocus sequence typing 
MLST was carried out as described by Enright et al. (2000), with minor modifications.  
Internal fragments of approximately 500 bp were amplified from 7 housekeeping 
genes.  All PCR assays were carried out in 50 µl volumes including final 
concentrations  of  1X  PCR buffer, 1.5 mM MgCl2 (JMR Holdings,  London,  UK),  
0.4 mM dNTP mix and 1 U of Taq polymerase (JMR Holdings, London, UK).  Primers 
synthesised by the Synthetic DNA Laboratory at the University of Cape Town (Cape 
Town, South Africa) were added at a final concentration of 0.5 µM each in the 
individual assays for the amplification of 7 housekeeping genes, including arcC 
(carbamate kinase), aroE (shikimate dehydrogenase), glpF (glycerol kinase), gmk 
(guanlyate kinase), pta (phosphate acetyltransferase), tpi (triosephosphate 
isomerase), and yqiL (acetyl co-enzyme A acetyltransferase).  The primer sequences 
are shown in Appendix E, while the primer names and target sequences are shown 
in Table 5.1.  The amount of genomic DNA [3.2.1] added to each reaction was 

















Table 5.1 Primers for the amplification of 7 housekeeping 
genes for multilocus sequence typing 
Primer Pair
a
 Housekeeping gene targeted 
arcC-Up 
arcC-Dn 
Carbamate kinase (arcC) 
aroE-Up 
aroE-Dn 
Shikimate dehydrogenase (aroE) 
glpF-Up 
glpF-Dn 
Glycerol kinase (glpF) 
gmk-Up 
gmk-Dn 
Guanlyate kinase (gmk) 
pta-Up 
pta-Dn 
Phosphate acetyltransferase (pta) 
tpi-Up 
tpi-Dn 
Triosephosphate isomerase (tpi) 
yqiL-Up 
yqiL-Dn 
Acetyl co-enzyme A acetyltransferase (yqiL) 
a
 Enright et al. (2000) (primer sequences available in Appendix E) 
 
All PCRs were carried out using an Applied Biosystems 2720 Thermocycler (Applied 
Biosystems, Carlsbad, CA, USA) and amplification parameters for all 7 assays were 
as follows: denaturation for 5 min at 95°C, followed by 30 cycles of denaturation for 1 
min at 95°C, annealing for 1 min at 55°C, elongation for 1 min at 72°C, and a final 
extension step of 5 min at 72°C. 
 
The resulting amplicons were visualised on 2 % agarose gels, and purified as 
described in Chapter 3 [3.2.3.2].  Both strands of the purified products were 
sequenced directly as described in Chapter 3 [3.2.3.2].  The chromatograms were 
examined in BioEdit Sequence Alignment Editor (version 7.0.5.2) (Hall, 1999), and 
any ambiguous bases were corrected.  The edited sequences were aligned to 
template sequences obtained from the MLST website 
(http://saureus.mlst.net/misc/info.asp).  The template sequences are internal to the 
amplified region; therefore trimming query sequences to the length of the 
corresponding template sequences excluded unreliable data from the final analysis.  
Allelic profiles and STs were assigned to each isolate by comparing the trimmed 
sequences of the 7 housekeeping genes to those present in the S. aureus MLST 















eBURST (version 3) (http://saureus.mlst.net/eburst/), using the stringent default 
parameters. 
 
5.2.4 dru typing 
The dru typing method of Goering et al. (2008a) was modified for use in this study.  
PCRs were carried out in a volume of 50 µl with a final concentration of 1X PCR 
buffer, 1.5 mM MgCl2 and 400 µM dNTP mix.  The primers dru1 and dru2 (Appendix 
E) were included at a final concentration of 0.5 µM each, and each reaction also 
contained 100 ng of template DNA [3.2.1] and 1.25 U of Taq polymerase.  The 
cycling conditions for each assay included an initial denaturation step of 2 min at 
94°C, followed by 30 cycles of denaturation at 94°C for 1 min, annealing at 52°C for 
1 min and annealing at 72°C for 1 min, with a final extension step of 2 min at 72°C.  
Amplification was carried out using an Applied Biosystems 2720 Thermocycler 
(Applied Biosystems, Carlsbad, CA, USA). 
 
The PCR products were visualised, purified and sequenced as described for MLST 
[5.2.3].  The raw sequencing data files were copied into DruID, which automatically 
determined the dru types of most isolates.  In the case of isolates where dru types 
were not assigned automatically, the quality of the sequencing data was assessed by 
examining the chromatograms in BioEdit Sequence Alignment Editor (version 
7.0.5.2) (Hall, 1999), and ambiguous bases were edited as necessary.  The edited 
sequencing files were then entered into DruID and a dru type was determined.  Novel 
dru types were assigned by submitting the sequencing data to the curators of the dru 
















5.3.1 spa typing 
Using Ridom StaphType, spa types were assigned to all 26 isolates selected for 
sequence-based characterisation.  In total, 12 spa types were assigned to the 26 
MRSA, as shown in Table 5.2 in conjunction with the PFGE cluster assignment, 




























spa type  
(spa-CC) 
dru type ST (CC) Antimicrobial resistance profile 
A1 A (4) III t037 (021) dt14e 
c
 239 (8) PEN, OXA, ERY, CLI, SXT, CIP, GEN 
B1 B (2) I t7185
c
 (045/002) dt10ar 
c
 5 (5) PEN, OXA, ERY, CLI, CIP 
B2 B (2) I t045 (045/002) dt10a 5 (5) PEN, OXA, ERY, CLI, GEN 
C5 C (35) I t045 (045/002) dt10a 5 (5) PEN, OXA, ERY, CLI 
C16 C (35) I t045 (045/002) dt10a 5 (5) PEN, OXA 
C31 C(35) I t045 (045/002) dt10a 5 (5) PEN, OXA, ERY, CLI, RIF 
D2 D (7) IVd t064 (064) dt10i ND PEN, OXA, ERY, CLI, RIF, SXT, GEN 
D4 D (7) IVd t064 (064) dt10i 612 (8) PEN, OXA, ERY, CLI, RIF, SXT, GEN 
D6 D (7) IVd t064 (064) dt10i ND PEN, OXA, ERY, CLI, RIF, SXT 
E3 E (33) IVd t1443 (064) dt10i 612 (8) PEN, OXA, RIF, SXT, CIP, GEN 






 612 (8) PEN, OXA, ERY, CLI, RIF, SXT, CIP, 
GEN 
E5 E (33) IVd t1443 (064) dt9ac 
c
 ND PEN, OXA, RIF, SXT, CIP, GEN 
E8 E (33) IVd t064 (064) dt9ad 
c
 ND PEN, OXA, ERY, CLI, RIF, SXT, CIP, 
GEN 















E26 E (33) IVd t1443 (064) dt10i ND PEN, OXA, RIF, SXT, CIP, GEN 
E32 E (33) IVd t1443 (064) dt8v 
c
 612 (8) PEN, OXA, RIF, SXT, CIP, GEN, FUS
e
 
F8 F (11) II t012 (021) dt9a 36 (30) PEN, OXA, ERY, CLI, CIP 
F9 F (11) II t021 (021) dt7s ND PEN, OXA, ERY, CLI, CIP 
S1 Sporadic isolate IVd t1443 (064) dt10aq 
c
 612 (8)  PEN, OXA, RIF, SXT, CIP, GEN 
S2 Sporadic isolate V t3092 
(Singleton) 
dt11a 72 (8)  PEN, OXA, ERY, CLI 
S3 Sporadic isolate II t021 (021) dt4c 
c
 36 (30) PEN, OXA, ERY, CLI, CIP, GEN 
S4 Sporadic isolate IVd t1257 (064) dt10i 612 (8) PEN, OXA, ERY, CLI, RIF, SXT, CIP, 
GEN 
S5 Sporadic isolate IVd t064 (064) dt10i 612 (8) PEN, OXA, RIF, SXT, GEN 
S6 Sporadic isolate IVd t064 (064) dt10i 612 (8) PEN, OXA, RIF, SXT, GEN 
S7 Sporadic isolate IVh t032 (Singleton) dt9j 22 (22) PEN, OXA, ERY, CLI, CIP, FUS
e
 
S8 Sporadic isolate IVb t002 (045/002) dt10t 
c
 ST650 (5) PEN, OXA 
a
 spa-CC, spa clonal complex; ST, sequence type; CC, clonal complex (based on multilocus sequence typing); PEN, penicillin; OXA, cloxacillin; ERY, 
erythromycin; CLI, clindamycin; RIF, rifampicin; SXT, co-trimoxazole; CIP, ciprofloxacin; GEN, gentamicin; FUS, fusidic acid; ND, not determined (STs 
inferred from representatives of PFGE cluster included for MLST).  
b
 Strain designations introduced in Chapter 2. 
c Novel types. 
d
 Excluded from BURP (based-upon repeat pattern) analysis as the spa sequence included less that 5 repeats.  
e















The 12 spa types were unevenly distributed among the 26 isolates with 3 spa types 
(t045, t064 and t1443) accounting for 16 isolates.  The isolates corresponding to t045 
(n = 4) included all 3 representatives of cluster C, and isolate B2.  The remaining 
member of cluster B, isolate B1, corresponded to t7185, which was the only novel 
spa type identified in this study.  The Ridom StaphType alignment of t045 and t7185 
detected 4 differences in their repeat sequences, as illustrated in Figure 5.4, and was 
assigned a genetic cost of 6 based on the BURP algorithm.  Scrutiny of the 
underlying sequences of the mismatched repeats r26 and r135 revealed a single 
nucleotide difference (Appendix H).  The remaining differences corresponded to the 
presence of additional repeats in t7185, which were absent in t045 (Figure 5.4).  
These repeats (r20-r17-r12) may represent a duplication event as two copies of the 
series are present in t7185, while only a single copy is present in t045 (Figure 5.4).   
 
Figure 5.4 Schematic diagram representing spa repeat sequence alignments 
of selected spa types.  The spa repeat sequences of interest were aligned using 
the spa type alignment function in Ridom StaphType.  Unique repeats are 
represented by different colours; differences are marked in bold; gaps are indicated 
by (-); single nucleotide differences are indicated by (*).  Alignment costs as 
calculated by the BURP (based upon repeat pattern) algorithm in Ridom 
StaphType. 
 
The other major spa types identified in this study, t064 and t1443, were co-dominant, 
accounting for 6 isolates each, which comprised almost half of the selected MRSA.  
The isolates consistent with t064 included all 3 representatives of cluster D, as well 
as a single representative of cluster E and 2 sporadic isolates (Table 5.2).  The co-
dominant t1443 was identified in 5 out of 7 representative isolates from cluster E, as 
well as in the sporadic isolate S1 (Table 5.2).  The alignment of the repeat 















a single difference: t1443 contains an additional copy of r24 compared to t064 
(Figure 5.4).  The detection of subtly different spa types within a single PFGE cluster 
was not unique to cluster E.  Although isolates F8 and F9 were indistinguishable by 
PFGE, the former was consistent with t012, while the latter corresponded to t021, as 
did the sporadic isolate S3.  An alignment of the repeat sequences of these two spa 
types was assigned a cost of 1, and indicated that t012 contains an additional copy of 
r24 that is not present in t021 (Figure 5.4).  The remaining representative isolates (A1 
and E4), as well as sporadic isolates S2, S4, S7 and S8, corresponded to spa types 
detected in single isolates (Table 5.2).   
 
Although the number of spa types detected in this study was small, it remained 
instructive to carry out a BURP analysis to infer the relatedness of the included 
isolates.  In accordance with the BURP parameters recommended by Ridom GmbH, 
isolate E4 was excluded from the analysis because it contained only 4 repeats.  The 
25 isolates included in the BURP analysis segregated into 3 spa clonal complexes 
















Figure 5.5 The clonal relatedness of 25 methicillin-resistant S. aureus isolates 
included in a BURP analysis of the spa typing data.  The parameters used in the 
BURP analysis corresponded to those recommended by Ridom GmbH, including a 
cluster cost of 6 or less and the exclusion of spa types with less than 5 repeats.  
Each circle or node represents a unique spa type.  Node size is proportional to the 
number of isolates corresponding to that particular spa type (number of isolates 
indicated below each node).  Blue nodes indicate putative founding spa types of 
each spa-CC.  The costs between spa types, as determined by the BURP 















The largest clonal complex was spa-CC064 (n = 13), named after its putative 
founding spa type, t064 (Figure 5.5).  This spa-CC consisted of 3 spa types (t064, 
t1443 and t1257), and included representative isolates from clusters D and E, as well 
as 3 sporadic isolates (Table 5.2).  The second largest clonal complex was spa-
CC045/002 (n = 6), which was assigned 2 putative founding spa types, t045 and t002 
(Figure 5.5).  This spa-CC included 3 spa types (t045, t002 and t7185) that were 
identified in representatives of clusters B and C, and the sporadic isolate S8 (Table 
5.2).  The remaining clonal complex, spa-CC021 (n = 4), also included 3 spa types 
(t021, t021 and t037), corresponding to representative isolates from clusters A and F, 
and the sporadic isolate S3.   
 
5.3.2 Multilocus sequence typing 
Using the online S. aureus MLST database, STs were assigned to all 19 isolates 
selected  for  complete  molecular characterisation.  The STs were  then  assigned to 
S. aureus CCs using eBURST (version 3) (http://saureus.mlst.net/eburst/).  The STs 
and corresponding CCs of the isolates are shown in Table 5.2. 
 
In accordance with current international conventions, the clonal types of the isolates 
were determined based on the combination of ST and SCCmec type.  Analysis of the 
MLST and SCCmec typing data identified 7 clones among the 19 isolates (Table 
5.2).  Examination of these data in conjunction with the PFGE results revealed that 
the representatives of the 6 PFGE clusters corresponded to 4 major clones.  Isolate 
A1 corresponded to ST239-MRSA-III, while the representative of cluster F, F8, 
corresponded to ST36-MRSA-II, as did the sporadic isolate S3.  The second-most 
prevalent clone identified among the MRSA was ST5-MRSA-I (n = 5), which 
corresponded to all representative isolates from clusters B and C (Table 5.2).  The 
dominant clone identified among the representative isolates was ST612-MRSA-IVd 
(n = 8), which included all representatives of clusters D and E, as well as 4 sporadic 
isolates.  The three remaining sporadic isolates were not consistent with any of the 
major clonal types identified in the 6 PFGE clusters.  Instead, these isolates 
corresponded to 3 sporadic clones: ST72-MRSA-V, ST22-MRSA-IVh and ST650-















5.3.3 dru typing 
The utility of dru typing for the sequence-based differentiation of isolates belonging to 
the same clonal type, or corresponding to identical PFGE profiles, was also 
investigated in this study.  Using DruID, dru types were assigned to all 26 isolates.  In 
total, 16 dru types were identified among the 26 MRSA, 9 of which were novel (Table 
5.2).  The dru repeat sequences of isolates assigned to ST612-MRSA-IVd, ST5-
MRSA-I and ST36-MRSA-II [5.3.2] were aligned manually to examine variation within 
the dru loci of these clonal types (Figure 5.6).   
 
Figure 5.6 Schematic diagram representing aligned dru repeat sequences of 
isolates corresponding to ST5-MRSA-I, ST612-MRSA-IVd and ST36-MRSA-II.  
For ST5-MRSA-I and ST612-MRSA-IVd isolates, dru repeat sequences were 
aligned to the most prevalent dru type (dt10a and dt10i, respectively); in the case of 
ST36-MRSA-II isolates, dru repeat sequences were aligned to dt9a.  Unique 
repeats are represented by different colours; repeat units containing mutations are 
underlined; (*) indicates one nucleotide difference; (-) indicates gaps. 
 
The alignments of dru types corresponding to ST5-MRSA-I and ST612-MRSA-IVd 
isolates were particularly interesting.  All ST5-MRSA-I isolates representative of 
cluster C shared dt10a, which was the second-most prevalent dru type identified in 















(ST5-MRSA-I); however, the remaining ST5-MRSA-I representative of cluster B, B1, 
corresponded to dt10ar, one of the novel dru types identified in this study.  Alignment 
of the repeat sequences of dt10a and dt10ar revealed a difference of 3 repeats 
(Figure 5.6).  Examination of the underlying sequences of the 3 discrepant repeats 
detected a total of 6 nucleotide differences between dt10a and dt10ar (Figure 5.6). 
 
All ST612-MRSA-IVd isolates representative of cluster D corresponded to dt10i, 
which was the most prevalent dru type identified in the current study (n = 8).  This dru 
type was also identified in 2 representatives of cluster E, and in 3 sporadic isolates 
that   corresponded   to   ST612-MRSA-IVd   (Table   5.2).      The  remaining   5 
ST612-MRSA-IVd isolates representative of cluster E, in addition to the remaining 
ST612-MRSA-IVd sporadic isolate S1, comprised a variety of dru types, including 5 
novel dru types (Table 5.2).  Alignment of the dru repeat sequences obtained for 
ST612-MRSA-IVd isolates with dt10i revealed that the underlying sequences are 
very similar with variation ranging from a single point mutation in dt10aq (S1) to 

















Seven clonal types, defined by ST and SCCmec type, were identified among 
nineteen representatives of the one hundred MRSA isolates included in this study.  
Examination of the distribution of clonal types across the PFGE dendrogram revealed 
that four clones accounted for the majority of the isolates, including all six PFGE 
clusters.  MLST was supplemented with spa typing and dru typing to obtain a more 
comprehensive characterisation of selected isolates, resulting in a greater 
understanding of the local and global epidemiology of MRSA from hospitals in Cape 
Town. 
 
The   smallest   PFGE   cluster, A,   corresponded   to   the   multidrug-resistant 
ST239-MRSA-III, t037, clone.  This HA-MRSA clone forms a major subgroup of CC8, 
one of the oldest and most diversified S. aureus clonal complexes (Figure 5.7) 
(Enright et al., 2002; Robinson and Enright, 2003).  Robinson and Enright (2003) 
used a combination of MLST, SCCmec typing, spa typing and sas typing to show that 
ST239-MRSA-III corresponds to several pandemic and epidemic clones, including 
those formerly known as the Brazilian Hungarian, Portuguese and Viennese clones, 
as well as EMRSA-1, -4, -7, -9 and -11 (Enright et al., 2002; Robinson and Enright, 
2003; Deurenberg and Stobberingh, 2008).  ST239-MRSA-III was first described as a 
cause of hospital epidemics in the UK, USA and Australia during the 1970s and 
1980s, and then, during the 1990s, as a pandemic clone prevalent in Europe and 
South America (Smyth et al., 2009).  This clone has been reported on every 
continent, and Africa is no exception as ST239-MRSA-III is predominant in major 
cities in Algeria, Morocco, Niger, Senegal, and South Africa (Deurenberg and 









































Figure 5.7 Graphical representation of patterns of descent among members of 
S. aureus clonal complex 8 as determined using the eBURST algorithm.  The 
predicted founder of clonal complex (CC) 8, ST8, is indicated by the blue circle.  
Descendants of ST8 are indicated by yellow (subgroups) and black circles with 
sequential nodes indicating the progressive accumulation of mutations in different 
housekeeping genes monitored by multilocus sequence typing (MLST).  For clarity, 
only the STs of subgroups are indicated.  STs identified in the current study are 
shown in bold and the nodes are circled in red. The relative sizes of the nodes are 

















In spite of its global success, ST239-MRSA-III represented the smallest clonal type 
identified in the current study, accounting for only four MRSA; however, this clone 
appears to be far more prevalent in other regions of South Africa.  A study on the 
epidemiology of S. aureus obtained from patients at Tygerberg Hospital (in the 
Western Cape province, approximately 20km from GSH) between 2008 and 2009 
indicated that 27.27 % of MRSA isolates corresponded to t037 (Salaam-Dreyer, 
2010).  That t037 is thought to represent the ancestral ST239-MRSA-III spa type 
(Harris et al., 2010) suggests this clone is predominant at Tygerberg Hospital; 
therefore the prevalence of ST239-MRSA-III may be variable within the Western 
Cape.  ST239-MRSA-III also seems to be more prevalent in the KwaZulu-Natal 
province  of South Africa than in central Cape Town.   Shittu et al. (2009) and  Essa  
et al. (2009) both identified ST239-MRSA-III as the second-most prevalent clone 
present in healthcare institutions in KwaZulu-Natal, reporting prevalence rates of  
16.4 % and 13 %, respectively.  In the national context ST239-MRSA-III, t037, 
appears to represent a major clone, accounting for 21.61 % of MRSA obtained from 
public and private diagnostic laboratories across all provinces except the Western 
Cape, which suggests an uneven distribution of this clone across South Africa 
(Moodley et al., 2010).  However, Moodley et al. (2010) did not indicate the 
proportion of isolates obtained from each province, and unequal provincial 
contributions may have resulted in the uneven distribution of MRSA clones observed 
in that study. 
 
It is interesting to consider the evolution of ST239-MRSA-III isolates from hospitals in 
Cape Town.  Of all the major MRSA clones, the population structure and evolution of 
ST239-MRSA-III is perhaps best understood.  A recent study utilising high-
throughput genomics has revealed that the widespread prevalence of this clone is 
due to its global dissemination, rather than its frequent emergence from ST239-
MSSA ancestors (Harris et al., 2010).  In the light of these studies, it is highly likely 
that ST239-MRSA-III has been imported into South Africa.   
 
Another extensive study on the population structure of a collection of ST239-MRSA-
III from 29 countries detected geographical clustering among the isolates, identifying 
three major clades corresponding to European, Asian and South American isolates, 
respectively (Smyth et al. 2009).  The same study found that the dru locus is 















isolates sharing similar dru types, most likely due to the stability of SCCmec type III 
within the lineage.  With this in mind, it was of interest that dt14e, the novel dru type 
identified in A1, the ST239-MRSA-III representative isolate, was most similar to 
dt15b, which was detected in isolates obtained from China, Vietnam and Korea 
(Figure 5.8) (Smyth et al., 2009).  As the dru locus is phylogenetically informative for 
this clone, it is possible to suggest that ST239-MRSA-III from Cape Town may be 
closely related to those from Asia. 
 
Figure 5.8 Aligned dru repeat sequences of ST239-MRSA-III isolates from 
Cape Town and Asia.  Alignment of dru sequences identified in ST239-MRSA-III 
from Cape Town and Asia (Smyth et al., 2009) detected a single repeat difference 
(highlighted in bold and underlined).  Countries of origin are indicated below the dru 
type.  RSA, Republic of South Africa.  
 
Local and global dissemination has been proposed to play a major role in shaping 
the population structure of ST239-MRSA-III (Smyth et al., 2009; Harris et al., 2010), 
and several other important EMRSA clones (Enright et al., 2002; Robinson and 
Enright, 2003); therefore it is worthwhile pausing to consider mechanisms of MRSA 
dissemination.  Over the past century, humans have become more mobile, resulting 
in increasingly frequent exchanges of individuals between distant regions.  Travel, 
including migration and tourism within and between countries, has been suggested 
as important factor in shaping bacterial populations (MacPherson et al., 2009; Gray 
et al., 2010; Nübel et al., 2010; Zanger et al., 2010).  In South Africa, migration and 
tourism, both domestic and international, are common, and may have influenced the 
composition of the local MRSA population.  The history of travel between South 
Africa and Asia may explain the possible relationship between ST239-MRSA-III 
isolates  from  Cape  Town  and  Asia;  however,  the  evolutionary  history  of  
ST239-MRSA-III, and other MRSA clones from South Africa, will only be resolved 
when local isolates are included in studies similar to those carried out by Smyth et al. 
















The other minor clonal type corresponding to multiple isolates in the present study 
was ST36-MRSA-II, which accounted for PFGE cluster F and the sporadic isolate S3.  
Robinson and Enright (2003) identified ST36-MRSA-II as an important subgroup 
within CC30, one of the major MRSA CCs (Figure 5.9).  ST36-MRSA-II, also known 
as EMRSA-16 (Enright et al., 2002), emerged during the 1990s as an epidemic clone 
in hospitals in the UK (Johnson et al., 2005), and has since been reported worldwide 
[1.7.2] (Deurenberg and Stobberingh, 2008).  In the present study, representatives of 
ST36-MRSA-II (CC30) and ST239-MRSA-III (CC8) were all assigned to spa-CC021, 
suggesting an underlying genetic relationship between the isolates; however, 
clustering of these spa types was unsurprising given that ST239-MRSA-III represents 
a hybrid S. aureus lineage with 80 % of its genome donated by an ST8 parent strain, 
and the remaining 20 %, including the spa locus, donated by an ST30 (CC30) parent 

















Figure 5.9 Graphical representation of patterns of descent among members of 
S. aureus clonal complex 30 as determined using the eBURST algorithm.  The 
predicted founder of clonal complex (CC) 30, ST30, is indicated by the blue circle.  
Descendants of ST30 are indicated by black and yellow circles.  Subgroups that 
have given rise to their own variants are indicated by yellow circles.  For clarity, only 
the STs of subgroups are indicated.  STs identified in the current study are shown in 
bold and the nodes are circled in red. The relative sizes of the nodes are 
















ST36-MRSA-II isolates are frequently highly homogeneous and indistinguishable by 
PFGE (Goering et al., 2008a).  Similarly, the PFGE macrorestriction profiles of three 
pairs of local ST36-MRSA-II isolates were indistinguishable [2.3], including isolates 
F8 and F9, which were selected for sequence-based characterisation.  
Homogeneous ST36-MRSA-II isolates from Scotland have been differentiated using 
dru typing (Goering et al., 2008a), and, based on the unique combinations of similar 
spa and dru types observed in F8 and F9, it is possible that these techniques hold 
promise for the differentiation of local isolates belonging to this clone.  
 
In addition to differentiating ST36-MRSA-II isolates with identical macrorestriction 
profiles, dru typing proved useful for examining the relationship between isolates 
from  cluster  F and the sporadic isolate, S3.   Although S3 was  consistent with  
ST36-MRSA-II, and corresponded to the same spa type as F9 (t021), the dru type of 
this isolate was markedly different to those detected in cluster F (Table 5.2; Figure 
5.6).  A review of the available laboratory data indicated that, while isolates from 
cluster F were obtained from adults at GSH and UCTPH, the sporadic isolate was 
obtained from a child at RCCH.  Collectively, these data suggest a different 
epidemiological origin for S3 compared to isolates from cluster F, supporting the 
PFGE clustering. 
 
While ST36-MRSA-II represented a minor clone in hospitals in Cape Town, 
accounting for 12 % of the isolates, the prevalence of this clonal type differed in other 
regions of South Africa.  In total, 18.75 % of MRSA isolates from Tygerberg Hospital 
were consistent with t012 or t021, but the STs and SCCmec types of these isolates 
were not determined (Salaam-Dreyer, 2010).  As these spa types were detected 
among ST36-MRSA-II isolates in the present study, it is possible that t021 and t021 
isolates at Tygerberg Hospital were also consistent with ST36-MRSA-II.  This would 
suggest slight differences in the prevalence of this clone in the Western Cape; 
however, MLST and SCCmec typing are required to confirm the clonal types of the 
t012 and t021 MRSA because these spa types have also been described in ST30 
isolates (http://spaserver.ridom.de/).  As described in Chapter 3 [3.4], SCCmec type 
II was most prevalent among MRSA obtained from the Steve Biko Academic Hospital 
in Pretoria, Gauteng, accounting for 64 % of the isolates (Makgotlho et al., 2009); 
however, whether these MRSA corresponded to ST36-MRSA-II remains to be 















isolates.    In  contrast  with  the  results  of  the  current  study  and   that   of 
Moodley et al. (2010), ST36-MRSA-II was not detected during two investigations into 
the epidemiology of MRSA from healthcare institutions in the KwaZulu-Natal province 
(Essa et al., 2009; Shittu et al., 2009).  In the national context, ST36-MRSA-II has 
been reported as the second-most prevalent MRSA clone (24.52 %), and has been 
identified in all provinces, except the Northern Cape and the North West provinces 
(see Appendix G for a provincial map of South Africa) (Moodley et al., 2010). 
 
Although the population structure and evolution of ST36-MRSA-II has not been 
analysed as rigorously as ST239-MRSA-III, studies have suggested that the 
worldwide prevalence of this clone is also likely due to dissemination (Enright et al., 
2002; Robinson and Enright, 2003).  All ST36 isolates reported to date have been 
MRSA associated with SCCmec type II (Feil and Enright, 2004), suggesting that the 
SCCmec element is stable within this lineage; therefore, it is possible that the dru 
locus may be phylogenetically informative for ST36-MRSA-II strains as observed for 
ST239-MRSA-III (Smyth et al., 2009).  The dru type of F8 (dt9a) corresponded to the 
second-most prevalent dru type identified among ST36-MRSA-II isolates from seven 
cities or towns in Scotland (Goering et al., 2008a).  Although the dru type of F9 (dt7s) 
was not detected among ST36-MRSA-II isolates from Scotland (Goering et al., 
2008a), it differs from that of F8 by just two repeats (Figure 5.6).  ST36-MRSA-II 
isolates from Cape Town were also resistant to erythromycin, clindamycin and 
ciprofloxacin, which is common of UK isolates corresponding to this clonal type 
(Johnson, 1998; Murchan et al., 2004; Gould et al., 2008).  Collectively, these data 
suggest that ST36-MRSA-II isolates from hospitals in Cape Town may be related to 
EMRSA-16 isolates from the UK.  Travel has previously been proposed as a driver of 
the dissemination of EMRSA-16 from the UK to Malta and the Canary Islands, both 
of which are popular tourist destinations for UK citizens (Montesinos et al., 2006; 
Gould et al., 2008; Scicluna et al., 2009); therefore, given the history of migration and 
tourism between South Africa and the UK, it is possible that international travel 
introduced ST36-MRSA-II into this country. 
 
The clonal types of three sporadic isolates, S2, S7 and S8, were not consistent with 
those of the six PFGE clusters, or any of the other sporadic MRSA.  Rather, these 















S7 was consistent with ST22-MRSA-IVh, t032, which belongs to CC22, one of the 













Figure 5.10 Graphical representation of patterns of descent among members 
of S. aureus clonal complex 22 as determined using the eBURST algorithm.  
The predicted founder of clonal complex (CC) 22, ST22, is indicated by the blue 
circle.  As indicated by the red circle, ST22 was the only member of CC22 identified 
in the current study.  Descendants of ST22 are indicated by black circles with the 
yellow circle representing the only known subgroup of CC22 (ST217).  For clarity, 
no other STs are indicated.  The relative sizes of the nodes are proportional to the 
corresponding number of isolates reported in the MLST database. 
 
ST22-MRSA-IV corresponds to the pandemic HA-MRSA clone known as EMRSA-15, 
which emerged during the 1990s in UK hospitals (Johnson et al., 2005), and has 
since been described throughout Europe, and also in Canada, the Middle East, New 
Zealand and Australia (Deurenberg and Stobberingh, 2008).  In addition to being 
described as a cause of ha-MRSA infections, ST22-MRSA-IV has more recently 
emerged as a cause of ca-MRSA infections, and has also been isolated from 
companion animals (Faria et al., 2005; Moodley et al., 2006; Strommenger et al., 
2006b; de Lencastre et al., 2007; Boakes et al., 2010).  A review of the body of work 
that formed the basis of the report by Moodley et al. (2010) revealed that the spa-CC 
including t032 (detected in S7) comprised just 1.78 % of the MRSA, with isolates 
obtained from only the Western Cape, Eastern Cape and KwaZulu-Natal 
(Oosthuysen, 2007).  Combined with the results of the current study, these data 
















Isolate S7 exhibited several molecular characteristics typical of the UK epidemic 
clone EMRSA-15.  S7 corresponded to t032, the spa type most frequently associated 
with EMRSA-15 (Deurenberg and Stobberingh; 2008), and dt9j, a common dru type 
among ST22-MRSA-IVh isolates from Scotland and Ireland (Goering et al., 2008a; 
Shore et al., 2010).  Additionally, the antimicrobial susceptibility profile of S7 was 
similar to that described for EMRSA-15 isolates (Johnson, 1998; Livermore, 2000; 
Johnson et al., 2005).  Travel between the UK and Malta and the Azores archipelago 
has been proposed as one possible route of entry of EMRSA-15 into hospitals on 
those islands (Gould et al., 2008; Scicluna et al., 2009; Conceição et al., 2010).  
Similarly, it is possible that travel has resulted in the introduction of ST22-MRSA-IVh 
into hospitals in South Africa, given its history of frequent exchanges with the UK. 
 
The  remaining  sporadic  clones  identified  in  this  study,  ST72-MRSA-V  and  
ST650-MRSA-IVb, have not, to the best of the author‘s kn wledge, been previously 
described  in  South Africa.  Isolate S2 was consistent with the sporadic  clone  
ST72-MRSA-V, which belongs to a successful subgroup of CC8 that has diversified, 
producing several SLVs and a DLV (Figure 5.7).  This isolate represents an unusual 
clone in that ST72 has typically been described in association with SCCmec type IV 
(McDougal et al., 2003; Kim et al., 2007; Park et al., 2007b; Bae et al., 2010; Lim et 
al., 2010; Tavares et al., 2010) and, on rare occasions, SCCmec type II (Peck et al., 
2009).  As suggested in Chapter 3 [3.4], S2 may contain a variant of SCCmec type V 
or, alternatively a composite SCCmec element, neither of which have been described 
in ST72-MRSA.  Isolate S2 and previously described ST72 isolates did, however, 
share similar antimicrobial susceptibility profiles, with members of this lineage 
typically susceptible to the non-β-lactam antibiotics, except erythromycin and 
clindamycin (McDougal et al., 2003; Lim et al., 2010; Tavares et al., 2010). 
 
Although this is the first report of ST72-MRSA in South Africa, ST72-MRSA-IV has 
been reported as a major MRSA lineage in Korea (Kim et al., 2007; Park et al., 
2007b; Peck et al., 2009; Bae et al., 2010; Lim et al., 2010), and as one of the eight 
major epidemic strain types (USA700) in the USA (McDougal et al., 2003).  In both of 
these countries, ST72-MRSA-IV has been described as a cause of both ca- and ha-
MRSA (McDougal et al., 2003; Kim et al., 2007; Park et al., 2007b; Tenover et al., 
2008; Peck et al., 2009; Bae et al., 2010) infections and, in Korea, the clone has also 















USA, there have only been isolated reports of ST72-MRSA-IV, including ca-MRSA 
isolates from Portugal (Tavares et al., 2010) and ha-MRSA isolates from Brazil 
(Scheunck et al., 2009) and Germany (Luedicke et al., 2010).  Although the definition 
of isolates as ca- and ha-MRSA in the current study was rudimentary, S2 was 
classified as ha-MRSA.  The low prevalence of ST72-MRSA-V in hospitals in Cape 
Town, and in the rest of South Africa, suggests that this clone may not have taken 
hold in local hospitals.  
 
Following a BURP analysis using the default parameters described by Ridom 
StaphType [5.2.2], the spa types of isolate S2 and ST72-MRSA from Korea, Portugal 
and the USA (McDougal et al., 2003; Peck et al., 2009; Bae et al., 2010; Tavares et 
al., 2010) were assigned to the same spa-CC (Figure 5.11).   
 
Figure 5.11 Graphical representation of clustering among spa types of ST72-
MRSA isolates as determined by a BURP analysis.  The blue circle indicates the 
putative founding spa type, and the yellow circle the founder of a subgroup.  The 
costs between spa types, as determined by the BURP algorithm, are shown in 
green text in boxes between nodes.  Countries in which the spa types have been 
previously described are indicated in brackets alongside each node (RSA, Republic 
of South Africa).  (McDougal et al., 2003; Peck et al., 2009; Bae et al., 2010; 















Further, individual alignments of these spa types indicated that t3092 of S2 was more 
similar to spa types commonly identified in ST72-MRSA clones described in Korea 
and Portugal (Peck et al., 2009; Bae et al., 2010; Tavares et al., 2010), than those 
reported in the USA (McDougal et al., 2003) (Figure 5.12).  Given that this clone is 
most prevalent in Korea, and that SCCmec type V has not been reported previously 
in South Africa, it is likely that ST72-MRSA-V was imported into South Africa as a 
result of travel, which commonly occurs between these two countries.  Future studies 
will be required to obtain a greater understanding of the evolution of ST72-MRSA-V. 
 
Figure 5.12 Aligned spa repeat sequences for spa types of ST72-MRSA 
isolates described in South Africa, Korea, the USA and Portugal.  Pairwise 
alignments were carried out in Ridom StaphType to compare all spa repeat 
sequences to t3092 (isolate S2 from Cape Town).  Unique repeats are represented 
by different colours and gaps indicated by (-).  Countries of origin and alignment 
costs as calculated by Ridom StaphType are indicated in parentheses adjacent to 
the spa type (country; cost). RSA, Republic of South Africa; USA, United States of 
America; K, Korea.  (*) indicates predominant spa types for ST72-MRSA (McDougal 
et al., 2003; Peck et al., 2009; Bae et al., 2010; Tavares et al., 2010). 
 
The only other sporadic clone, corresponding to isolate S8, was consistent with 
ST650-MRSA-IVb.  ST650 (allelic profile 81-4-1-4-12-1-10) is a SLV of ST5 (1-4-1-4-
12-1-10), varying at the arcC locus, which indicates that it is a member of one of the 
oldest and most diverse S. aureus lineages, CC5 (Figure 5.13).  ST650 appears to 
be a rare genotype and has been reported only once previously (personal 
































Figure 5.13 Graphical representation of patterns of descent among members 
of S. aureus clonal complex 5 as determined using the eBURST algorithm.  
The predicted founder of clonal complex (CC) 5, ST5, is indicated by the blue circle.  
Descendants of ST5 are indicated by black and yellow circles.  Subgroups that have 
given rise to their own variants are indicated by yellow circles.  For clarity, only the 
STs of subgroups are indicated.  STs identified in the current study are shown in 
bold and the nodes are circled in red. The relative sizes of the nodes are 
proportional to the corresponding number of isolates reported in the MLST 
database. 
 
Isolate S8 contai ed SCCmec type IVb, was susceptible to non-β-lactam antibiotics, 
corresponded to an unusual ST uncommon among HA-MRSA, and was the PFGE 
outlier, all of which are characteristics typical of CA-MRSA (Millar et al., 2007).  It 
was, therefore, surprising that this isolate was classified as ha-MRSA.  This may 
suggest that ST650-MRSA-IVb has not been successful in hospitals in South Africa, 
regardless of whether it evolved in this setting or was imported from the community. 
 
The evolution and origin of ST650-MRSA-IVb in South Africa is unclear.  Previous 
reports of ST5-MRSA from South Africa have indicated that these isolates typically 
contain SCCmec type I (Moodley et al., 2010), or, in some cases SCCmec type III 















author‘s knowledge, the only ST5-MRSA-IV reported in South Africa to date include 
two isolates from the KwaZulu-Natal province (Essa et al., 2009); however, the spa 
types and SCCmec subtypes of these isolates are unknown.  It seems unlikely that 
ST650-MRSA-IVb arose from ST5-MRSA-I/III following the acquisition of a mutation 
in arcC, and the replacement of SCCmec type I/III with IVb.  Instead, it seems more 
plausible that ST650-MRSA-IVb emerged locally from an ST8-MRSA-IV ancestor.  
Interestingly, although the epidemiology of MSSA in South Africa is poorly 
understood, the recent characterisation of S. aureus isolates from Tygerberg hospital 
reported that t002 accounted for approximately 8.70 % of MSSA isolates, suggesting 
that the S. aureus population in the Western Cape may include ST5-MSSA (Salaam-
Dreyer, 2010).  This observation makes it possible to suggest that ST650-MRSA-IVb 
arose locally from ST5-MSSA following the acquisition of SCCmec type IVb and a 
mutation in the arcC gene, either of which may have occurred first; however, the 
possibility that ST650-MRSA-IVb was imported from another region cannot be 
excluded at present. 
 
The second-most prevalent clone identified among isolates from hospitals in Cape 
Town was ST5-MRSA-I.  ST5-MRSA-I corresponded to a pandemic HA-MRSA clone 
assigned to CC5 (Figure 5.13), which is also known as EMRSA-3.  EMRSA-3 
emerged in the UK (Johnson et al., 2005) and is now prevalent worldwide 
(Deurenberg and Stobberingh).  In the current study, the identification of three 
putative ca-MRSA isolates among the ST5-MRSA-I suggests that this clone is also 
present in communities in Cape Town (Appendix A).  The similarities between the ca- 
and ha-MRSA corresponding to ST5-MRSA-I suggest transmission between 
hospitals and communities or vice versa, highlighting a need for further studies to 
obtain a better understanding of the dissemination of MRSA between hospitals and 
communities in Cape Town. 
 
Epidemiological studies from South Africa suggest that ST5-MRSA-I, t045, is far 
more prevalent in hospitals in Cape Town (37 %) than in other regions of the country.  
The spa types of MRSA collected from Tygerberg Hospital did not include t045 or 
any related spa types, suggesting that ST5-MRSA-I, t045, was not present in that 
hospital (Salaam-Dreyer, 2010). Similarly, no isolates corresponding to ST5-MRSA-I 
were described in studies recently carried out in the KwaZulu-Natal (Essa et al., 















minor clone in KwaZulu-Natal, accounting for 9.8 % of the isolates, while Essa et al. 
(2009) described ST5-MRSA-IV as a minor clone, accounting for 8.33 % of the 
isolates in that province.  SCCmec type I was not detected among MRSA from the 
Steve Biko Academic Hospital in Pretoria, suggesting that the ST5-MRSA-I clone 
was absent in that institution (Makgotlho et al., 2009); however, the prevalence of 
ST5-MRSA carrying other SCCmec elements remains to be determined as the 
isolates were not characterised using sequence-based typing methods.  In contrast 
to these regional studies, Moodley et al. (2010) reported that ST5-MRSA-I 
represented one of five major MRSA clones within the South African context, 
accounting for 6.77 % of isolates.  As observed for the other common clonal types 
identified in this study, the national distribution of ST5-MRSA-I was uneven, as this 
clone was not detected in the KwaZulu-Natal, Northern Cape and Gauteng provinces 
(Moodley  et al.,  2010).   Whether  the  apparently  uneven  national  distribution  of  
ST5-MRSA-I (and ST36-MRSA-II and ST239-MRSA-III) was simply due to the 
sampling strategy of Moodley et al. (2010), or perhaps due to differences in clonal 
dissemination, or local infection control practices and antibiotic prescription policies, 
is yet to be determined.  
 
While it is possible that ST5-MRSA-I isolates present in Cape Town evolved from an 
imported ancestral clone, it is interesting to consider its evolution in the light of the 
study reported by Nübel et al. (2008).  Nübel et al. (2008) found that, at least in the 
case of ST5-MRSA, the acquisition of SCCmec has been grossly underestimated, 
and the global prevalence of ST5-MRSA is in fact due to the frequent emergence of 
methicillin-resistant lineages from ST5-MSSA in distinct geographic locations.  The 
detection of ccrC in local ST5-MRSA-I isolates was surprising.  The SCCmec content 
of these strains appears to differ from ST5-MRSA-I isolates previously described in 
South Africa, and indeed from their counterparts from the rest of the world; to the 
best of the author‘s knowledge, ccrC has only been previously described in two 
SCCmec type I isolates (Kondo et al., 2007).  When considered in conjunction with 
the  results  of  Nübel  et  al.  (2008),  these  data  suggest  that  the  ccrC-positive  
ST5-MRSA-I present in Cape Town may have emerged locally when an MSSA 
ancestor acquired an unusual SCCmec element.  Alternatively, if ccrC is present 
within a mobile genetic element distinct from SCCmec type I, this element may have 
















As described in Chapter 3 [3.3 and 3.4], isolate B1 corresponded to the only local 
representative of ST5-MRSA-I that did not contain the ccrC gene.  At that point, it 
was suggested that B1 and B2 may not be as closely related as estimated by PFGE.  
The spa typing and dru typing data support this suggestion: B1 corresponded to the 
similar yet distinct t7185 and dt10ar, while all the other ST5-MRSA-I isolates shared 
t045 and dt10a.  Taken together, these data suggest that B1, the only ST5-MRSA-I 
isolate from UCTPH, was divergent from the remaining ST5-MRSA-I isolated at 
MMH, GSH and RCCH.  In this context, it was of interest that ST5-MRSA-I isolates 
from MMH, GSH and RCCH all corresponded to t045 and dt10a, and shared high 
levels of similarity as determined by PFGE.  It is possible that ST5-MRSA-I has only 
recently been introduced into local hospitals, and that the low degree of genetic 
diversity observed in this study is the result of the founder effect.  Alternatively, it is 
possible that this study has obtained a snapshot of the local ST5-MRSA-I population 
after a bottleneck event, resulting in the limited genetic diversity.  It is also possible 
that these results reflect a genetic background that does not readily accommodate 
genetic change, although this seems less likely given the diversity previously 
observed within the ST5 genotype (Nübel et al. 2008).  Regardless of the reasons for 
the lack of variation in this clone, these dat  suggest that dru typing may not be 
suitable for the discrimination of ST5-MRSA-I isolates from hospitals in Cape Town at 
present. 
 
In this study, the predominant clone did not correspond to any pandemic MRSA 
lineages.  Instead, the predominant clone in hospitals in Cape Town corresponded to 
the infrequently described multidrug-resistant, pvl-negative ST612-MRSA-IVd (3-3-1-
1-4-88-83).  As it is a DLV of ST8 (3-3-1-1-4-4-3) varying at the tpi and yqiL loci, 
ST612 was assigned to CC8 (Figure 5.7). The ST612-MRSA-IVd clone collectively 
accounted for 44 % of MRSA, including all isolates from PFGE clusters D and E, as 
well as the sporadic isolates S1, S4, S5 and S6.  Three and four isolates from 
clusters D and E, respectively, were classified as ca-MRSA (Appendix A), which hints 
that this clone may be present in both hospitals and communities in Cape Town.  
These  data  also  indicate  that  there  is  little  difference  between  ca-  and  ha-
ST612-MRSA-IVd, suggesting that there has been transmission of MRSA between 
hospitals and communities in Cape Town.  There may be a similar prevalence of this 
clone at Tygerberg Hospital as a recent study characterising S. aureus isolates from 















corresponding to spa types detected among ST612-MRSA-IVd in the current study 
(Salaam-Dreyer, 2010).   
 
Although apparently most prevalent in the Western Cape, ST612-MRSA-IV in fact 
represents the predominant South African clone, accounting for 26.13 % of isolates 
included in a nationwide study on the epidemiology of MRSA from public and private 
diagnostic  laboratories  (Moodley  et  al.,  2010).   In  that  study,  two  major   
ST612-MRSA-IV PFGE clusters were identified, and accounted for 19.68 % and  
6.45 % of isolates, respectively.  Isolates belonging to the larger PFGE cluster were 
obtained from all nine provinces; MRSA from the smaller PFGE cluster were 
obtained from all provinces, except for the North West, Gauteng and Limpopo 
provinces.  A low prevalence of SCCmec type IV (4 %) has been reported among 
MRSA from the Steve Biko Academic Hospital situated in Pretoria, Gauteng 
(Makgotlho et al., 2009), suggesting that ST612-MRSA-IVd may be present at a low 
frequency at least in that institution; however, these isolates may have corresponded 
to a clonal type other than ST612-MRSA-IVd as th y were pvl-positive, whereas all 
ST612-MRSA-IV isolates described to date have been pvl-negative.  Two regional 
studies, both carried out in KwaZulu-Natal (Essa et al., 2009; Shittu et al., 2009), 
have reported results that conflict with those described by Moodley et al. (2010).  
ST612-MRSA-IV was not identified in these studies; instead, Essa et al. (2009) 
reported that 66.67 % of isolates corresponded to ST8-MRSA-IV, while Shittu et al. 
(2009) indicated that two DLVs of ST8, ST1173-MRSA-IV (3-3-1-1-4-131-3) and 
ST1338-MRSA-IV (3-3-1-1-4-131-83), collectively accounted for 62.3 % of the 
MRSA. 
 
ST612-MRSA-IVd isolates from hospitals in Cape Town exhibited a marked degree 
of genetic variation as indicated by PFGE, and by the detection of four spa types and 
seven dru types among the fourteen representative isolates.  This degree of genetic 
variation may not be unique to ST612-MRSA-IV isolates included in the current 
study.  Five spa types were present among the fourteen putative ST612-MRSA-IV 
isolates from Tygerberg Hospital (Salaam-Dreyer, 2010), while eleven spa types 
were detected among the two major and twelve minor PFGE clusters corresponding 
to ST612-MRSA-IV isolates obtained from public and private laboratories across 
South Africa (Moodley et al., 2010).  It is possible that ST612-MRSA-IV represents 















accumulating the genetic variation observed among local isolates.  Alternatively, it is 
possible that the genetic background of ST612-MRSA-IV is readily able to 
accommodate mutations and the acquisition of mobile genetic elements, resulting in 
the diversity observed in recent studies.  These explanations are not mutually 
exclusive, and may both have played a role in generating the level of genetic 
diversity observed in ST612-MRSA-IV isolates from South Africa.  Given the variation 
observed at the spa and dru loci of ST612-MRSA-IV isolates, it is possible that spa 
typing and dru typing, in conjunction with PFGE, will prove particularly useful for 
investigating potential outbreaks and intra- and inter-hospital transmission in South 
Africa. 
 
While ST612-MRSA-IV appears to be endemic to South Africa, it does not seem to 
be prevalent elsewhere.  To the best of the author‘s knowledge, this clone has only 
been reported previously in Australia and the UK, and then rarely.  In Australia, 
ST612-MRSA-IV, dubbed WA MRSA-20, has only been isolated once each in 2004 
and 2008 (Coombs et al., 2005; Nimmo and Coombs, 2008; Coombs et al., 2009).  
Both isolates were obtained from healthcare workers; the 2004 isolate was cultured 
from a nasal swab and classified as ca-MRSA, while the 2008 isolate was cultured 
from a clinical specimen (Coombs et al., 2005; Coombs et al., 2009).  To date, 
ST612-MRSA-IV isolates reported in the UK appear to be restricted to equine-
associated veterinary workers (Williams, 2008; Clegg, 2010).  That the dominant 
clone present in South Africa should correspond to an unusual genotype apparently 
largely restricted to the region was not completely surprising.  Studies carried out in 
China (Fan et al., 2009), Mali (Ruimy et al., 2008), Cameroon, Madagascar, 
Morocco, Senegal and Niger (Breurec et al., 2010) also reported that the S. aureus 
populations in these countries included unusual genotypes largely endemic to the 
region, as well as pandemic clones frequently described worldwide.  Additionally, the 
extensive epidemiological studies of Nübel et al. (2008 and 2010) and Grundmann  
et al. (2010) have clearly indicated that certain MRSA clones, or variants thereof, are 
endemic to particular geographical regions. 
 
It is interesting to speculate on the possible evolutionary relationship between 
ST612-MRSA-IV isolates from South Africa, Australia and the UK.  Considering that 
ST612-MRSA-IV appears to represent a rare lineage, combined with the fact that it is 















possible that the isolates from these three countries are related.  In further support of 
this hypothesis, ST612-MRSA-IV isolates from Australia and the UK had 
antimicrobial resistance profiles (resistant to rifampicin, co-trimoxazole and 
gentamicin) similar to the South African isolates (Frances O‘Brien and Julie Pearson, 
personal communication; Williams, 2008; Clegg, 2010).  Interestingly, one of the 
Australian ST612-MRSA-IV isolates also corresponded with one of the most common 
South African spa types, t064, while the other was consistent with the closely related 
t7571.  Unfortunately, the information available on the UK ST612-MRSA-IV isolates 
did not include spa typing data.  It is likely that the frequent exchange of individuals, 
perhaps particularly healthcare workers, between South Africa, Australia and the UK 
has  resulted  in  the  observed  distribution  of  ST612-MRSA-IV.   Given  that  
ST612-MRSA-IV appears to be most prevalent in South Africa, it is tempting to 
suggest that the clone emerged locally and was exported to Australia and the UK.  
However, given the prevalence of ST612-MRSA-IV and related putative ancestral 
clones among veterinary workers in the UK (Moodley et al., 2006; Williams, 2008; 
Clegg, 2010), it is possible that the clone was imported from that country into South 
Africa, and subsequently flourished in its new environment 
 
There are several possible routes of descent for ST612-MRSA-IV, regardless of in 
which country these processes occurred.  An ST8 ancestor may have acquired 
mutations in tpi and then yqiL, or yqiL and then tpi, going through one of two possible 
intermediary SLVs (ST828 or ST995) to become ST612, with SCCmec type IV 


























Figure 5.14 Schematic diagram illustrating possible evolutionary histories for 
ST612-MRSA-IV.  Different genotypes are represented by circles with STs and 
allelic profiles indicated in their centres.  Mutations in housekeeping genes are 
indicated adjacent to the stepwise progressions between ancestral and descendant 
STs, and in also in the allelic profile of the descendant genotype.  SCCmec type IV 
may have been acquired at any stage during the evolution of ST612, as indicated 
by the grey arrows. 
 
The eBURST analysis of the S. aureus MLST database suggested ST828 as the 
intermediary for ST612 (Figure 5.7); however, it is important to acknowledge that this 
is simply one possible evolutionary scenario, and it is also possible that ST995 was 
the intermediary for ST612 (Figure 5.14).  ST828 and ST995 represent single entries 
in the S. aureus database, corresponding to an MSSA isolate obtained from the 
Netherlands, and an ST995-MRSA-IV strain isolated in Norway, respectively 
(www.mlst.net), where to the best of the author‘s knowledge, ST612-MRSA-IV has 
not been described.  To date, no MSSA or MRSA intermediaries of ST612-MRSA-IV 
have been described in South Africa, the UK or Australia.  Interestingly, putative 
ST612-MSSA isolates corresponding to spa types typical of ST612-MRSA-IV have 
been described at Tygerberg Hospital (Salaam-Dreyer, 2010).  This may suggest the 
local emergence of ST612-MRSA-IV upon acquisition of SCCmec type IV.  















SCCmec cassette has been excised, as appears to be common in the case of 
SCCmec type IV (Jansen et al., 2006). 
 
In the context of the emergence of the ST612 genotype, the detection of ST8-MRSA-
IV as the predominant clone in a recent study carried out in the KwaZulu-Natal 
province (Essa et al., 2009) makes it possible to suggest that ST612-MRSA-IV arose 
locally from this lineage.  Further, the identification of ST1173-MRSA-IV, t064, and 
ST1338-MRSA-IV, t064, two dominant DLVs of ST8, in KwaZulu-Natal hints at the 
evolution of the ST8-MRSA-IV lineage within South Africa (Shittu et al., 2009).  
Larger future studies on the epidemiology of MRSA and MSSA isolates from the 
South   Africa   may   well   provide    additional    clues   as   to   the   evolution   of 
ST612-MRSA-IV.  Ultimately, it will be necessary to analyse larger portions of the 
genomes of ST612-MRSA-IV isolates obtained from different time periods and 
geographical regions, as well as those of any putative ancestral or descendant 
genotypes, in order to resolve the evolutionary history of this clone. 
 
Regardless of its origins and evolutionary history, ST612-MRSA-IV appears to have 
been most successful in South Africa.  Reasons as to why the success of this clone 
has been limited to South Africa are likely to be complex and multifactorial.  The 
widespread prevalence of ST612-MRSA-IV in South Africa may be directly related to 
the transmissibility of this clone, or to factors related to its host population.  
Alternatively, it is possible that local infection control practices, either in terms of 
current policies or adherence to the recommended guidelines, are inadequate for 
controlling ST612-MRSA-IV.  Additionally, the possibility that the community is a 
reservoir of this clone cannot be dismissed until studies examining the molecular 
epidemiology of both ca-MRSA and carriage isolates have been performed.  It is also 
possible that certain aspects of the biology of ST612-MRSA-IV have contributed to its 
local success.  For example, the presence of the smaller SCCmec type IV may have 
conferred an advantage on this clone as the other major clones present in South 
Africa are associated with the larger SCCmec type I – III elements, which are thought 

















Finally, it is interesting to consider the contribution of antimicrobial usage to the 
success of ST612-MRSA-IV in South Africa.  ST612-MRSA-IVd isolates from 
hospitals in Cape Town were largely multidrug-resistant, and the combined reports of 
Moodley et al. (2010) and Marais et al. (2009) suggest that ST612-MRSA-IV isolates 
from other regions of South Africa may be similarly resistant.  ST612-MRSA-IV 
isolates from hospitals in Cape Town were universally resistant to rifampicin, and all 
but two were resistant to co-trimoxazole; however, resistance to these antibiotics was 
rare among other clones detected in hospitals in Cape Town.  As described in 
Chapter 2 [2.4], previous studies have shown that the use of rifampicin and co-
trimoxazole selects for S. aureus strains resistant to these antibiotics (Martin et al., 
1999; Sekiguchi et al., 2006).  If the genetic background of ST612-MRSA-IV is in fact 
plastic, it is possible that the frequent use of these antimicrobial agents in South 
Africa may have driven the de novo acquisition of mutations and genetic elements 
conferring resistance on local isolates as observed in Japan and Spain (Sekiguchi et 
al., 2006; Mick et al., 2010).  Alternatively, it is possible that the frequent use of 
rifampicin and co-trimoxazole in South Africa has driven the clonal expansion of a 
resistant ST612-MRSA-IV ancestral strain.  These possibilities will be investigated 

















The Detection of an Uncommon Double Mutation Conferring 
High-level Rifampicin-resistance and Additional Conserved 
Synonymous Single Nucleotide Polymorphisms Suggests 
Clonal Expansion of ST612-MRSA-IV in Cape Town Hospitals 
 
6.1 Introduction 
In  South  Africa,  rifampicin  is  used  in combination  therapies  for  the  treatment  of 
S. aureus infections and, perhaps more importantly, is one of the first line drugs used 
for the treatment of M. tuberculosis infections (South African Department of Health, 
2004).  Given the frequent use of rifampicin to treat the latter infections, it is likely that 
this selective pressure may have effected the emergence and high prevalence rate of 
rifampicin-resistant MRSA in South Africa.  In recent studies carried out on MRSA 
from public hospitals in KwaZulu-Natal and Gauteng, 73.80 % and 100 % of isolates, 
respectively were rifampicin-resistant (Shittu and Lin, 2006; Groome et al., 2009).  A 
recent  nationwide  antimicrobial  susceptibility  surveillance  survey  showed  that  
52.82 % of MRSA obtained from South African public hospitals were rifampicin-
resistant (Marais et al., 2009).  The proportion of rifampicin-resistant MRSA detected 
in this study was similar at 45 %.  Resistance to rifampicin was universal among the 
forty-four isolates corresponding to the dominant local clone, ST612-MRSA-IV, 
accounting for all bar one of the rifampicin-resistant isolates identified in this study.  
The only other rifampicin-resistant isolate was C31, a representative ST5-MRSA-I 
isolate from PFGE cluster C.  Worryingly, all MRSA isolates selected for rifampicin E-
tests had high levels of resistance (MICs ≥ 256 µg/ml). 
 
Rifampicin is a bactericidal antimicrobial agent that inhibits transcription by binding to 
the β-subunit of the bacterial DNA-dependent RNA polymerase (Chambers, 1997; 
Greenwood et al., 2007).  The β-subunit of RNA polymerase is encoded by rpoB, and 
mutations within conserved regions of the gene have been shown to confer 
resistance to rifampicin in S. aureus, M. tuberculosis, Escherichia coli, Neisseria 















of the β-subunit decreases the affinity of RNA polymerase for rifampicin, thus 
conferring resistance to this antibiotic.  The majority of mutations that confer 
rifampicin resistance in S. aureus have been mapped to a conserved region of the 
rpoB gene known as the rifampicin resistance-determining region (RRDR), as shown 
in  Figure  6.1  (O‘Neill  et  al.,  2006).   The  RRDR  spans  amino  acids  462  to  
550 (S. aureus co-ordinates) and includes two conserved regions shown to be 
rifampicin  resistance   hotspots   in   the   corresponding   regions   in   E. coli  and  
M. tuberculosis (Aboshkiwa et al., 1995; Aubry-Damon et al., 1998; Wichelhaus et 
al., 1999; O‘Neill et al., 2006).  These conserved regions are known as clusters I and 
II, and also include most mutations known to confer rifampicin resistance in S. aureus 
(Figure 6.1) (Aubry-Damon et al., 1998; Wichelhaus et al., 1999). 
 
Figure 6.1. Alignment of E. coli and S. aureus RpoB amino acid sequences.  
Mutations conferring rifampicin resistance in E.coli commonly occur in clusters I, II 
and III, which are highlighted in blue, green and orange, respectively.  In S. aureus 
most mutations conferring resistance to rifampicin occur within the rifampicin-
resistance determining region (bold black text).  Dots (.) indicate identical amino 
acids and dashes (–) represent gaps.  For each sequence, commonly mutated 
residues are highlighted in yellow.  Deletions are indicated by downward-pointing 
arrows and insertions by inverted triangles.  Residues known to be involved in 
rifampicin binding in S. aureus are marked with a red asterisk.  Adapted from Aubry-















Although  there  are  few  studies   describing   rifampicin  resistance  genotypes  in 
S. aureus, both in vitro and in vivo data suggest a bias towards certain mutations 
(Figure 6.1) (O‘Neill et al., 2006).  Additionally, the level of rifampicin resistance has 
been shown to be dependent on the location and nature of amino acid substitutions 
within the β-subunit (Aubry-Damon et al., 1998; Wichelhaus et al., 1999; 
Wichelhaus et al., 2002).  Residues commonly mutated in S. aureus include Q468, 
F469, H481, R484, and S486, all of which have been shown to be involved in rifampicin 














Figure 6.2 Rifampicin binding to the β-subunit of S. aureus RNA polymerase.  
Rifampicin is shown in yellow.  The five important β-subunit residues known to 
make direct H-bonding contact with the rifampicin molecule (Q468, F469, H481, R484, 
and S486) are marked.  Figure taken from O‘Neill et al. (2006). 
 
The level of resistance conferred by a particular mutation is dependent on the type of 
amino acid substitution (Wichelhaus et al., 1999), as illustrated by changes at H481, 
one of the most frequently substituted residues identified to date (O‘Neill et al., 2006).  
At H481, substitution of the histidine residue with asparagine confers low level 
rifampicin resistance, while substitution with tyrosine confers high level resistance.  
Although single mutations such as H481Y can confer high-level rifampicin-resistance, 
clinical strains with high levels of resistance frequently carry two or more mutations 
(Wichelhaus et al., 1999; O‘Neill et al., 2006).  A large proportion of double and triple 















conjunction with additional mutations, is associated with high-level resistance 
(Wichelhaus et al., 1999; Wichelhaus et al., 2002; O‘Neill et al., 2006).  These results 
indicate that one knock-on effect of secondary and tertiary mutations within the rpoB 
gene is increased levels of rifampicin resistance (O‘Neill et al., 2006). 
 
Although mutations within rpoB confer a selective advantage in the presence of 
rifampicin, they do come at a physiological price (Reynolds, 2000; Lipsitch, 2001; 
Wichelhaus et al., 2002).  A number of in vitro studies in S. aureus and E. coli have 
shown that rifampicin-resistant mutants are often less fit than their parent strains 
(Reynolds, 2000; Wichelhaus et al., 2002).  It has been suggested that resistance 
modifications in RNA polymerase decrease the affinity of the enzyme for DNA and 
destabilise the transcription complex, which results in lowered levels of transcription 
(O‘Neill et al., 2006).  In the absence of rifampicin, mutations in rpoB would be 
disadvantageous and one might expect reversion to the wild-type protein.  Reynolds 
et al. (2000) showed that, in E. coli, this is not the case as intragenic, or extragenic, 
compensatory mutations restored levels of transcription and bacterial fitness.  
Similarly, O‘Neill et al. (2006) showed that the secondary mutations present in clinical 
S. aureus isolates not only increased levels of rifampicin resistance, but in some 
cases restored bacterial fitness, or both restored fitness and increased levels of 
resistance.   
 
As mentioned previously, the available information on rifampicin resistance 
genotypes is limited to a small number of studies which, to the best of the author‘s 
knowledge, have not included rifampicin-resistant MRSA from South Africa.  The 
investigations described in this chapter were prompted by two related questions: 
what is the mechanism of rifampicin resistance in the local and previously described 
ST612-MRSA-IV isolates, and is the prevalence of rifampicin-resistance in this clone 

















6.2 Experimental Protocol 
6.2.1 Selection of MRSA for rpoB genotyping 
Twelve MRSA isolates described in this study were selected for rpoB genotyping, 
including 2 rifampicin susceptible isolates: the sporadic isolate designated S7, and 
the  representative  from  cluster  F  known  as  F9  (Appendix  A).   Isolate C31  
(ST5-MRSA-I), the only rifampicin-resistant isolate outside the local dominant clone, 
was included as were 9 ST612-MRSA-IV isolates identified in this study: 2 sporadic 
isolates, S1 and S4, 2 isolates from cluster D (D2 and D4) and 5 isolates from cluster 
E (E5, E8, E19, E26 and E32), which were selected to include MRSA from across the 
PFGE cluster (Appendix A).  Additionally, the 2 ST612-MRSA-IV isolated from 
healthcare workers in Australia (Coombs et al., 2005; Nimmo and Coombs, 2008; 
Coombs et al., 2009), as well as 2 previously described ST612-MRSA-IV isolates 
from South Africa (Goering et al., 2008b), were also included for rpoB genotyping.  
The Australian ST612-MRSA-IV isolates (04-17532 and 09-15543) were obtained 
from Dr Frances O‘Brien and Ms Julie Pearson (Department of Microbiology and 
Infectious Diseases, PathWest Laboratory Medicine WA, Royal Perth Hospital, Perth, 
Australia), while the 2 isolates previously described in South Africa (N83 and N84) 
were provided by Professor Richard Goering (Department of Medical Microbiology 
and Immunology, Creighton University Medical Center, Omaha, NE, USA).  All 
isolates selected for rpoB genotyping had rifampicin E-test MICs ≥ 256 µg/ml, except 
isolate S7 and the representative of cluster F, which were rifampicin susceptible with 
E-test MICs ≤ 0.016 µg/ml.  
 
6.2.2 rpoB genotyping 
A 702 bp region of rpoB spanning amino acid residues 441 to 673 (S. aureus co-
ordinates), including the RRDR (Figure 6.1), was amplified as described by Aubry-
Damon et al. (1998).  Each PCR was carried out in a final volume of 100 µl with 1X 
PCR buffer, 1.5 mM MgCl2 (JMR Holdings, London, UK), 40 pmol of the primers F3 
and F4 (Synthetic DNA Laboratory, University of Cape Town, Cape Town, South 
Africa) (Appendix E) and 400 µM of each dNTP (Thermo Scientific, Wilmington, DE, 
USA).  One hundred nanograms of template DNA and 1 U of Taq polymerase (JMR 
Holdings, London, UK) were added to the reaction volume.  Amplification was carried 
out using an Applied Biosystems 2720 Thermocycler (Applied Biosystems, Carlsbad, 















min at 94°C, followed by 35 cycles of denaturation at 94°C for 30 s, annealing at 
52°C for 45 s, elongation at 72°C for 45 s, with a final extension step of 3 min at 
72°C. 
 
The PCR products were separated on 1.5 % agarose gels and visualised as 
previously described [3.2.2].  The 702 bp fragment was purified and both strands 
were sequenced at the Central Analytical Facility at the University of Stellenbosch as 
described in Chapter 3 [3.2.3.2].  After the sequences were viewed and edited 
[3.2.3.2], they were aligned to the rpoB sequence of RN4220, a rifampicin 
susceptible S. aureus strain (accession number X64172), using the ClustalW 
algorithm in BioEdit Sequence Alignment Editor (version 7.0.5.2) (Hall, 1999).  The 
aligned sequences were trimmed in order to exclude regions with poor quality 
sequencing data and the resulting final fragment used for analysis was 669 
nucleotides in length.  The predicted amino acid sequences of the selected isolates, 
spanning amino acid residues 442 to 664, were inferred using the translation function 

















6.3.1 Characterisation of mutations in the rpoB gene  
Three rpoB genotypes were detected among the 14 rifampicin-resistant isolates 
characterised in this study.  The rpoB genotypes and other available molecular 
characteristics of all 16 isolates included in this investigation are shown in Table 6.1.  
A multiple sequence alignment of the DNA and amino acid sequences is shown in 
Appendix H.  No amino acid substitutions were observed in the RpoB protein 
sequences of rifampicin-susceptible isolates S7 and F9.  C31 (ST5-MRSA-I), the only 
rifampicin-resistant isolate identified outside the dominant local clonal type, carried a 
single H481Y substitution known to confer high-level rifampicin resistance (Table 6.1; 
Appendix H).  The 9 local ST612-MRSA-IV isolates all carried the same double 
mutational changes within the RRDR, H481N, I527M (Table 6.1; Appendix H), which 
have previously been associated with high-level rifampicin resistance in S. aureus.  
Both of the ST612-MRSA-IV previously identified in South Africa also carried the 
H481N, I527M double substitution.  These mutational changes were also observed in 
the 2 ST612-MRSA-IV isolates from Australia; however an additional novel amino 
acid substitution, K579R, was observed outside the RRDR in isolate 09-15543 (Table 
6.1; Appendix H).  
 
In addition to the mutations associated with amino acid substitutions in RpoB, 
synonymous single nucleotide polymorphisms (SNPs) were detected in all 16 
isolates when the rpoB nucleotide sequences were compared to that of RN4220 
(Table 6.1; Appendix H).  All isolates contained an identical synonymous SNP, 
thymine instead of guanine, at the third base of the codon for alanine at position 498 
(Table 6.1; Appendix H).  Otherwise between 1 and 3 additional synonymous SNPs 
particular to each clonal type were identified in the nucleotide sequences.  Of note is 
the conserved cytosine present instead of thymine at the third base of the codon for 
arginine at amino acid position 512, which was detected in the 9 local and 4 

















Table 6.1. Molecular typing data and rpoB genotypes of selected methicillin-resistant S. aureus isolates 


























GCG→GCT 498 - 
CAT→CAC 554 - 





(t021; dt7s); CC30 
F ≤0.016 
AAC→AAT 474 - 
GCG→GCT 498 - 
GTA→GTG 502 - 
ACA→ACG 518 - 
C31 
ST5-MRSA-I  
(t045; dt10a); CC5 
C ≥256 
CAT→TAT 481 H481Y 
GCG→GCT 498 - 
AAT→AAC 630 - 
GGT→GGA 658 - 
S1 
ST612-MRSA-IV 




CAT→AAT 481 H481N 
GCG→GCT 498 - 
CGT→CGC 512 - 
ATT→ATG 527 I527M 
S4 
ST612-MRSA-IV  




CAT→AAT 481 H481N 
GCG→GCT 498 - 
CGT→CGC 512 - 



















   
(t064; dt10i); CC8 
D ≥256 
CAT→AAT 481 H481N 
GCG→GCT 498 - 
CGT→CGC 512 - 
ATT→ATG 527 I527M 
D4 
ST612-MRSA-IV  
(t064; dt10i); CC8 
D ≥256 
CAT→AAT 481 H481N 
GCG→GCT 498 - 
CGT→CGC 512 - 




   
(t1443; dt9ac); CC8 
E ≥256 
CAT→AAT 481 H481N 
GCG→GCT 498 - 
CGT→CGC 512 - 




   
(t064; dt9ad); CC8 
E ≥256 
CAT→AAT 481 H481N 
GCG→GCT 498 - 
CGT→CGC 512 - 




   
(t1443; dt10o); CC8 
E ≥256 
CAT→AAT 481 H481N 
GCG→GCT 498 - 
CGT→CGC 512 - 




   
(t1443; dt10i); CC8 
E ≥256 
CAT→AAT 481 H481N 
GCG→GCT 498 - 
CGT→CGC 512 - 


















(t1443; dt8v); CC8 
E ≥256 
CAT→AAT 481 H481N 
GCG→GCT 498 - 
CGT→CGC 512 - 









CAT→AAT 481 H481N 
GCG→GCT 498 - 
CGT→CGC 512 - 





(t064; dt10i); CC8 
ND ≥256 
CAT→AAT 481 H481N 
GCG→GCT 498 - 
CGT→CGC 512 - 





(t064; dt10i); CC8 
ND ≥256 
CAT→AAT 481 H481N 
GCG→GCT 498 - 
CGT→CGC 512 - 






   
(t7571; dt10i); CC8 
ND ≥256 
CAT→AAT 481 H481N 
GCG→GCT 498 - 
CGT→CGC 512 - 
ATT→ATG 527 I527M 
AAA→AGA 579 K579R 
a
 Isolate designations as introduced in Chapter 2. 
b
 S. aureus co-ordinates. 
c
 Sequence Types (STs) inferred from those assigned to representative isolates from respective PFGE clusters. 
d
 Previously described ST612-MRSA-IV isolates obtained from South Africa (N83 and N84) and Australia (04-17532 and 09-15543). 
e
















It has long been acknowledged that the use of antimicrobial agents in the clinical 
setting exerts selective pressure on bacteria resulting in the emergence of drug-
resistant organisms (Lowy, 2003; Levy and Marshall, 2004; Hawkey, 2008).  The 
proportion of rifampicin-resistant isolates detected in this study, particularly within the 
dominant clone, ST612-MRSA-IV, prompted the characterisation of the rpoB gene in 
a selection of MRSA isolates.  Analysis of the RRDR of one ST5-MRSA-I isolate 
(C31) and thirteen representatives of ST612-MRSA-IV that all expressed high-level 
rifampicin-resistance identified three rpoB genotypes; no amino acid substitutions 
were detected in the rifampicin-susceptible isolates S7 and F9.   
 
C31, ST5-MRSA-I, was the only rifampicin-resistant isolate outside of the dominant 
clonal type and carried a single mutational change within rpoB: H481Y.  This 
substitution, associated with high-level resistance, is one of the most common 
rifampicin resistance genotypes and has previously been reported in several 
laboratory mutants and clinical isolates (Aubry-Damon et al., 1998; Wichelhaus et al., 
1999; Schmitz et al., 2000; Wichelhaus et al., 2002; O‘Neill et al., 2006).  Molecular 
modelling has provided valuable insights as to how the H481Y mutation is refractory to 
rifampicin-binding.  The imidazole side chain in histidine typically forms a hydrogen 
(H) bond with rifampicin (Figure 6.2) but, because the phenolic side chain of tyrosine 
is larger than the imidazole ring of histidine, the conformation of the modified RNA 
polymerase is altered, thereby eliminating the original H-bond between rifampicin and 
its target.  Additionally, the altered conformation allows for a slight movement of 
rifampicin within the binding cavity, which decreases drug-enzyme hydrophobic 
interactions.  It is these changes that are thought to be responsible for the significant 
decrease in the binding energy of RNA polymerase for rifampicin and the elevated 
MICs associated with the H481Y genotype (O‘Neill et al., 2006). 
 
Mick et al. (2010), detected four markedly different rifampicin resistance genotypes 
among thirty-two ST228-MRSA-IV isolates, expressing varied levels of resistance, 
which were collected from a single hospital over three years.  This contrasted with 
the results obtained in the current study where only two rpoB genotypes were 
identified among the nine local and four previously described ST612-MRSA-IV 















ST612-MRSA-IV isolates, including two previously identified South African isolates, 
and one of the Australian isolates.  This genotype is relatively uncommon and, to the 
best of the author‘s knowledge, has only been reported previously in two clinical 
rifampicin-resistant MRSA isolates from Italy (Wichelhaus et al., 1999; O‘Neill et al., 
2006).  The third rpoB genotype was present in the remaining Australian ST612-
MRSA-IV isolate and included a triple amino acid substitution: H481N, I527M, K579R.  
To the best of the author‘s knowledge, K579R, which occurs outside the RRDR, has 
not been reported previously, hence H481N, I527M, K579R is a novel genotype. 
 
Studies have shown that substituting asparagine for histidine at position 481 
weakens the H-bond with rifampicin, thereby reducing the affinity of RNA polymerase 
for the drug (O‘Neill et al., 2006); however, the effects of the I527M substitution have 
not been characterised.  As the single mutational change H481N typically confers low-
level rifampicin resistance, it can be assumed that high-level resistance develops in a 
stepwise fashion due to the acquisition of additional mutations within rpoB 
(Wichelhaus et al., 1999).  That H481N, I527M isolates described to date have 
expressed high-level rifampicin resistance (Wichelhaus et al., 1999), supports the 
assumption that the secondary I527M substitution augments the level of resistance 
conferred by the primary substitution.  In addition to these substitutions, the most 
recent of the Australian ST612-MRSA-IV isolates, 09-15543, isolated in 2009, 
contains a third novel K579R substitution, which likely represents the latest 
substitution in this clone.  The impact of the K579R substitution on rifampicin-
resistance is yet to be determined. 
 
A number of synonymous SNPs were detected in the sixteen isolates when using the 
nucleotide sequence of RN4220 as a reference (Table 6.1; Appendix H).  One SNP 
(GCG→GCT) in the codon for alanine at position 498 was common to all sixteen 
isolates, which belonged to a number of S. aureus lineages (Table 6.1).  The SNP 
(GCG→GCT) has also been reported in S. aureus strains ATCCBAA44 and PER88 
(ST247-MRSA-I control strains) and ST228-MRSA-I isolates from Spain (Mick et al., 
2010).  Codon usage tables derived from the genome sequences of six S. aureus 
strains (NCTC8325 (ST8-MSSA), COL (ST250-MRSA-I), Newman (ST8-MRSA-II), 
USA300 (ST8-MRSA-IV), N315 (ST5-MRSA-II) and Mu50 (ST5-VISA-II)), indicated 
that the codon GCT is twice as prevalent as GCG (http://www.kazusa.or.jp/codon/).  















once in RN4220, rather than on separate occasions in diverse S. aureus lineages.  
This can, however, only be confirmed when more rpoB sequences of S. aureus 
isolates from a variety of genetic backgrounds become available. 
 
The only other conserved synonymous SNP (CGT→CGC in the codon for arginine at 
amino acid position 512) was observed in all ST612-MRSA-IV isolates (Table 6.1; 
Appendix H).  This mutation was noteworthy for two reasons: firstly, AT-rich 
organisms such as S. aureus more commonly contain thymine or adenine at the third 
base of codons rather than cytosine or guanine (Ermolaeva, 2001; 
http://www.kazusa.or.jp/codon/); secondly, codon usage tables indicated that the 
codon CGT is more common than CGC in S. aureus 
(http://www.kazusa.or.jp/codon/).  Thus it is possible to suggest that the SNP 
(CGT→CGC) did not arise on multiple occasions, but was instead inherited from a 
common ancestor, and has been conserved within ST612-MRSA-IV.  Further, this 
supports a hypothesis of clonal expansion of a rifampicin-resistant ST612-MRSA-IV 
ancestor in hospitals in Cape Town.  Significantly, the four previously described 
ST612-MRSA-IV isolates carried the same synonymous SNPs observed in the local 
isolates, suggesting that ST612-MRSA-IV described in this study may share a 
common ancestor with the isolates previously described in South Africa and 
Australia. 
 
Although the reasons for the dominance of ST612-MRSA-IV in hospitals in Cape 
Town are likely to be complex, it is probable that the frequent use of rifampicin in 
South Africa has contributed to the emergence and local expansion of this clone.  
Albeit that resistance mutations frequently come at an initial fitness cost to the 
organism (Lipsitch, 2001), it has been shown that rifampicin-resistant E. coli do not 
revert to a wild-type susceptible RNA polymerase in the absence of rifampicin 
(Reynolds, 2000).  Rather, they persist because of their capacity to develop 
compensatory mutations, which restore bacterial fitness (Reynolds, 2000).  Similarly, 
S. aureus isolates have also been shown to acquire compensatory mutations that 
negate the fitness costs caused by the primary resistance mutation (O‘Neill et al., 
2006). Disturbingly, if the ST612-MRSA-IV isolates from local hospitals have 
accumulated intragenic or extragenic compensatory mutations, reduced use of 
rifampicin may have little to no effect on the prevalence of this multidrug-resistant 


















At the onset of this study, there was a paucity of comprehensive molecular 
epidemiological data available on MRSA from South Africa; however, a number of 
reports describing aspects of the molecular epidemiology of MRSA from South Africa 
have been published in the past eighteen months (Essa et al., 2009; Makgotlho et al., 
2009; Shittu et al., 2009; Moodley et al., 2010), which is evidence of an increasing 
global appreciation of the importance of epidemiological investigations.  To the best 
of the author‘s knowledge, the current study represents the first comprehensive 
molecular characterisation of MRSA from hospitals in Cape Town.  Additionally, 
along with the studies reported by Shittu et al. (2009) and Moodley et al. (2010), this 
represents one of the first comprehensive molecular characterisations of MRSA from 
South Africa, including techniques for the investigation of aspects of both local and 
global epidemiology.  The results of this study have essentially provided a snapshot 
of the molecular epidemiology of MRSA present in five hospitals in Cape Town 
during 2007 and 2008. 
 
PFGE proved a useful starting point in the molecular characterisation of the hundred 
isolates, providing valuable insights into the epidemiology of MRSA from hospitals in 
Cape Town.  A comprehensive molecular characterisation was carried out including 
MRSA isolates representative of the PFGE clusters, as well as the sporadic isolates, 
using a combination of SCCmec typing, MLST and spa typing, as is the international 
convention.  Using this data, it was possible to determine the identities of the MRSA 
clones present in hospitals in Cape Town, and investigate the epidemiology of local 
isolates within the broader South African and global contexts. 
 
Several frequently described pandemic clones were identified among the hundred 
isolates, some of which have been previously reported in South Africa, albeit at 
different frequencies (Essa et al., 2009; Shittu et al., 2009; Moodley et al., 2010).  
Two well-known pandemic HA-MRSA clones, ST239-MRSA-III and ST36-MRSA-II, 
were identified in this study but, in contrast to reports from other regions of South 















studies, it seems likely that ST239-MRSA-III and ST36-MRSA-II were imported into 
South Africa, and have subsequently disseminated throughout the country due to 
emigration, tourism and local travel (Enright et al., 2002; Robinson and Enright, 2003; 
Smyth et al., 2009; Harris et al., 2010).   
 
The second-most prevalent clone identified in this study, ST5-MRSA-I, also 
corresponded to a pandemic HA-MRSA lineage.  As suggested for ST239-MRSA-III 
and ST36-MRSA-II, ST5-MRSA-I may have been imported into South Africa; 
however, in the light of recent studies regarding the evolution of ST5-MRSA (Nübel  
et al., 2008), it is also interesting to consider the possibility that this clone emerged 
locally.  ST5-MRSA-I was markedly more prevalent in hospitals in Cape Town than in 
other regions of South Africa (Essa et al., 2009; Shittu et al., 2009; Moodley et al., 
2010), and also appears to be present in local communities.  It remains to be 
determined whether the nationwide differences in the prevalence of ST5-MRSA-I, 
ST239-MRSA-III and ST36-MRSA-II might be due to the uneven dissemination of 
these clones, or to regional changes in clonal composition, or to the fact that these 
clones are equipped to thrive in some regions, but not others.  The high prevalence 
of ST5-MRSA-I detected in the current study may also be linked to the recent 
dissemination of this clone in the maternity and neonatal services at GSH and MMH, 
which is currently being investigated further. 
 
Interestingly, all but one of the local ST5-MRSA-I isolates carried the ccrC gene, 
which is uncommon in strains containing SCCmec type I.  Similarly, isolate S2, 
corresponding to ST72-MRSA-V, a lineage not previously reported in South Africa, 
was also atypical in terms of its SCCmec content, as ST72-MRSA isolates are 
typically associated with SCCmec types II and IV (McDougal et al., 2003; Kim et al., 
2007; Park et al., 2007b; Peck et al., 2009; Bae et al., 2010; Lim et al., 2010; Tavares 
et al., 2010).  Additionally, isolate S2 appeared to contain at least two alleles of ccrC, 
and may also contain divergent J regions.  It is possible that the ST5-MRSA-I and 
ST72-MRSA-V isolates contain composite SCCmec elements, which include multiple 
ccr complexes (Ito et al., 2009).  Mosaic SCCmec elements are commonly described 
among CNS species, and it is possible that the unusual SCCmec elements that 
appear to be present in local MRSA originated in the CNS population present in 
hospitals in Cape Town (Garza-González et al., 2010).  Additional studies are 















MRSA-V isolates.  If these isolates do contain novel mosaic SCCmec elements, 
studies characterising the origins of these elements may improve our understanding 
of  the  local  evolution  of MRSA and the genetic  exchanges  taking  place  between 
S. aureus and CNS. 
 
While a number of commonly described pandemic clones were identified in this 
study, the dominant clone present in hospitals in Cape Town was the infrequently 
described ST612-MRSA-IVd.  ST612-MRSA-IV has recently been shown to be 
endemic in South Africa (Moodley et al., 2010), but does not appear to be common 
elsewhere.  To the best of the author‘s knowledge, the clone has only been 
previously  reported  on  two  occasions  in  Australia  (Coombs  et  al.,  2005;  
Coombs et al., 2009), and also rarely in horses and their veterinary workers in the UK 
(Williams, 2008; Clegg, 2010).  This multidrug-resistant clone was detected in all of 
the included Cape Town hospitals, and also appears to be present in local 
communities.   
 
It is interesting to consider the emergence and evolution of ST612-MRSA-IV.  It is not 
yet clear whether ST612-MRSA-IV was imported into South Africa or whether it 
emerged locally in either the hospital or community setting.  Given the restricted 
geographical distribution of ST612-MRSA-IV, it is quite possible that this clone 
emerged locally, and has since undergone clonal expansion to become the dominant 
clone in South Africa, subsequently being disseminated to Australia and the UK.  The 
detection of an uncommon double mutation that confers high-level rifampicin 
resistance and a unique synonymous SNP in local ST612-MRSA-IV supports the 
suggestion of clonal expansion in hospitals in Cape Town.  Furthermore, the fact that 
ST612-MRSA-IV isolates described previously in South Africa and Australia shared 
the same uncommon double mutation and unique SNP suggests that these MRSA 
may share a common ancestor with those present in hospitals in Cape Town.  
Further studies investigating larger portions of the ST612-MRSA-IV genome are 
required to clarify the emergence and evolution of this clone. 
 
The genetic diversity detected among ST612-MRSA-IV isolates both in the current 
study and in that of Moodley et al. (2010) was also of interest.   In both studies, a 















ST612-MRSA-IV isolates with these strains assigned to multiple clusters.  
Additionally, several spa types were detected among ST612-MRSA-IV isolates in 
both studies.  In the present study, dru typing, a new single-locus sequence-based 
typing technique was also used to characterise the MRSA.  Although dru typing was 
unable to differentiate the highly similar ST5-MRSA-I isolates, the technique detected 
a marked degree of genetic variation among the ST612-MRSA-IV isolates.  
Collectively, these data may suggest that ST612-MRSA-IV represents an ancient 
South African clone that has accumulated genetic variation over time, or, 
alternatively, it is possible that the genetic background of this clone is highly plastic 
and readily, and rapidly, accommodates genetic changes.  These explanations are 
not mutually exclusive and both factors may have contributed to the level of genetic 
diversity observed among ST612-MRSA-IV isolates. 
 
The six PFGE clusters corresponding to the major four clones included isolates from 
between two and five hospitals in Cape Town, which suggested the transmission of 
MRSA within and between local healthcare institutions.  It was noted that three of 
these clones (ST239-MRSA-III, ST36-MRSA-III, and particularly ST612-MRSA-IV) 
included large proportions of multidrug-resistant isolates that were obtained from 
multiple hospitals.  The transmission of multidrug-resistant MRSA within and between 
local hospitals is worrying given the therapeutic challenges posed by these strains.  
These findings have highlighted the need for further investigations into the underlying 
factors contributing to the dissemination of MRSA in hospitals in Cape Town, and 
have provided an indication of where such studies should be directed.   
 
In addition to providing an understanding of the local epidemiology of MRSA from 
hospitals in Cape Town, the current study has also raised several questions that may 
form the basis of future community-based studies on MRSA.  Of particular interest is 
the possible role that widespread use of rifampicin and co-trimoxazole in local 
communities plays in shaping the MRSA population structure, and future studies will 
be carried out to investigate this issue.  Additionally, future studies will be required to 
determine whether or not there are in fact differences between adult and paediatric 
community-acquired MRSA as hinted by the current study.  Current molecular 
markers of CA-MRSA have been determined on the basis of studies carried out 















epidemiology of CA-MRSA from South Africa will also prove invaluable in 
determining molecular markers appropriate for the local identification of these clones.   
 
In the future, it will also be important to carry out studies similar to the one described 
here at regular intervals in order to monitor changes in the epidemiology of MRSA 
from hospitals in Cape Town.  These studies will generate the data necessary for the 
evaluation and modification of existing infection control policies and antibiotic 
prescription guidelines, and will inform future studies, which will ultimately improve 
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Laboratory data obtained from the NHLS Experimental data obtained during this study 
















Substitutions P Clo E Cli R Sxt Ci G F V L 
A1 R R R R S R R R S S - 10.02.2007 Blood GSH ICU A III 239 t037 dt14e
b
 - 
A2 R R R R S R R R S S S 01.10.2007 Pus swab GSH OPC A III - - - - 
A3 R R R R S R R R S S S 17.10.2008 RTS RCCH ICU A III - - - - 
A4 R R R R S R R R S S S 13.02.2007 RTS RCCH OPC A III - - - - 
S1 R R S S R R R R S S S 23.04.2008 CVCT GSH MED 
Sporadic 
Isolate 
IVd 612 t1443 dt10aq
b
 H481N; I527M 
S2 R R R R S S S S S S - 10.07.2007 Pus swab GSH OPC 
Sporadic 
Isolate 
V 72 t3092 dt11a - 
S3 R R R R S S R R S S - 12.07.2007 Blood RCCH ICU 
Sporadic 
Isolate 
II 36 t021 dt4c
b
 - 
S4 R R R R R R R R S S S 23.07.2008 Pus swab RCCH MED 
Sporadic 
Isolate 
IVd 612 t1257 dt10i H481N; I527M 





B2 R R R R S S S R S S S 26.08.2008 Pus swab GSH SUR B I 5 t045 dt10a - 
C1 R R R R S R S S S S - 17.06.2007 Urine MMH GYN C I - - - - 
C2 R R S S S S S S S S - 23.06.2007 RTS GSH GYN C I - - - - 
C3 R R R R S S S S S S - 26.06.2007 Urine MMH GYN C I - - - - 
C4 R R R R S S S R S S S 07.10.2007 Urine MMH ICU C I - - - - 
C5 R R R R S S S S S S S 14.12.2007 Pus MMH GYN C I 5 t045 dt10a - 
C6 R R R R S S S S S S S 13.04.2008 Pus swab MMH GYN C I - - - - 
C7 R R R R S S S S S S - 26.04.2008 Pus swab MMH GYN C I - - - - 
C8 R R R R S S S R S S S 16.07.2008 Pus swab MMH ICU C I - - - - 
C9 R R R R S S S S S S S 05.10.2007 Urine MMH GYN C I - - - - 
C10 R R R R S S S S S S - 22.04.2008 Pus swab MMH GYN C I - - - - 
C11 R R R R S S S R S S S 11.06.2008 Pus swab GSH GYN C I - - - - 
C12
c
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MRSA 
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C13 R R R R S S S R S S - 27.02.07 Pus swab GSH GYN C I - - - - 
C14 R R R R S S S R S S - 28.02.07 Pus swab GSH ICU C I - - - - 
C15 R R S S S S S S S S - 12.06.07 Urine MMH GYN C I - - - - 
C16
c
 R R S S S S S S S S - 12.06.07 Urine MMH GYN C I 5 t045 dt10a - 
C17
c
 R R R R S S S S S S - 18.06.07 Urine RCCH OPC C I - - - - 
C18 R R R R S S S S S S - 07.09.07 Urine MMH GYN C I - - - - 
C19 R R R R S S S S S S - 12.12.07 Blood GSH ICU C I - - - - 
C20 R R R R S S S S S S - 12.12.07 Blood GSH ICU C I - - - - 
C21 R R R R S S S S S S S 22.01.08 Pus swab GSH SUR C I - - - - 
C22 R R R R S S S S S S - 16.04.08 RTS MMH ICU C I - - - - 
C23 R R R R S S S R S S S 04.06.08 CVCT RCCH SUR C I - - - - 
C24 R R R R S S S R S S S 26.06.08 Pus swab GSH SUR C I - - - - 
C25 R R R R S S S S S S - 24.07.08 Pus swab GSH SUR C I - - - - 
C26 R R R R S S S S S S S 28.07.08 Pus swab GSH SUR C I - - - - 
C27 R R R R S S S R S S - 26.02.07 Pus swab MMH ICU C I - - - - 
C28 R R R R S S S S S S S 30.05.08 Pus swab MMH GYN C I - - - - 
C29 R R R R S S S S S S S 11.06.08 Pus swab GSH EMERG C I - - - - 
C30 R R R R S S S R S S S 17.06.08 Pus swab MMH OPC C I - - - - 
C31 R R R R R S S S S S S 20.06.08 Pus swab MMH GYN C I 5 t045 dt10a H481Y 
C32 R R R R S S S S S S S 27.09.2008 CVCT RCCH SUR C I - - - - 
C33 R R R R S S S S S S S 28.09.2008 Pus swab GSH OPC C I - - - - 
C34 R R R R S S S S S S S 28.09.2008 Pus swab MMH ICU C I - t045 dt10a - 
C35 R R R R S S S S S S S 14.12.08 Pus swab GSH GYN C I - - - - 
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D2 R R R R R R S R S S S 24.08.2008 Pus swab RCCH SUR D IVd - t064 dt10i H481N; I527M 
D3
c
 R R R R R R S S S S S 06.11.2008 Pus swab GSH MED D IVd - - - - 
D4
c
 R R R R R R S R S S S 10.10.2008 RTS GSH EMERG D IVd 612 t064 dt10i H481N; I527M 
D5 R R R R R R S R S S - 12.06.2007 Pus swab RCCH MED D IVd - - - - 
D6 R R R R R R S S S S S 11.06.2008 Pus swab VH MED D IVd - t064 dt10i - 
D7
c
 R R S S R R S R S S - 28.02.2007 Pus swab GSH MED D IVd - - - - 
S5 R R S S R R S R S S S 12.02.2008 Pus swab RCCH NP 
Sporadic 
Isolate 
IVd 612 t064 dt10i - 
E1
c
 R R S S R R R R S S - 10.06.2007 Pus swab RCCH ICU E IVd - - - - 
E2 R R R R R R R S S S - 28.07.2007 Blood GSH ICU E IVd - - - - 
E3 R R S S R R R R S S S 23.04.2008 Pus swab RCCH SUR E IVd 612 t1443 dt10i - 
E4 R R R R R R R R S S - 28.01.2007 RTS GSH ICU E IVd 612 t2196 dt10ap
b
 - 
E5 R R S S R R R R S S S 23.07.2008 Pus swab GSH SUR E IVd - t1443 dt9ac
b
 H481N; I527M 
E6
c
 R R R S R R S R S S S 01.09.2008 Pus RCCH ICU E IVd - - - - 
E7 R R R R R R S R S S - 12.06.2007 RTS VH OPC E IVd - - - - 
E8 R R R R R R R R S S S 11.02.2008 RTS UCTPH SUR E IVd - t064 dt9ad
b
 H481N; I527M 
E9 R R S S R R S R S S - 11.06.2007 Pus swab GSH OPC E IVd - - - - 
E10 R R S S R R S R S S - 29.01.2007 RTS GHS OPC E IVd - - - - 
E11 R R R R R R R R S S S 12.11.2008 Pus swab GSH MED E IVd - - - - 
E12 R R S S R R R R S S - 18.07.2007 Pus swab GSH OPC E IVd - - - - 
E13 R R S S R R R R S S S 23.05.2008 Pus swab GSH SUR E IVd - - - - 
E14 R R R R R R R R S S - 26.02.2007 Pus swab VH MED E IVd - - - - 
E15 R R S S R R R R S S - 11.07.2007 Pus swab GSH MED E IVd - - - - 
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E17 R R S S R R R R S S S 23.07.2008 Pus swab GSH SUR E IVd - - - - 
E18 R R S S R R R R S S S 16.04.2008 Pus swab GSH SUR E IVd - - - - 
E19 R R S S R R R R S S - 28.02.2008 Pus RCCH MED E IVd - t1443 dt10o H481N; I527M 
E20 R R S S R S R S S S - 11.07.2007 Pus swab GSH OPC E IVd - - - - 
E21 R R S S R R R R S S S 25.06.2008 Pus swab GSH SUR E IVd - - - - 
E22
c
 R R S S R R R R S S - 28.02.2007 Urine RCCH EMERG E IVd - - - - 
E23 R R R R R R R R S S - 06.07.2007 Pus swab RCCH NP E IVd - - - - 
E24 R R S S R R R R S S S 18.07.2007 Pus GSH OPC E IVd - - - - 
E25
c
 R R R R R R R R S S S 08.04.2008 Pus swab RCCH SUR E IVd - - - - 
E26 R R S S R R R R S S - 29.02.2008 RTS VH MED E IVd - t1443 dt10i H481N; I527M 
E27 R R S S R R R R S S S 11.03.2008 Pus swab GSH ICU E IVd - - - - 
E28 R R R R R R R R S S S 04.06.2008 Pus swab MMH ICU E IVd - - - - 
E29 R R S S R R R R S S - 12.06.2007 Pus swab GSH MED E IVd - - - - 
E30 R R R S R R R R S S S 29.09.2007 Pus swab GSH MED E IVd - - - - 
E31 R R R R R R R R S S S 29.09.2008 Pus swab RCCH OPC E IVd - - - - 
E32 R R S S R R R R I S S 03.11.2008 CVCT GSH MED E IVd 612 t1443 dt8v
b
 H481N; I527M 
E33 R R R R R S S R S S S 17.06.2008 CVCT RCCH SUR E IVd - - - - 
S6 R R S S R R S R S S - 23.09.2007 Blood GSH MED 
Sporadic 
Isolate 
IVd 612 t064 dt10i - 
S7 R R R R S S R S I S S 12.11.2008 Pus swab GSH MED 
Sporadic 
Isolate 
IVh 22 t032 dt9j None 
F1 R R R R S S R S S S S 09.10.2008 RTS GSH ICU F II - - - - 
F2 R R R R S S R S S S S 16.10.2008 RTS UCTPH OPC F II - - - - 
F3 R R R R S S R R S S S 09.06.2008 Pus swab GSH EMERG F II - - - - 
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F5 R R R R S S R R S S S 28.06.2008 Pus swab GSH ICU F II - - - - 
F6 R R R R S S R S S S S 15.07.2008 Pus swab GSH SUR F II - - - - 
F7 R R R R S S R S S S S 31.01.2008 Pus swab GSH SUR F II - - - - 
F8 R R R R S S R S S S - 24.09.2007 Blood UCTPH ICU F II 36 t012 dt9a - 
F9 R R R R S S R S S S S 12.12.2007 CVCT GSH ICU F II - t021 dt7s
b
 None 
F10 R R R R S S S R S S - 27.02.2008 Pus swab GSH SUR F II - - - - 
F11 R R R R S S R S S S S 31.12.2007 Pus swab GSH SUR F II - - - - 
S8 R R S S S S S S S S S 23.06.2008 Pus swab RCCH OPC 
Sporadic 
Isolate 
IVb 650 t002 dt10t - 
a
 NHLS, National Health Laboratory Service; MRSA, methicillin-resistant S. aureus; P, penicillin; Clo, cloxacillin; E, erythromycin; Cli, clindamycin; R, rifampicin; Sxt, co-trimoxazole; 
Ci, ciprofloxacin; G, gentamicin; F, fusidic acid; V, vancomycin; L, linezolid; PFGE, pulsed-field gel electrophoresis; SCCmec, staphylococcal cassette chromosome mec; ST, 
Sequence Type (multilocus sequence typing); RTS, respiratory tract specimen; CVCT, central venous catheter tips; GSH, Groote Schuur Hospital; RCCH, Red Cross War 
Memorial Children‘s Hospital; UCTPH, University of Cape Town Private Hospital; MMH, Mowbray Maternity Hospital; VH, Victoria Hospital; ICU, intensive care unit; OPC, 
outpatient clinic; MED, medical ward; SUR, surgical ward; GYN, gynaecology and obstetrics; EMERG, emergency services; NP, data not provided; (-), test or experiment not 
carried out. 
b
 Novel spa or dru type. 
c

















Buffers and Solutions 
 




10 mM Tris-Cl 
1.0 mM EDTA 
1% SDS 
1 mg/ml Proteinase K  
pH 8.0 
Add 0.788g Tris-Cl and 0.186g EDTA to approximately 480 ml of distilled water, then 
adjust to pH 8.0 and make up to a final volume of 500 ml.  Dissolve 1g SDS and 
100mg proteinase K (Roche Diagnostics GmbH, Mannheim, Germany) in 100 ml of 
this buffer.  Prepare 20 ml aliquots and store at -20º C for up to 6 months. 
 
EC Buffer  
6 mM Tris-Cl 
1.0 M NaCl 
0.1 M EDTA 
0.5% Brij 58 
0.5% Sarkosyl (pH 7.5) 
Autoclave and store at room temperature up to 6 months. 
 
TAE Buffer (50X) 
242 g Tris base  
100 ml EDTA (0.5M, pH 8.0) 















Make up to final volume of 1L using distilled water.   
Store at room temperature. 
 
TBE Buffer (10X) 
54 g Tris base 
27.5 g Boric acid  
4.65 g EDTA 
pH 8.0 
Make up to final volume of 500 ml using distilled water.  
Autoclave and store at room temperature. 
 
TE Buffer 
10 mM Tris HCl 
1 mM EDTA 
pH 8.0 
Autoclave and store at room temperature for up to 6 months 
 
TEN Buffer 
0.1M Tris Cl 
0.15M NaCl 
0.1M EDTA 









































Figure C1 Lambda Ladder PFG Marker N0340S. Manufactured by New England 












































Figure C2 Hyperladder I Molecular Weight Marker. Manufactured by Bioline 













































Figure C3 Hyperladder IV Molecular Weight Marker.  Manufactured by Bioline 









































Figure D1 SmaI macrorestriction profile for S. aureus pulsed-field gel electrophoresis 
control strain NCTC8325.  Molecular weights are only indicated for fragments used during 
















Table E1 Primer sequences 
 


























Multiplex PCR assay 
for the detection of 
SCCmec types I – VI  
[3.2.3.1] 




CIF2 R2 ATTTACCACAAGGACTACCAGC 
ccrC F2 GTACTCGTTACAATGTTTGG 
WIS 
ccrC R2 ATAATGGCTTCATGCTTACC 
RIF5 F10 TTCTTAAGTACACGCTGAATCG 
ANS46 
RIF5 R13 GTCACAGTAATTCCATCAATGC 
SCCmec V J1 F TTCTCCATTCTTGTTCATCC 
WIS 
SCCmec V J1 R AGAGACTACTGACTTAAGTGG 
dcs F2 CATCCTATGATAGCTTGGTC COL, BK2464, 
MW2, and 
HDE288 dcs R1 CTAAATCATAGCCATGACCG 
ccrB2 F2 AGTTTCTCAGAATTCGAACG BK2464 and 
MW2 ccrB2 R2 CCGATATAGAAWGGGTTAGC 
kdp F1 AATCATCTGCCATTGGTGATGC 
BK2464 
kdp R1 CGAATGAAGTGAAAGAAAGTGG 
SCCmec III J1 F CATTTGTGAAACACAGTACG 
ANS46 
















Multiplex PCR assay 
for the detection of 
SCCmec types I – VI  
[3.2.3.1] 





mecI P3 GCGGTTTCAATTCACTTGTC 




mecA P7 CCACTTCATATCTTGTAACG 
PCR assays for the 
detection of ccr 










PCR assays for the 
detection of class A, 
B, and C2 mec 
complexes [3.2.3.3] 
mI6 CATAACTTCCCATTCTGCAGATG ANS46 (A) 
Kondo et al., 
(2007) 
IS7 ATGCTTAATGATAGCATCCGAATG COL (B) 
IS2(iS-2) TGAGGTTATTCAGATATTTCGATGT WIS (C2) 
















Multiplex PCR assay 
for the detection of 
SCCmec type IV 
subtypes IVa – Ivh 
[3.3.4] 









ccrB2 R TTGGCWATTTTACGATAGCC 
J IVa F ATAAGAGATCGAACAGAAGC 
JCSC4744 
J IVa R TGAAGAAATCATGCCTATCG 
J IVb F TTGCTCATTTCAGTCTTACC 
JCSC2172 
J IVb R TTACTTCAG TGCATTAAGC 
J IVc F CCATTGCAAATTTCTCTTCC DEN2949; 
AR43/3330.1 J IVc R ATAGATTCTACTGCAAGTCC 
J IVd F TCTCGACTGTTTGCAATAGG 
BK2529  
J IVd R CAATCATCTAGTTGGATACG 
J IVg F TGATAGTCAAAGTATGGTGG 
M03-68 
J IVg R GAATAATGCAAAGTGGAACG 
J IVh F TTCCTCGTTTTTTCTGAACG 
HAR22 
















PCR assay for the 










































spa typing [5.2.2] 
spa-1113f TAAAGACGATCCTTCGGTGAGC 
COL 







dru typing [5.2.4] 
dru-1 GTTAGCATATTACCTCTCCTTGC 
COL 
Goering et al. 

































Figure F1 BLAST result for the 449 bp product amplified from C17 with primer 
pair ccrC F2/ccrC R2. Print-screen of the portion of the BLAST results indicating 
that the 449 bp product amplified from isolate C17 was 96% identical to the ccrC 












































Figure F2 BLAST result for the PCR product amplified from isolate S2 with the 
primer pair mA7/IS2 (iS-2) specific for the class C2 mec complex.  Print-screen 
of a portion of the BLAST results indicating that the PCR product amplified from 
isolate S2 with was 99% identical to the class C2 mec complex present in the 




































Figure G1 Provincial Map of the Republic of South Africa indicating the location of the 





















Figure H1 Ridom StaphType alignment of spa repeats r26 and r135 indicating 















                      10        20        30        40        50        60        70        80        90                  
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
RN4220       ATCACACCTCAACAATTAATTAATATTCGACCTGTTATTGCATCTATTAAAGAATTCTTTGGTAGCTCTCAATTATCACAATTCATGGAC  
              I  T  P  Q  Q  L  I  N  I  R  P  V  I  A  S  I  K  E  F  F  G  S  S  Q  L  S  Q  F  M  D  
ST22-MRSA-IV ..........................................................................................  
(S7)          I  T  P  Q  Q  L  I  N  I  R  P  V  I  A  S  I  K  E  F  F  G  S  S  Q  L  S  Q  F  M  D  
ST36-MRSA-II ..........................................................................................  
(F9)          I  T  P  Q  Q  L  I  N  I  R  P  V  I  A  S  I  K  E  F  F  G  S  S  Q  L  S  Q  F  M  D  
ST5-MRSA-I   ..........................................................................................  
(C31)         I  T  P  Q  Q  L  I  N  I  R  P  V  I  A  S  I  K  E  F  F  G  S  S  Q  L  S  Q  F  M  D  
ST612-MRSA-IV..........................................................................................  
              I  T  P  Q  Q  L  I  N  I  R  P  V  I  A  S  I  K  E  F  F  G  S  S  Q  L  S  Q  F  M  D  
ST612-MRSA-IV..........................................................................................  
(09-15543)    I  T  P  Q  Q  L  I  N  I  R  P  V  I  A  S  I  K  E  F  F  G  S  S  Q  L  S  Q  F  M  D  
 
 
                     100       110       120       130       140       150       160       170       180         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
RN4220       CAAGCAAACCCATTAGCTGAGTTAACGCATAAACGTCGTCTATCAGCATTAGGACCTGGTGGTTTAACACGTGAACGTGCGCAAATGGAA  
              Q  A  N  P  L  A  E  L  T  H  K  R  R  L  S  A  L  G  P  G  G  L  T  R  E  R  A  Q  M  E  
ST22-MRSA-IV ................................................................................T.........  
(S7)          Q  A  N  P  L  A  E  L  T  H  K  R  R  L  S  A  L  G  P  G  G  L  T  R  E  R  A  Q  M  E  
ST36-MRSA-II ........T.......................................................................T.........  
(F9)          Q  A  N  P  L  A  E  L  T  H  K  R  R  L  S  A  L  G  P  G  G  L  T  R  E  R  A  Q  M  E  
ST5-MRSA-I   ...........................T....................................................T.........  
(C31)         Q  A  N  P  L  A  E  L  T  Y  K  R  R  L  S  A  L  G  P  G  G  L  T  R  E  R  A  Q  M  E  
ST612-MRSA-IV...........................A....................................................T.........  
              Q  A  N  P  L  A  E  L  T  N  K  R  R  L  S  A  L  G  P  G  G  L  T  R  E  R  A  Q  M  E  
ST612-MRSA-IV...........................A....................................................T.........  















                     190       200       210       220       230       240       250       260       270         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
RN4220       GTACGTGACGTTCACTACTCTCACTATGGCCGTATGTGTCCAATTGAAACACCTGAGGGACCAAACATTGGATTGATTAACTCATTATCA  
              V  R  D  V  H  Y  S  H  Y  G  R  M  C  P  I  E  T  P  E  G  P  N  I  G  L  I  N  S  L  S  
ST22-MRSA-IV ..........................................................................................  
(S7)          V  R  D  V  H  Y  S  H  Y  G  R  M  C  P  I  E  T  P  E  G  P  N  I  G  L  I  N  S  L  S  
ST36-MRSA-II ..G...............................................G.......................................  
(F9)          V  R  D  V  H  Y  S  H  Y  G  R  M  C  P  I  E  T  P  E  G  P  N  I  G  L  I  N  S  L  S  
ST5-MRSA-I   ..........................................................................................  
(C31)         V  R  D  V  H  Y  S  H  Y  G  R  M  C  P  I  E  T  P  E  G  P  N  I  G  L  I  N  S  L  S  
ST612-MRSA-IV................................C............................................G............  
              V  R  D  V  H  Y  S  H  Y  G  R  M  C  P  I  E  T  P  E  G  P  N  I  G  L  M  N  S  L  S  
ST612-MRSA-IV................................C............................................G............  
(09-15543)    V  R  D  V  H  Y  S  H  Y  G  R  M  C  P  I  E  T  P  E  G  P  N  I  G  L  M  N  S  L  S  
 
 
                     280       290       300       310       320       330       340       350       360         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
RN4220       AGTTATGCACGTGTAAATGAATTCGGCTTTATTGAAACACCATATCGTAAAGTTGATTTAGATACACATGCTATCACTGATCAAATTGAC  
              S  Y  A  R  V  N  E  F  G  F  I  E  T  P  Y  R  K  V  D  L  D  T  H  A  I  T  D  Q  I  D  
ST22-MRSA-IV ....................................................................C.....................  
(S7)          S  Y  A  R  V  N  E  F  G  F  I  E  T  P  Y  R  K  V  D  L  D  T  H  A  I  T  D  Q  I  D  
ST36-MRSA-II ..........................................................................................  
(F9)          S  Y  A  R  V  N  E  F  G  F  I  E  T  P  Y  R  K  V  D  L  D  T  H  A  I  T  D  Q  I  D  
ST5-MRSA-I   ..........................................................................................  
(C31)         S  Y  A  R  V  N  E  F  G  F  I  E  T  P  Y  R  K  V  D  L  D  T  H  A  I  T  D  Q  I  D  
ST612-MRSA-IV..........................................................................................  
              S  Y  A  R  V  N  E  F  G  F  I  E  T  P  Y  R  K  V  D  L  D  T  H  A  I  T  D  Q  I  D  
ST612-MRSA-IV..........................................................................................  















                     370       380       390       400       410       420       430       440       450         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
RN4220       TATTTAACAGCTGACGAAGAAGATAGCTATGTTGTAGCACAAGCAAACTCTAAATTAGATGAAAATGGTCGTTTCATGGATGATGAAGTT  
              Y  L  T  A  D  E  E  D  S  Y  V  V  A  Q  A  N  S  K  L  D  E  N  G  R  F  M  D  D  E  V  
ST22-MRSA-IV ..........................................................................................  
(S7)          Y  L  T  A  D  E  E  D  S  Y  V  V  A  Q  A  N  S  K  L  D  E  N  G  R  F  M  D  D  E  V  
ST36-MRSA-II ..........................................................................................  
(F9)          Y  L  T  A  D  E  E  D  S  Y  V  V  A  Q  A  N  S  K  L  D  E  N  G  R  F  M  D  D  E  V  
ST5-MRSA-I   ..........................................................................................  
(C31)         Y  L  T  A  D  E  E  D  S  Y  V  V  A  Q  A  N  S  K  L  D  E  N  G  R  F  M  D  D  E  V  
ST612-MRSA-IV..........................................................................................  
              Y  L  T  A  D  E  E  D  S  Y  V  V  A  Q  A  N  S  K  L  D  E  N  G  R  F  M  D  D  E  V  
ST612-MRSA-IV....................................................G.....................................  
(09-15543)    Y  L  T  A  D  E  E  D  S  Y  V  V  A  Q  A  N  S  R  L  D  E  N  G  R  F  M  D  D  E  V  
 
 
                     460       470       480       490       500       510       520       530       540         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
RN4220       GTATGTCGTTTCCGTGGTAACAATACAGTTATGGCTAAAGAAAAAATGGATTATATGGATGTATCGCCGAAGCAAGTTGTTTCAGCAGCG  
              V  C  R  F  R  G  N  N  T  V  M  A  K  E  K  M  D  Y  M  D  V  S  P  K  Q  V  V  S  A  A  
ST22-MRSA-IV .......................C..................................................................  
(S7           V  C  R  F  R  G  N  N  T  V  M  A  K  E  K  M  D  Y  M  D  V  S  P  K  Q  V  V  S  A  A  
ST36-MRSA-II ..........................................................................................  
(F9)          V  C  R  F  R  G  N  N  T  V  M  A  K  E  K  M  D  Y  M  D  V  S  P  K  Q  V  V  S  A  A  
ST5-MRSA-I   ..........................................................................................  
(C31          V  C  R  F  R  G  N  N  T  V  M  A  K  E  K  M  D  Y  M  D  V  S  P  K  Q  V  V  S  A  A  
ST612-MRSA-IV..........................................................................................  
              V  C  R  F  R  G  N  N  T  V  M  A  K  E  K  M  D  Y  M  D  V  S  P  K  Q  V  V  S  A  A  
ST612-MRSA-IV..........................................................................................  















                     550       560       570       580       590       600       610       620       630         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
RN4220       ACAGCATGTATTCCATTCTTAGAAAATGATGACTCAAACCGTGCATTGATGGGTGCGAACATGCAACGTCAAGCAGTGCCTTTGATGAAT  
              T  A  C  I  P  F  L  E  N  D  D  S  N  R  A  L  M  G  A  N  M  Q  R  Q  A  V  P  L  M  N  
ST22-MRSA-IV ..........................................................................................  
(S7)          T  A  C  I  P  F  L  E  N  D  D  S  N  R  A  L  M  G  A  N  M  Q  R  Q  A  V  P  L  M  N  
ST36-MRSA-II ..........................................................................................  
(F9)          T  A  C  I  P  F  L  E  N  D  D  S  N  R  A  L  M  G  A  N  M  Q  R  Q  A  V  P  L  M  N  
ST5-MRSA-I   ..........................C...............................................................  
(C31)         T  A  C  I  P  F  L  E  N  D  D  S  N  R  A  L  M  G  A  N  M  Q  R  Q  A  V  P  L  M  N  
ST612-MRSA-IV..........................................................................................  
              T  A  C  I  P  F  L  E  N  D  D  S  N  R  A  L  M  G  A  N  M  Q  R  Q  A  V  P  L  M  N  
ST612-MRSA-IV..........................................................................................  
(09-15543)    T  A  C  I  P  F  L  E  N  D  D  S  N  R  A  L  M  G  A  N  M  Q  R  Q  A  V  P  L  M  N  
 
 
                     640       650       660       670    
             ....|....|....|....|....|....|....|....| 
RN4220       CCAGAAGCACCATTTGTTGGTACAGGTATGGAACACGTT-  
              P  E  A  P  F  V  G  T  G  M  E  H  V   
ST22-MRSA-IV .......................................-  
(S7)          P  E  A  P  F  V  G  T  G  M  E  H  V   
ST36-MRSA-II .......................................-  
(F9)          P  E  A  P  F  V  G  T  G  M  E  H  V   
ST5-MRSA-I   ....................A..................-  
(C31)         P  E  A  P  F  V  G  T  G  M  E  H  V   
ST612-MRSA-IV.......................................-  
              P  E  A  P  F  V  G  T  G  M  E  H  V   
ST612-MRSA-IV.......................................-  















Multiple alignment of nucleotide and predicted amino acid sequences of rpoB 
amplified from rifampicin-susceptible and -resistant methicillin-resistant 
Staphylococcus aureus isolates.  The nucleotide and predicted amino acid 
sequences of isolates S7 (ST22-MRSA-IV), F9 (ST36-MRSA-II), C31 (ST5-MRSA-I) 
and 09-15543 (Australian ST612-MRSA-IV), as well as the sequence representative 
of all other ST612-MRSA-IV isolates selected for rpoB genotyping, were aligned to 
rifampicin-susceptible control strain RN4220 (accession number X64172) using the 
Clustal W algorithm in BioEdit Sequence Alignment Editor (version 7.0.5.2) (Hall, 
1999). For each isolate, the nucleotide sequence is shown above the predicted 
amino acid sequence.  The amino acid sequence of each isolate is presented in full 
as single letter code.  Grey shading indicates identical amino acid sequences and 
mutations are indicated by breaks in the shading.  The nucleotide sequence of 
RN4220 only is shown in full; dots (.) indicate identical residues in the sequences of 
the study isolates with discrepant nucleotides shown in full.  Mutational changes are 
also indicated at the nucleotide level.  Altered codons are underlined with the 
relevant nucleotide residue shown in full. 
 
